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Abstract 
 
Pre-eclampsia is a multisystem obstetric disease of unknown aetiology that is associated 
with enhanced coagulation, endothelial activation and reduced placental function. A two-
stage model for pre-eclampsia has been proposed involving abnormal placentation and the 
maternal response to this. 
 
 
In this thesis, I have identified a possible relationship between annexin V expressed on the 
surface of syncytiotrophoblasts and fibrin deposition, suggesting that annexin V may serve 
to protect the surface of placental villi from excessive coagulation. A prothrombinase assay 
was developed for the purpose of measuring maternal plasma microparticle procoagulant 
activity  between  pre-eclamptic  women  and  healthy  pregnant  control  women.  No 
significant difference was found in microparticle procoagulant activity between these two 
groups. However, quantitation of fetal Corticotrophin-Releasing Hormone mRNA (CRH 
mRNA) in maternal plasma as a measure of placental cell debris was undertaken between 
pre-eclamptic and healthy control groups. There were four-fold higher levels of placental 
cell debris in the maternal blood of pre-eclamptic patients compared to healthy pregnant 
controls and the mean fetal CRH mRNA level was greater in the group of pre-eclamptic 
patients over 36 weeks’ gestation compared to  pre-eclamptic patients under 36 weeks’ 
gestation. Factor VII coagulant activity was also positively correlated with placental cell 
debris in maternal circulation in pre-eclampsia which suggests that placental cell debris 
may  have  procoagulant  potential.  Measures  of  coagulation  activation,  endothelial 
activation  and  placental  function  in  maternal  plasma  were  in  keeping  with  the  pattern 
expected for pre-eclamptic patients. Maternal erythrocyte fatty acid status was measured in 
pre-eclamptic  patients  and  Body  Mass  Index-matched  healthy  pregnant  controls.  Pre-
eclamptic patients were found to have a lower percentage of total polyunsaturated fatty 
acids  and  total  n-6  fatty  acids  as  well  as  lower  amounts  of  dihomo-γ-linolenic  acid, 
arachidonic acid and docosahexaenoic acid compared to healthy pregnant controls. This 
change in maternal fatty acid profile would be consistent with a greater synthesis of the 
potent eicosanoid thromboxane A2. In summary, these results are overall consistent with a 
state of enhanced coagulation priming in pre-eclampsia.   3 
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A STUDY OF COAGULATION POTENTIAL IN PRE-ECLAMPSIA 
 
 
 
Chapter 1  Introduction 
 
 
1.1  Introduction 
 
 
1.1.1  Clinical features of pre-eclampsia 
 
 
Pre-eclampsia is a disease of pregnancy resulting from a maternal physiological response 
to abnormal placentation. It is a multisystem disorder affecting approximately 2-7% of all 
pregnancies  in  the  United  Kingdom  and  is  a  significant  cause  of  maternal  and  fetal 
morbidity  and  mortality(1).  According  to  the  International  Society  for  the  Study  of 
Hypertension in Pregnancy, pre-eclampsia is defined as having a diastolic blood pressure 
greater than 110mmg Hg on one occasion, or greater than 90 mmHg on repeated readings, 
with proteinuria of greater than or equal to 0.3g / 24 hours, or 2+ proteinuria on dipstick 
testing,  in  the  absence  of  renal  disease  or  infection.  In  the  seventh  report  of  the 
Confidential Enquiry into Maternal and Child Health (CEMACH) report 2003-2005, there 
were 295 maternal deaths in the UK. Of these, 19 maternal deaths were attributable to pre-
eclampsia  and  its  associated  complications(2).  With  regards  to  perinatal  mortality, 
according to the CEMACH report 2007 on perinatal mortality, there were 120 antenatal 
fetal deaths as a result of pre-eclampsia(3). While there has been a gradual reduction over 
the  years, pre-eclampsia nevertheless remains a significant cause of maternal  and fetal 
morbidity  and  mortality.  Risk  factors  for  developing  pre-eclampsia  include  being 
primiparous, having a previous history of pre-eclampsia (particularly if onset was before 
the third trimester), a family history of pre-eclampsia, chronic hypertension, diabetes or 
kidney  disorder,  obesity  [greater  than  30  kg/m
2  body  mass  index  (BMI)],  multiple 
gestation, maternal age under 20 years or over 35 years of age, thrombophilia, renal and 
connective tissue diseases(4).  
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Maternal  complications  of  pre-eclampsia  include  disseminated  coagulopathy  /  HELLP 
(Haemolysis, Elevated Liver enzymes and Low Platelets) syndrome, cerebral haemorrhage, 
abruption  placentae,  pulmonary  oedema,  renal  failure,  liver  failure  or  haemorrhage, 
cerebro-vascular accident and death(1). In severe uncontrolled cases of pre-eclampsia, the 
patient may go into grand-mal seizures (an eclamptic fit) which can be life threatening and 
lead to maternal and fetal mortality. Pre-eclampsia can also affect the fetus as the condition 
is associated with abnormal placentation, placental thrombosis and infarction. This can 
lead to a reduction in nutrient supply to the fetus and may manifest clinically as reduced 
fetal movement, reduced liquor volume and a fetal size below that expected for gestational 
age. Worsening pre-eclampsia, progressive placental thrombosis and subsequent reduced 
blood supply to the fetus may eventually lead to intrauterine fetal death as a result of 
hypoxia. Other fetal complications of pre-eclampsia include pre-term delivery (with its 
associated  complications),  hypoxic-neurologic  injury  and  perinatal  death(1).  Normal 
healthy  pregnancy  is  known  to  be  a  pro-thrombotic  condition  in  preparation  for  the 
haemostatic demands of delivery and there is an increase in pro-coagulant activity and a 
decrease in anti-coagulant activity as pregnancy progresses(5;6). In pre-eclampsia, there is 
a shift in the haemostatic balance towards a pro-thrombotic state, together with changes in 
endothelial  and  placental  function(1;7).  The  exact  causes  of  pre-eclampsia  are  still 
undefined, however various factors such as an imbalance between pro-and anti-coagulant 
activity,  endothelial  dysfunction,  endothelial  inflammation  and  syncytiotrophoblast 
shedding have been proposed. 
 
 
Pre-eclampsia can sometimes but not always be associated with fetal intrauterine growth 
restriction (IUGR). IUGR is a failure of the fetus to achieve the growth potential that is 
expected  by  its  genetic  constitution  and  environmental  influences  endogenous  to  the 
pregnancy. The fetus has subnormal body weight or mass and is growing under the 10
th 
centile for its gestational age. IUGR can manifest as a result of various causes and these 
causes can be divided into maternal, placental and fetal factors. Maternal factors include 
cardiac  disease,  renal  disease,  cigarette  smoking  and  excessive  alcohol  consumption. 
Placental  factors  include  pre-eclampsia,  placental  abruption,  thrombosis,  infection  and 
vasculitis.  Fetal  factors  can  include  intrauterine  infection,  cardiac  disease  and 
chromosomal  abnormalities(8).  While  the  causes  of  pre-eclampsia  are  likely  to  be 
multifactorial, it is accepted that the placenta and the mother’s response to placentally-
derived factors and proteins plays a major role in its pathogenesis.  
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1.2  The Placenta 
 
 
1.2.1  Development of the normal placenta 
 
 
The placenta functions as a feto-maternal interface which supplies the growing fetus with 
essential nutrients obtained from the maternal blood supply. Post-conception, the fertilized 
zygote develops into a flattened vesicle (the blastocyst) which comprises of an outer wall 
of cells called trophoblasts, the blastocystic cavity and an inner cell mass. The trophoblasts 
eventually develop into the placenta while the inner cell mass develops into the embryo, 
umbilical cord and amnion. Within days after implantation, the trophoblasts proliferate to 
form a layer which invades into the endometrium. The trophoblast gives rise to three main 
cell types; the syncytiotrophoblast (which forms the main epithelial covering of the villous 
tree and is in direct contact with the maternal blood space), the cytotrophoblast (which is 
the germinative population that proliferates throughout pregnancy and fuses to generate the 
syncytiotrophoblast) and the extravillous trophoblast cells which are non-proliferative and 
invade the maternal endometrium. The syncytiotrophoblast layer is a continuous structure, 
without boundaries between neighbouring syncytiotrophoblast cells. On the villous side of 
the syncytiotrophoblast are numerous microvilli which serve to increase the cell surface 
area. As pregnancy progresses, the syncytial layer becomes variable in thickness. It may be 
thinned to become the vasculosyncytial membrane or the syncytiotrophoblast nuclei may 
become piled up in areas forming syncytial knots. The syncytiotrophoblast is involved in 
various  activities  such  as  protein  and  lipid  synthesis  and  breakdown,  water  and  gas 
diffusion  between  fetal  and  maternal  circulation,  transfer  of  glucose,  amino  acids  and 
electrolytes  and  production  of  hormones  (Human  Placental  Lactogen  and  Human 
Chorionic Gonadotrophin). If there is damage to the trophoblast layer, fibrin deposition 
occurs and cytotrophoblast cells proliferate to repair the damage(9). 
 
 
Stem villi form the ‘trunks’ and ‘branches’ of the villous tree. They function to support the 
structure of the villous trees and but not have a significant role in feto-maternal exchange. 
The stroma consists of collagen fibre bundles, occasional fibroblasts, macrophages and 
mast cells. Larger stem villi often have a central artery and vein with smaller vessels and 
capillaries within its stroma. Approximately half of the stromal volume is taken up by 
vascular lumen and there are no vessels other than capillaries and sinusoids. Terminal villi   23 
are the final outgrowths of the villous tree. Terminal villi are formed from capillary growth 
and coiling, not by outgrowths. Terminal villi appear as bulbous structures and may be 
single  or  have  side  branches.  Terminal  villi  have  a  thin  trophoblastic  surface  in  close 
contact  with  dilated  capillaries  within  and  functions  as  the  main  site  of  feto-maternal 
exchange. At term, terminal villi will make up 45% or more of placental volume. 
 
 
The decidua is supplied by uteroplacental arteries which are derived from uterine spiral 
arterioles. During placental growth and trophoblastic invasion into the decidua, trophoblast 
cells invade into the walls of uteroplacental arteries. There is proteolysis of the elastic and 
smooth  muscle  cells  of  the  spiral  artery  walls  by  invasive  extravillous  trophoblast 
cells(10). There is ‘fibrinoid’ material deposition in the walls of these spiral arteries in 
which cytotrophoblastic cells are embedded. As a result, the spiral arterioles change from 
flexible channels to large diameter (up to 5 times its original size) rigid channels, now 
incapable of vasoconstriction. This change to spiral arterioles occurs in the majority of 
myometrial spiral arteries located in the centre of the placenta and to lesser extent at the 
peripheral  vessels.  The  net  effect  of  which  is  the  reduction  of  uteroplacental  flow 
resistance leading to increased blood flow to the placental villi thereby increasing feto-
maternal transfer(10). By losing their elastic lamina and smooth muscle, these remodelled 
spiral arteries also lose their responsiveness to vasoactive agents such as thromboxane(11).  
 
 
The intervillous space is an area where maternal blood flows freely around the placental 
villi thereby facilitating feto-maternal exchange. Maternal blood flows into the intervillous 
space from decidual arteries located near the centres of the villous trees and this blood is 
drained via outlets to decidual veins located in between the villous trees. Each villous tree 
has a corresponding perfused portion of the intervillous space and together they make up a 
feto-maternal circulatory unit (placentone). There are about 40 to 60 placentones in total in 
a normal placenta. 
 
 
1.2.2  Placental changes in pre-eclampsia 
 
 
In pre-eclampsia there is failure of extravillous trophoblast invasion into the myometrium 
and spiral arteries(10;12) and uterine spiral arteries are not converted into large capacitance   24 
channels as they would in healthy pregnancy. This leads to inadequate maternal blood 
perfusion into the intervillous spaces to supply  the developing fetus  and reduced  feto-
maternal exchange. The failure of extravillous trophoblast spiral artery invasion into the 
uterine spiral arteries also leads to these spiral arteries maintaining their thick muscular 
coat which in turn allows them to be influenced by vasoactive agents such as thromboxane 
A2.  
 
 
Within the arterioles of placental bed arteries, there is atherosis of the uterine vascular 
endothelium (where the vessel wall is replaced by  fibrin and the intima is invaded by 
macrophages which engulf lipid, becoming foam cells) and fibrinoid necrosis. This tends 
to  occur  in  arterioles  which  have  failed  to  convert  to  large  capacitance  vessels(13). 
Damage  to  the  endothelium  leads  to  thrombosis  and  a  mural  thrombus  may  develop, 
further occluding blood flow, leading to reduced intervillous blood flow. If blood flow is 
significantly impaired, this may lead to placental hypoxia with resultant cell death. This 
can be seen macroscopically as areas of infarction. In pre-eclampsia placentas, there is a 
greater  percentage  of  villi  with  fibrinoid  deposits  compared  to  healthy  pregnant 
controls(14). 
 
 
1.2.3  Placental changes in IUGR 
 
 
IUGR is associated with a reduced numbers of stem, intermediate and terminal villi as well 
as  a  reduction  of  the  intervillous  space.  There  is  also  an  associated  reduction  in  the 
trophoblast volume, stromal volume and fetal capillary volume. Furthermore there is a 
reduction in villous surface and capillary surface(15). There is reduced linear growth of 
villi and fetal capillaries along with  reduced capillary volume and surface(16). This results 
in  a  reduction  in  the  exchange  area  between  fetal  and  maternal  circulation  which 
contributes to the clinical condition of IUGR. 
 
 
IUGR has been found to be associated with maternal placental floor infarction. There is 
gross deposition of perivillous fibrinoid material among the basal villi of the maternal floor 
of  the  placenta(17-19)  which  suggests  there  is  a  disorder  of  coagulation.  Increased 
trophoblastic  cell  apoptosis  in  IUGR  has  been  noted  using  electron  microscopy  and   25 
confirmed  by  terminal  deoxynucleotidyl  transferase-mediated  dUTP  nick  end  labelling 
(TUNEL) staining(20). A significantly higher index of M30 cytodeath antibody (which 
recognises a fragment of cytokeratin 18 which is cleaved by caspases in early apoptosis) 
staining has also been found in the trophoblast of IUGR patients(21), suggesting there is 
increased trophoblast apoptosis in IUGR. 
 
 
1.2.4  Coagulation in the placenta 
 
 
1.2.4.1 Placental Tissue Factor 
 
 
Tissue  factor  (TF)  is  a  membrane-bound  protein  and  functions  as  a  potent  initiator  of 
coagulation  by  acting  as  a  cell-surface  receptor  for  activated  factor  VII(22).  TF  is 
expressed on subendothelial cells such as vascular adventitial cells and smooth muscle 
cells(23).  In  its  subendothelial  location,  TF  forms  a  boundary  around  blood  vessels. 
Mechanical or chemical damage of the blood vessel endothelium can lead to blood leakage 
from the vascular space into the subendothelial space, allowing circulating activated factor 
VII (FVIIa) to become exposed to subendothelial TF leading to the formation of the FVIIa-
TF complex, a key step in coagulation activation. The FVIIa-TF complex  increases the 
enzymatic activity of activated factor VII approximately 2x10
7-fold towards factors IX and 
factor X in the extrinsic coagulation cascade [illustrated in figure 1.4.1 and reviewed in 
(22;24)]. 
 
 
In healthy pregnancy, high concentrations of TF have been detected in the placenta(25). TF 
expression has been localised to placental macrophages, endothelial cells and fibroblast-
like cells in loose connective tissue but was not observed in trophoblast or trophoblastic 
basement membranes(26) although cultured syncytiotrophoblast cells have been found to 
express TF(27). Higher levels of TF mRNA have been found in pre-eclamptic placentas 
compared  to  healthy  pregnant  control  placentas(28)  and  Estelles  et  al  noted  greater 
amounts of TF antigen and TF mRNA in the placentas of women who had severe pre-
eclampsia with associated IUGR compared to healthy pregnant controls(29). Addition of 
tumour  necrosis  factor-α  (TNF-α)  into  cytotrophoblasts  isolated  from  healthy  and  pre-
eclamptic placentas in vitro has been found to increase the amount of TF expressed by   26 
trophoblasts. The amount of TF expressed was greater in pre-eclamptic samples compared 
to healthy pregnant samples, suggesting that TF expression by pre-eclamptic placentas may 
be more sensitive to pro-inflammatory cytokines(30). 
 
 
1.2.4.2 Placental fibrinoid 
 
 
In haemostasis, fibrin is the end product in the process of coagulation. In the placenta, 
placental fibrin-type fibrinoid is extracellularly deposited materials composed mostly of 
fibrin.  Electron  microscopy  of  fibrinoid  material  reveals  a  longitudinal  filamentous 
structure similar to that of true fibrin(18). Fibrinoid is a product of maternal blood and is 
present  at  all  stages  of  pregnancy.  It  is  present  in  both  healthy  and  pathological 
pregnancies [reviewed in(10)]. Perivillous fibrin deposition is a normal finding in healthy 
placentas. Various functions of perivillous fibrinoid have been proposed, such as having a 
role  in  maintaining  the  mechanical  stability  of  the  placenta  and  regulating  blood  flow 
between the villi and villous repair(10). Cultured cellular trophoblasts have been grown on 
a  fibrin  matrix  and  morphological  differentiation  into  trophoblast  resembling  the 
trophoblast of term villi occurred, suggesting that perivillous fibrin may be involved in 
trophoblast repair(31). 
 
 
As  normal  pregnancy  progresses,  there  is  often  loss  of  areas  of  syncytiotrophoblast 
(possibly  due  to  syncytial  degeneration  or  trophoblast  turnover)  and  these  areas  of 
trophoblast discontinuity are replaced by perivillous fibrinoid(32;33). Electron microscopy 
has  revealed  apoptotic  changes  of  syncytiotrophoblast  in  these  areas  of  fibrinoid 
deposits(34). While fibrinoid material may have physiological functions, the deposition of 
perivillous  fibrinoid  at  the  trophoblast  surface  obstructs  feto-maternal  exchange  and  in 
cases of gross deposition, may lead to placental insufficiency. Excessive perivillous fibrin 
deposition  has  been  found  in  conditions  of  IUGR(17)  and  pre-eclampsia(14;35),  both 
conditions that are associated with placental insufficiency. 
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1.2.4.3 Placental annexin V 
 
 
Annexin V belongs to the family of annexins, which are highly homologous phospholipid 
binding  proteins.  Annexin  V  can  be  found  in  various  cell  types  such  as  platelets  and 
endothelial  cells  and  has  also  been  detected  in  maternal  blood  and  amniotic  fluid(36). 
While  the  plasma  concentration  of  annexin  V  is  low  (0-5ng/ml),  it  is  high  within  the 
placenta at approximately 250mg/kg (37). Within the placenta, annexin V has been found 
in various cell types such as capillary endothelial cells, fibroblasts, Langhans cells and 
Hofbauer  cells.  However  annexin  V  is  most  abundant  within  trophoblastic  cells(38). 
Annexin V is expressed constitutively by syncytiotrophoblast cells(39) and has been found 
to be localised to the microvillous surface of syncytiotrophoblastic cells(40). Annexin V is 
expressed by the placenta from as early as 7 weeks’ gestation and is highly expressed on 
the syncytiotrophoblast microvillous surface throughout gestation(41). Annexin V has a 
high affinity to negatively-charged phospholipids such as phosphatidylserine and therefore 
can  act  to  bind  phosphatidylserine-exposing  cell  membranes  [reviewed  in(36)].  The 
presence  of  annexin  V  on  a  cell  surface  confers  anticoagulant  properties.  Annexin  V 
trimerises  on  the  phospholipid  cell  membrane  and  these  trimers  polymerise  to  form 
hexagonal 2-dimensional crystals that form a lattice over the phospholipid membrane(42). 
This lattice is stabilized by protein-protein interactions(36). The presence of the annexin V 
lattice reduces lateral mobility of already-bound coagulation factors on cell membranes(39) 
thus preventing the propagation of these coagulation factors.  
 
 
A  deficiency  of  annexin  V  has  been  implicated  in  the  procoagulant  effects  of  the 
antiphospholipid  syndrome  (which  is  associated  with  increased  arterial  and  venous 
thrombosis, placental thrombosis and fetal death) as reduced amounts of annexin V have 
been found on the syncytiotrophoblast apical membranes of these patients(43). In vitro 
experiments have shown that antiphospholipid immunoglobulins lead to reduced annexin 
V binding to phospholipid bilayers(43;44) as well as trophoblast cell surfaces(45) with an 
associated  increase  in  prothrombin  binding  on  these  trophoblast  cells(45).  In  pregnant 
mice,  infusions  of  antibodies  towards  annexin  V  were  found  to  lead  to  placental 
thrombosis,  placental  necrosis  and  fetal  loss(46).  Injections  of  phosphatidylserine-
containing  vesicles  (which  are  prothrombotic)  into  mice  also  led  to  thrombosis  of  the 
placental bed and IUGR, while subsequent injection of recombinant annexin V led to a 
reversal of these effects(47).   28 
Lower amounts of annexin V expression on trophoblasts has been noted in pre-eclamptic 
patients compared to healthy pregnant controls(39;48). In association with lower annexin 
V  expression  on  the  trophoblasts,  higher  amounts  of  fibrin  degradation  products  and 
thrombin-antithrombin  complexes  has  been  noted,  suggesting  an  inverse  relationship 
between the expression of annexin V and coagulation(48). Several studies have suggested 
that annexin V may afford the syncytial surface protection against clot formation(45-47). 
Therefore, it is possible there may be a relationship between the distribution of annexin V 
and fibrin deposition on the syncytial surface of the placenta.  
 
 
1.2.5  Placental apoptosis 
 
 
As the placenta develops, its tissues undergo remodelling and central to this process of 
remodelling is cellular apoptosis. Apoptosis is one of the main types of programmed cell 
death which involves a series of biochemical events leading to changes in cell morphology 
and  ultimately  the  cellular  death.  The  characteristic  morphology  of  cells  undergoing 
apoptosis  are  cell  membrane  blebbing,  changes  to  the  cell  membrane  such  as  loss  of 
membrane asymmetry and attachment, cell shrinkage, nuclear fragmentation, chromatin 
condensation and chromosomal DNA fragmentation. Finally, the apoptotic cell breaks into 
small membrane-wrapped fragments known as apoptotic bodies or microparticles which 
are eventually engulfed by phagocytic cells. Apoptosis is distinct from necrosis in that 
apoptosis is an active form of cell death which is controlled, while necrosis is accidental 
cell death as a result of external factors. The processes associated with apoptosis in the 
disposal of cellular debris do not damage the organism. In necrosis the whole cell along 
with its organelles swell as the plasma membrane becomes unable to control the passage of 
ions  and  water  into  and  out  of  the  cell,  leading  to  leakage  of  cellular  contents  and  
inflammation of surrounding tissues(49). 
 
 
Apoptosis  occurs  during  organ  development  and  is  part  of  normal  cellular  turnover. 
Apoptosis  involves  a  complex  set  of  signalling  molecules  such  as  Fas  ligands,  Fas 
receptors and death signalling genes such as Bcl-2. Bcl-2 has been immunolocalised to 
syncytiotrophoblasts  of  normal  pregnancies  throughout  pregnancy.  Apoptosis  can  be 
identified  using  cellular  cytokeratin  18  which  has  been  found  to  be  cleaved  in  early 
apoptosis.  M30  CytoDEATH  (Roche  Molecular  Biochemicals)  is  a  mouse  monoclonal   29 
antibody  that  detects  a  specific  caspase  cleavage  site  within  cytokeratin  18  that  is  not 
revealed in normal healthy cells. Thus, M30 is a useful tool for localising apoptotic cells. A 
previous  study  looking  at  M30  localisation  within  the  healthy  placenta  in  the  third 
trimester  showed  that  the  majority  of  M30  staining  was  localised  to  extravillous 
trophoblasts  as  well  as  syncytiotrophoblast  cells  with  abundant  M30  staining  of 
syncytiotrophoblast  cells  in  areas  of  greater  perivillous  fibrinoid  deposition(50).  As 
cytokeratin is located within the cell cytoplasm, M30 immunoreactivity is confined to the 
cytoplasm although non-specific M30 staining of the nuclei of highly proliferating cells 
has also been recorded(51). 
 
 
In the developing placenta, cytotrophoblast cells continually proliferate, differentiate and 
fuse into the syncytiotrophoblast layer. A second differentiation process occurs at the outer 
syncytiotrophoblast layer where syncytial apoptosis occurs and ageing syncytiotrophoblast 
nuclei are packed into syncytial knots and extruded into the maternal circulation to be 
replaced by a younger population (9;49). These apoptotic syncytial knots are cleared away 
by villous stromal macrophages as well as circulating macrophages (which occurs to a 
large  degree  in  maternal  lungs)  [reviewed  in(52)].  The  ingestion  of  apoptotic  cells 
(exposing phosphatidylserine) by macrophages has been shown in vitro to produce TGFβ-1 
which suggests that macrophages may attenuate the maternal inflammatory response in the 
placenta(53). In normal pregnancy, in the first trimester, there is a greater cytotrophoblast 
volume in relation to syncytiotrophoblast volume. However this changes towards the end 
of pregnancy where the syncytiotrophoblast volume becomes greater along with a greater 
amount of syncytial knots and bridges(54). 
 
 
Pre-eclamptic and IUGR placentas have a greater degree of syncytiotrophoblast apoptosis 
as  well  as  a  greater  number  of  syncytial  knots  and  bridges  in  comparison  to  healthy 
placentas(20;55;56).  In  pre-eclampsia,  the  increased  apoptosis  is  associated  with  a 
reduction in syncytiotrophoblast area and almost all terminal villi in late pregnancy show 
syncytial  knots(57).  In  vitro,  hypoxia  has  also  been  shown  to  induce  apoptosis  in 
trophoblasts(58;59). As  the syncytiotrophoblast layer is in contact with the intervillous 
space which is in turn in contact with the maternal systemic circulation, it is possible that 
apoptotic syncytiotrophoblasts would release microparticles into the maternal circulation. 
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1.3  Placental debris and microparticles 
 
 
1.3.1  Microparticle generation and characteristics 
 
 
Microparticles range from 0.1 to 2µm in size and are produced during cellular activation 
and  apoptosis.  In  normal  cell  conditions,  membrane  aminophospholipids  such  as 
phosphatidylserine and phosphatidylethanolamine are actively transported from the outer 
leaflet to the inner (cytosolic) leaflet of the cell membrane by cell membrane translocase. 
During  cellular  apoptosis,  there  is  release  of  calcium  from  the  endoplasmic  reticulum 
resulting  in  an  increase  in  intracellular  calcium  levels  leading  to  the  inhibition  of 
translocase.  As  a  result  of  inhibition  of  translocase,  phosphatidylserine  is  no  longer 
actively maintained at the inner leaflet and becomes exposed on the outer surface of the 
cell membrane[reviewed in (60)]. This increase in calcium also activates cytosolic calpain 
which cleaves cytoskeletal filaments leading to blebbing of the cell membrane and the 
eventual  release  of  these  cell  membrane  blebs  into  the  extracellular  environment  as 
microparticles[reviewed  in(61)].  The  released  microparticles  contain  cytoplasmic 
components  with  phosphatidylserine  exposed  on  their  membrane  surface.  Cell-specific 
antigens particular to the cell type that the microparticles originated from are exposed on 
the  microparticle  membrane  surface(62).  For  example,  microparticles  derived  from 
endothelial cells express CD31, CD51, CD54 and CD62E and CD106. Microparticles have 
been  identified  from  various  cell  types  such  as  endothelium,  T-cells,  monocytes  and 
platelets(63-66). Microparticles have been found to activate platelets(66) and they have 
also been found to increase the adhesion of monocytes to human umbilical vein endothelial 
cells(HUVEC)  via  an  up-regulation  of  intracellular  cell  adhesion  molecule-1  (ICAM-
1)(64). 
 
 
Microparticles  have  been  proposed  to  be  procoagulant  in  nature  due  to  the  exposed 
phosphatidylserine  on  their  surface,  as  phosphatidylserine  provides  a  surface  for  the 
assembly of coagulation factors in the conversion of prothrombin to thrombin via the tissue 
factor pathway (67;68). Indeed, plasma levels of microparticles have been found to be 
raised  in  various  prothrombotic  conditions  such  as  acute  coronary  syndrome(69), 
diabetes(70),  heparin  induced  thrombocytopenia(71),  paroxysmal  nocturnal   31 
haemoglobinuria(72)  and  severe  hypertension(73).  Microparticle  levels  have  also  been 
found  to  be  raised  in  women  with  a  history  of  idiopathic  pregnancy  loss(74). 
Microparticles  may  however  also  possess  anti-coagulant  properties.  Tans  et  al  showed 
increased platelet inactivation of activated factor V after thrombin stimulation and this was 
associated with microparticle release(75). 
 
 
1.3.2  Syncytiotrophoblast membrane particles 
 
 
The syncytiotrophoblast layer of the placenta is in direct contact with the intervillous space 
and  therefore  is  in  contact  with  maternal  blood.  In  healthy  pregnancy,  with  constant 
placental remodelling and renewal of the syncytiotrophoblast layer, there is apoptosis of 
syncytiotrophoblasts  (9)  and  this  has  been  proposed  to  result  in  the  shedding  of 
syncytiotrophoblast  membrane  fragments(STBMs)  into  the  maternal  side  of  placental 
circulation(76). In healthy pregnancy, STBMs have been identified in the maternal uterine 
vein circulation (77;78). While STBMs have been found in the uterine vein circulation of 
60% of healthy pregnant women, only 10 % of these healthy pregnant women had STBMs 
detected  in  their  peripheral  circulation(78).  As  the  mechanism  of  STBM  generation  is 
similar  to  that  of  microparticle  generation  (i.e.  a  consequence  of  cellular  apoptosis); 
STBMs may be considered to be microparticles of syncytiotrophoblast origin. 
 
 
In pre-eclampsia, there is greater trophoblast apoptosis compared to healthy pregnancy(79) 
and  higher  levels  of  STBMs  have  been  found  in  the  maternal  blood  of  pre-eclamptic 
women compared to healthy pregnant controls(78;80). Goswami et al(81) measured STBM 
levels in pre-eclamptic patients by means of ELISA using an anti-trophoblast antibody 
(NDOG2)  to  capture  the  particles  and  STBM  levels  were  found  to  be  significantly 
increased  in  early  onset  pre-eclampsia  patients  (patients  who  developed  pre-eclampsia 
under  34  weeks’  gestation)  compared  to  healthy  pregnant  controls  but  they  were  not 
statistically different when compared between late onset pre-eclamptics (over 34 weeks’ 
gestation) and healthy pregnant controls. STBMs have been found in the uterine veins of 
71% of pre-eclamptic women but only 10% of these women had STBMs detected in their 
peripheral circulation which suggests that while there is greater trophoblast apoptosis in 
pre-eclampsia compared to healthy pregnancy, relatively little STBMs reach the maternal 
peripheral circulation(78). There was also an increased amount of STBMs found in the   32 
peripheral  circulation  of  early-onset  pre-eclamptic  women  compared  to  normotensive 
IUGR pregnancies (81). In in vitro studies, STBMs from pre-eclamptic patients have been 
shown to interfere with endothelial cell proliferation (82) as well as impair small artery 
relaxation(83;84) although another study of myometrial arteries perfused with STBMs in 
levels  up  to  100  times  that  reported  in  pre-eclampsia  failed  to  show  any  effect  on 
bradykinin-mediated arteriolar dilatation(85).  Therefore, there is evidence that STBMs 
may affect endothelial function and blood flow in pre-eclampsia. 
 
 
1.3.3  Microparticles in healthy pregnancy 
 
 
Microparticle levels in peripheral blood have been measured in healthy pregnant and non-
pregnant controls using flow cytometry. In a study of 15 healthy pregnant women and 19 
non-pregnant  controls,  Bretelle  et  al  showed  that  platelet  and  endothelial-derived 
microparticles were higher in healthy pregnant compared to non-pregnant controls(86). In 
contrast, in another study of 10 healthy pregnant individuals and 10 non-pregnant controls, 
Van Wijk et al did not find any significant difference in platelet, monocyte, granulocyte or 
endothelial-derived microparticle levels between pregnant and non-pregnant controls(87). 
With regards to coagulation, using a prothrombinase assay, Bretelle et al(86) found that 
total microparticle pro-coagulant activity was significantly increased in healthy pregnant 
individuals compared to their non-pregnant controls. However, VanWijk et al measured 
microparticle  thrombin  generating  ability  in  vitro  and  did  not  find  any  significant 
difference between healthy pregnant and non-pregnant controls(88). 
 
 
1.3.4  Microparticles in pre-eclampsia 
 
 
When  microparticle  levels  were  compared  between  pre-eclamptic  women  and  healthy 
pregnant controls, increased numbers of microparticles derived from endothelial, T-helper, 
T-suppressor,  monocyte,  granulocyte  cells  were  found  in  the  plasma  of  pre-eclamptic 
patients compared to healthy pregnant controls(80;87;89;90) although some studies did not 
detect  any  significant  difference  in  endothelial-derived  microparticles  between  pre-
eclamptic and healthy pregnant controls(86;87). The highest proportion of microparticles 
in both pre-eclamptic and healthy pregnant women has been found to be platelet-derived   33 
microparticles(87) although in contrast, Bretelle et al found a lower amount of platelet-
derived  microparticles  in  pre-eclamptic  pregnancies  compared  to  healthy  pregnant 
controls(86). Despite differences in microparticle levels in these cell subpopulations, no 
differences  have  been  found  in  the  total  number  of  microparticles  in  maternal  plasma 
between pre-eclamptic  and healthy control  groups(86;87). With regard  to microparticle 
pro-coagulant activity, in a study of 10 pre-eclamptic and 10 healthy controls, VanWijk et 
al  measured  microparticle  thrombin  generating  ability  in  vitro  and  did  not  find  any 
significant difference between pre-eclamptic and healthy pregnant controls (88). Bretelle et 
al(86)  using  a  prothrombinase  assay  did  not  find  any  difference  in  microparticle  pro-
coagulant activity between pre-eclamptic and healthy pregnant control groups. 
 
 
1.3.5  Fetal Corticotrophin-releasing hormone mRNA 
 
 
For purposes of measuring placental cell debris in maternal circulation, a measure of fetal 
cellular products in maternal circulation may be undertaken. Several studies have shown 
that fetal DNA was detectable in maternal plasma from as early as 6 weeks’ gestation 
onwards  with  a  gradual  increase  of  fetal  DNA  levels  as  pregnancy  progresses(91-93). 
However, the use of fetal DNA as a measure has limitations as in order to differentiate 
placental cellular debris from maternal cellular debris, only male offspring DNA could be 
used and this precluded the study of pregnancies carrying female fetuses(94). Fetal mRNA 
was  then  discovered  to  be  detectable  in  maternal  plasma  by  using  a  2-step  reverse 
transcription-PCR  assay(95)  and  fetal  mRNA  appeared  to  be  protected  from  serum 
RNAses as they were circulating within apoptotic bodies(96;97). Fetal mRNA in maternal 
plasma would be presumed to originate from the placenta as the placenta is genetically 
identical to the fetus and is in direct contact with the maternal circulation. The measure of 
fetal mRNA in maternal blood would therefore be a reflection of the amount of placental 
cell debris in maternal systemic circulation. 
 
 
In  human  physiology,  Corticotrophin-releasing  hormone  (CRH)  is  a  neurotransmitter 
synthesised and released from the hypothalamus into the hypothalamo-hypophyseal portal 
system  where  it  acts  on  the  anterior  pituitary  gland.  Due  to  the  blood-brain  barrier, 
maternal CRH mRNA is not detectable in the maternal systemic circulation. The placenta 
and fetal membranes produce CRH (98) and immunohistochemical studies have shown   34 
intense  CRH  staining  at  the  syncytiotrophoblast  layer  of  the  chorionic  villi,  fetal 
membranes  and  the  invasive  trophoblast  cells  in  the  decidua(99;100).  Therefore,  any 
measurable  CRH  mRNA  in  maternal  circulation  should  come  from  the  placenta.  The 
measurement  of  fetal  corticotrophin  releasing  hormone  mRNA  (CRH  mRNA)  can 
therefore  be  used  as  a  measure  of  placental-derived  cell  debris  in  maternal  systemic 
circulation. 
  
 
Fetal CRH mRNA levels have been measured in maternal plasma in healthy pregnancy and 
have  been  found  to  increase  as  pregnancy  progresses(101)  and  in  labour(102).  The 
presence of fetal CRH mRNA was found to clear from maternal circulation within 2 hours 
after caesarean delivery(103). In pre-eclampsia, higher levels of placental-derived CRH 
have been found in the maternal serum as well as in the placental circulation compared to 
healthy pregnant controls(104;105) and the fetal CRH mRNA concentration in maternal 
plasma  has  also  found  to  be  higher  in  pre-eclampsia  compared  to  healthy  pregnant 
controls(106;107). Fetal CRH mRNA levels have been found to be higher in early-onset 
pre-eclamptics  compared  to  late-onset  cases,  possibly  reflecting  increased  placental 
damage in early onset pre-eclamptic patients(107).  
 
 
1.4  Blood coagulation (haemostasis) 
 
 
In order to place the coagulation changes in pregnancy and pre-eclampsia in context, it is 
useful to review the function of various coagulation factors in normal haemostasis and then 
examine the changes in pregnancy and pre-eclampsia. Normal haemostasis is an important 
physiological  reaction  to  prevent  loss  of  blood  from  damaged  blood  vessels  into  the 
extravascular space. This is achieved by the formation of a localised insoluble blood clot (a 
fibrin mesh) to plug the damaged area of the blood vessel. As the damage is repaired, the 
clot is gradually removed by fibrinolysis.  
 
 
Haemostasis is initiated and terminated in a controlled fashion. This is necessary to ensure 
formation of a blood clot in the correct location and to prevent excessive propagation of 
the  clot.  Various  components  of  blood  and  the  blood  vessel  wall  are  involved  in 
haemostasis, such as the haemostatic factors, platelets, tissue factor and the endothelium. A   35 
fine balance of activation and inactivation of various coagulation factors is necessary to 
control clotting and this occurs by various feedback loops in the haemostatic network. 
Dissolution of the fibrin mesh is controlled by the plasminogen activation system. The 
normal haemostatic network will now be reviewed.  
 
 
1.4.1  The haemostatic network 
 
 
With reference to figure 1.4.1, there are two main pathways (the intrinsic pathway and the 
extrinsic  pathway)  that  leads  to  the  formation  of  activated  factor  X  (FXa)  which  is 
involved  in  the  formation  of  the  prothrombinase  complex.  The  intrinsic  pathway  is 
initiated when the proteins prekallikrein, kallikrein, factor XI (FXI) and factor XII (FXII) 
are exposed to a negatively-charged surface such as collagen on the blood vessel wall. This 
is the contact phase. Prekallikrein is converted to kallikrein which then activates FXII. 
Activated factor XII (FXIIa) hydrolyses more prekallikrein to kallikrein thus amplifying 
this  cascade.  FXIIa  also  activates  factor  XI  (FXI).  Activated  factor  XI  (FXIa)  in  the 
presence of calcium ions then activates factor IX (FIX). The main function of activated 
factor IX (FIXa) is to combine with activated factor VIII (FVIIIa) to form the factor Xase 
(FXase) complex. The FXase complex then activates factor X (FX). 
 
 
The extrinsic pathway (see figure 1.4.1) is initiated when circulating activated factor VII 
(FVIIa) comes into contact with tissue factor (TF). Tissue factor is normally located at the 
subendothelial  matrix  of  blood  vessels.  Damage  to  the  vasculature  leads  to  circulating 
FVIIa coming into contact with TF at the subendothelial matrix leading to formation of the 
FVIIa-TF  complex which then activates factor  X (FX). Activated  factor X (FXa) then 
activates  factor  V  by  proteolysis.  FXa  assembles  with  prothrombin,  activated  factor  V 
(FVa) and calcium ions on the phospholipid surface provided by cell membranes in vivo to 
form  the  prothrombinase  complex.  FXa  can  also  directly  generate  small  amounts  of 
thrombin from prothrombin (the ‘initiation’ stage) and these small amounts of thrombin 
back-activate  FV  and  factor  VIII  (FVIII)  initiating  the  ‘amplification’  phase  of 
coagulation.  
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Prothrombin is a protein. It is converted to thrombin by cleavage of 2 peptide bonds by the 
prothrombinase complex. Fully cleaved thrombin is termed α-thrombin and is active in free 
solution. Thrombin cleaves the fibrinogen molecule at it’s α- and β- chains thus exposing 
N-terminal sequences that allow attachment of another cleaved fibrinogen molecule. This 
allows progressive polymerization in either direction of cleaved fibrinogen molecules thus 
forming elongating fibrils of fibrin, the blood clot. Thrombin has several positive feedback 
mechanisms to enhance coagulation (see figure 1.4.1). Thrombin can activate factor V. 
Thrombin can also activate circulating factor XIII to form activated factor XIII (FXIIIa) 
which functions to crosslink fibrin and other proteins in the clot thereby stabilising the 
whole  clot  structure.  Factor  VIII  (FVIII)  circulates  in  blood  bound  to  VonWillebrand 
Factor (vWF) and is proteolysed by thrombin to form activated factor VIII (FVIIIa) which 
functions as an essential co-factor in the FXase activation of Factor X. Thrombin can also 
affect the intrinsic coagulation cascade by cleaving FXI into FXIa. 
 
 
There are several anticoagulant pathways in the haemostatic network (see figure 1.4.1). 
Protein C, a potent anticoagulant is synthesized by the liver and is activated by cleavage to 
form  activated  protein  C  (APC).  APC  acts  to  inactivate  FVa  as  well  as  FVIIIa,  thus 
interfering  with  the  formation  of  the  prothrombinase  complex  as  well  as  the  FXase 
complex. The cleavage of protein C to APC can be accelerated by thrombin, thus acting as 
a negative feedback loop toward the generation of further thrombin. Antithrombin (AT) is 
synthesized by the liver and functions to inactivate thrombin by cleavage resulting in an 
inactive  complex,  the  thrombin-antithrombin  complex  (TAT).  Antithrombin  can  also 
inactivate FIXa, FXIa and FXIIIa, but to a much lesser degree than thrombin itself. Tissue 
factor  pathway  inhibitor  (TFPI)  is  synthesized  by  platelets,  endothelial  cells,  smooth 
muscle  cells,  monocytes  and  fibroblasts.  When  there  is  endothelial  damage,  platelets 
aggregate and when activated by thrombin, release TFPI into the site of coagulation. TFPI 
forms a complex with TF-FVIIa-FXa, inactivating these co-factors and directly affecting 
the formation of the prothrombinase complex. 
 
 
1.4.2  The plasminogen-activation system of fibrinolysis 
 
 
Fibrinolysis  is  important  to  ensure  that  fibrin  deposition  does  not  exceed  beyond  that 
which is required to prevent loss of blood from the vasculature. Following repair to the   37 
vasculature, the process of fibrinolysis ensures that the fibrin mesh is removed as part of 
the process of tissue repair and remodelling. Fibrinolysis mainly occurs on the surface of 
cells in close proximity with the cross-linked fibrin itself. These steps are illustrated with 
reference to figure 1.4.2. 
 
 
Factor XII (FXII) is known as Hageman factor and is synthesised in the liver. FXII is 
cleaved  by  kallikrein  and  plasmin  into  activated  FXII  (FXIIa).  FXIIa  activates 
prekallikrein  on  the  surface  of  endothelial  cells  to  become  kallikrein.  Kallikrein  then 
breaks down high molecular weight kininogen (HMWK) to bradykinin. Bradykinin then 
stimulates  the  release  of  endothelial  cell  tissue-type  plasminogen  activator  (tPA)  from 
endothelial cells(108). tPA is also secreted by endothelial cells when stimulated by other 
factors such as venous occlusion, adrenaline and thrombin. Circulating tPA is inactive until 
it becomes bound to fibrin, forming tPA-fibrin which converts fibrin-bound plasminogen 
to  plasmin.  Urinary  plasminogen  activator  (uPA)  is  synthesised  by  kidney  tubules  and 
collecting ducts. uPA is secreted in an inactive form (pro-urokinase) which is cleaved by 
kallikrein and plasmin to become active uPA. 
 
 
Plasmin  plays  a  major  role  in  the  plasminogen-activation  pathway  of  fibrinolysis  (see 
figure 1.4.2). Plasmin hydrolyses the fibrinogen and fibrin components of the blood clot 
into  small  soluble  peptides  [known  collectively  as  fibrin  degradation  products  (FDPs)] 
leading to clot dissolution. Fibrin-bound plasminogen is converted to plasmin by tPA and 
uPA. It can be seen that fibrin combines with tPA to activate plasmin. Thus, fibrin plays a 
major  role  in  its  own  lysis.  Plasmin  can  enhance  its  anticoagulant  effect  indirectly  by 
activating FXII (thus leading to greater conversion of prekallikrein to kallikrein) as well as 
by activating pro-urokinase to active uPA. The action of these plasminogen activators are 
regulated  by  plasminogen  activator  inhibitors  (PAI)  (see  figure  1.4.2).  Plasminogen 
activator inhibitor 1 (PAI-1) is secreted by endothelial cells and platelets and functions to 
inactivate  tPA,  uPA  and  plasmin.  Plasminogen  activator  inhibitor  2  (PAI-2)  is  mainly 
produced by the placenta where it is synthesised by monocytes and trophoblast cells. It acts 
to bind both tPA and uPA but its potency is at least 10-fold less than PAI-1.   38 
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Figure  1.4.1:  The  haemostasis  network  (adapted  from  Postgraduate  Haematology  5
th 
Edition, Blackwell Publishing 2005. Hoffbrand AV, Catovsky D, Tuddenham EDG).(24) 
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Figure  1.4.2:  The  plasminogen-activation  pathway  of  fibrinolysis  (Adapted  from 
Postgraduate  Haematology  5
th  Edition,  Blackwell  Publishing  2005.    Hoffbrand  AV, 
Catovsky D, Tuddenham EDG)(24)   40 
 
1.4.3  Markers of coagulation in pregnancy and pre-eclampsia 
 
 
1.4.3.1 Soluble Tissue Factor 
 
 
Tissue factor is not expressed by the endothelium or circulating monocytes under normal 
physiological  conditions  and  therefore,  there  is  little  appreciable  contact  of  TF  with 
circulating blood. However, when stimulated by various cytokines or mediators, TF can be 
expressed  by  the  endothelium,  monocytes  and  macrophages  [reviewed  in(22;23)].  The 
endothelium has been shown to express TF when stimulated by cytokines such as tumour 
necrosis factor-α (TNF-α) and interleukin 1-β (IL-β)(109) or when stimulated by mediators 
such as thrombin, oxidized LDL(110) or vascular endothelial growth factor. Monocytes 
can  express  tissue  factor  when  stimulated  by  endotoxins,  C-reactive  protein(CRP)  and 
oxidised LDL (111)[reviewed in(23)].  
 
 
Soluble TF has been found to be present in blood(112) as well as expressed by endothelial 
cells after stimulation by proinflammatory cytokines such as TNFα and interleukin-6(113). 
Giesen et al (112) has identified neutrophils and monocytes containing tissue factor in the 
circulation and this tissue factor was found to be actively procoagulant. Higher plasma 
levels  of  soluble  TF  have  been  associated  with  sepsis,  atherosclerosis  and  diabetes 
[reviewed in (114)], diseases which are associated with a procoagulant state. Therefore, 
increased levels of tissue factor reflect a state of increased coagulation potential. 
 
 
TF expression by monocytes was found to be significantly lower in healthy pregnancy 
compared to non-pregnant controls(115). In pre-eclampsia, plasma levels of TF has been 
found  to  be  significantly  elevated  compared  to  healthy  pregnant  controls(28;116;117). 
However in a prospective study involving 2190 pregnant women, Djurovic et al did not 
find  any  difference  in  plasma  TF  levels  at  18  weeks’  gestation  between  women  who 
subsequently developed pre-eclampsia and their matched controls(118). 
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1.4.3.2 Tissue Factor Pathway Inhibitor (TFPI) 
 
 
Tissue factor pathway inhibitor (TFPI) antagonises the effects of TF by inactivating the 
FVIIa/TF  complex,  thereby  preventing  the  production  of  FIXa  and  FXa(119).  Higher 
plasma levels of TFPI have been found in various pro-thrombotic conditions such as acute 
myocardial  infarction,  diabetes  mellitus  and  disseminated  intravascular  coagulation 
[reviewed  in(119;120)].  Plasma  levels  of  TFPI  have  also  been  found  to  be  raised  in 
hypercholesterolemic patients and TFPI was strongly correlated with total cholesterol and 
low  density  lipoprotein  levels(121).  It  was  hypothesised  that  this  increase  may  be  a 
compensatory  mechanism  to  prevent  activation  of  the  extrinsic  coagulation  system  by 
tissue factor and factor VII in hypercholesterolemic patients(121). 
 
 
TFPI  can  be  synthesized  by  the  liver,  monocytes,  macrophages,  megakaryocytes  and 
cultured  human  umbilical  vein  endothelial  cells.  TFPI  is  produced  constitutively  by 
microvascular endothelial cells [reviewed in (119)]. Approximately 50 to 80% of TFPI is 
located in the endothelium with 10 to 50% circulating in plasma and a small amount in 
platelets  [reviewed  in  (122)].  Plasma  levels  of  TFPI  has  been  shown  to  be  positively 
associated with markers of endothelial cell activation such as t-PA, thrombomodulin and 
von Willebrand factor (vWF)(123). The plasma form of TFPI may therefore be a marker of 
endothelial cell activation(120). In the placenta, TFPI has been found to be expressed by 
cytotrophoblasts,  syncytiotrophoblasts  and  the  vascular  endothelium(124).  Cultured 
syncytiotrophoblasts  express  higher  TF  levels  but  lower  TFPI  levels  in  comparison  to 
cultured  human  umbilical  vein  endothelial  cells.  This  suggests  there  is  a  need  for  an 
increased pro-coagulant activity in the placental intervillous space, perhaps in preparation 
to prevent excessive haemorrhage [reviewed in (122)]. Higher levels of TFPI in plasma 
have  been  found  in  pre-eclamptic  patients  compared  to  healthy  pregnant 
controls(117;125;126). 
 
 
1.4.3.3 Thrombin-antithrombin complex 
 
 
Once thrombin is formed, it circulates in the systemic circulation bound to endogenous 
serine protease inhibitors such as antithrombin. This results in an inactive complex, the   42 
thrombin-antithrombin complex (TAT)(24). A measurement of TAT levels can therefore 
be used to reflect the amount of thrombin in circulation(127). Serum TAT levels have been 
found to gradually increase as pregnancy progresses(88;128-131). In one study, the median 
TAT levels went up between 4.1 to 7.8 times from the start of labour to the end stages of 
labour(132) which  may reflect increased levels of circulating thrombin in preparation for 
haemostasis  at  delivery.  TAT  levels  have  been  found  to  reduce  and  normalise 
approximately 24 hours postpartum(128).  
 
 
Higher TAT levels have been found in the maternal plasma of pregnancies complicated by 
pre-eclampsia  when  compared  against  healthy  pregnant  controls(125;128;129;133)  and 
TAT levels have been found to significantly increase in tandem with both systolic and 
diastolic  blood  pressures(88).  In  pre-eclampsia,  higher  TAT  levels  have  been  found  in 
uterine veins compared to the maternal systemic circulation, which may reflect increased 
pro-coagulant activity of the placental circulation in pre-eclampsia(134). Lower levels of 
anti-thrombin  have  been  found  in  patients  with  severe  pre-eclampsia(125;129;133) 
possibly reflecting antithrombin utilisation by increased levels of thrombin in this pro-
coagulant state. In an attempt to reduce the harmful effects of increased coagulation in pre-
eclampsia,  a  double-blinded  randomised  controlled  trial  was  undertaken  to  administer 
antithrombin to patients with pre-eclampsia. Antithrombin was administered over a 7 day 
period which resulted in an improvement in maternal symptoms, fetal biophysical profile 
and fetal weight gain(135). This suggested a beneficial effect of antithrombin, possibly by 
reducing  available  circulating  thrombin,  reducing  coagulation  activation,  reducing 
placental thrombosis and leading to a consequent improvement in the clinical condition.  
 
 
1.4.3.4 Prothrombin fragment 1+2 
 
 
During the conversion of prothrombin to thrombin, prothrombin fragment 1+2 (F1+2) is 
released. F1+2 may therefore be used as a surrogate marker to quantify the amount of 
thrombin generated(127;136). Increased levels of F1+2 have been found in various pro-
thrombotic  conditions  such  as  end-stage  renal  disease(137),  disseminated  intravascular 
coagulation(138), septic shock(139), haematological malignancies(140), unstable angina 
and acute myocardial infarction(140-142). 
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In healthy pregnancy, it was found that there was a progressive rise in F1+2 levels as 
pregnancy  progressed(131;140;142-144).  This  rise  was  found  to  be  associated  with 
increasing levels of fibrinogen(143), TAT(88;131;140) and APC resistance(88). In pre-
eclampsia, levels of F1+2 were found to be higher when compared to healthy pregnant 
patients(88).  Patients  who  had  a  history  of  severe  pre-eclampsia  were  found  to  have 
increased  levels  of  F1+2  and  thrombin-antithrombin(TAT)  six  to  fifteen  months  after 
delivery(145). 
 
 
1.4.3.5 Factor VIIc 
 
 
Factor  VII  (FVII)  is  activated  by  cleavage,  yielding  a  2-chain  disulphide-linked  FVIIa 
molecule. With damage to the blood vessel and disruption of the endothelial cell layer, 
circulating factor VIIa comes into contact with tissue factor at the subendothelial matrix. 
This leads to the formation of the TF-FVIIa complex that initiates coagulation by directly 
activating  FX  and  FIX(24).  Recombinant  FVIIa  has  been  successfully  used  as  a 
procoagulant  to  control  excessive  postpartum  haemorrhage(146)  and  also  in  bleeding 
disorders  such  as  haemophilia(147).  The  factor  VII  coagulant  activity  (FVIIc)  can  be 
measured  in  a  bioassay  that  is  sensitive  to  FVIIa,  which  would  be  a  more  accurate 
assessment of the activity of FVIIa in comparison to measuring levels of FVIIa antigen in 
blood. FVIIc levels have been found to be raised in healthy pregnancy(148). There is little 
in the literature regarding FVII levels in pre-eclampsia although one study did not find any 
significant  difference  in  FVII  levels  between  women  who  had  hypertension  and 
superimposed  pre-eclampsia  and  healthy  control  groups(149).  Postnatally,  FVII  levels 
have been found to be significantly raised in pre-eclamptic pregnancies 6 to 15 months 
after delivery compared to healthy pregnant controls(145). 
 
 
1.4.3.6 Factor XIIa 
 
 
The  precise  role  of  FXIIa  is  not  well  defined  as  FXIIa  may  have  both  pro-  and  anti-
coagulant effects. It has a pro-coagulant effect in that it activates factor XI to become 
factor  XIa  which  participates  in  the  intrinsic  coagulation  pathway.  It  also  has  anti-
coagulant effects in that it leads to production of plasmin which is involved in blood clot   44 
dissolution.  FXII  deficiency  has  been  found  in  recurrent  venous  thrombosis(150),  but 
found to be raised in diabetes mellitus(151) and septic shock(139;152). Several studies 
have shown an association of FXII deficiency with recurrent miscarriage(153-155) and as 
early  pregnancy  loss  is  associated  with  placental  thrombosis,  FXII  deficiency  may 
predispose to thrombosis. 
 
 
In normal pregnancy, FXII has been shown to be raised up to 150% in the third trimester 
compared to non-pregnant controls(156). Higher levels of FXIIa were also found in the 
third  trimester  compared  to  the  first  trimester(152).  A  longitudinal  study  of  FXIIa  in 
normal  pregnancy  showed  a  progressive  increase  of  FXIIa  in  pregnancy  but  which 
decreased postpartum. This increase was most significant at 3 points between 12 to 35 
weeks’  gestation(157).  In  a  study  of  12  pre-eclamptic  patients,  FXII  levels  were 
significantly higher compared to healthy pregnant controls(158). Therefore, FXII levels 
appear to be raised in pregnancy and further raised in pre-eclampsia. 
 
 
1.4.3.7 Activated protein C (APC) 
 
 
FVIIIa  and  FVa  are  potent  coagulation  factors  in  the  formation  of  the  FXase  and 
prothrombinase  complexes  respectively.  FVIIIa  and  FVa  activity  is  inhibited  by  the 
‘protein C pathway’. Protein C is a vitamin K-dependent serine protease that is synthesised 
in the liver. Protein C is activated by cleavage of its heavy chain by thrombin to form 
activated protein C (APC).  This reaction is accelerated on the surface of endothelial cells 
by receptors for both thrombin and protein C. APC functions to bind to Protein S in the 
presence of thrombin and thrombomodulin leading to the inactivation of FVa and FVIIIa in 
the  extrinsic  coagulation  cascade.  Therefore,  APC  is  anticoagulant  in  nature  [reviewed 
in(24)]. 
 
 
The activity of protein C can be measured as the APC ratio. A lower ratio corresponds to 
APC resistance and reduced anticoagulant properties. The APC ratio has been found to 
progressively reduce in  healthy pregnancy and this is most significant after 20 weeks’ 
gestation(142;159;160).  APC  resistance  has  been  found  to  be  higher  in  patients  who 
suffered first and second trimester losses(161). Administration of APC has been found to   45 
reverse the effects of IUGR induced by procoagulant phospholipid vesicles in mice(162). 
A point mutation in the factor V gene (FV:Q506) causes a condition known as factor V 
Leiden  which  leads  to  APC  resistance.  A  prospective  study  of  2480  women  in  early 
pregnancy  showed  less  intrapartum  haemorrhage  in  patients  who  had  factor  V 
Leiden(163). Factor V Leiden is also associated with an increased risk of developing pre-
eclampsia (88;164-166). 
 
 
1.4.3.8 Plasminogen activator inhibitor type 1 (PAI-1) 
 
 
Plasminogen activator inhibitor type 1 (PAI-1) is produced by endothelial cells, platelets, 
kidney tubule cells, adipose tissue, liver, the placenta and myometrium(167). Active PAI-1 
may  be  freely  circulating  in  plasma  or  bound  to  and  stabilised  in  its  active  form  by 
vitronectin which is found in abundance in the subendothelial matrix. With damage to the 
endothelium and activation of the pro-coagulant system, PAI-1 bound to vitronectin in the 
subendothelial matrix is ideally placed to participate in and influence the process of clot 
dissolution and vascular repair(168). Platelets store large amounts of PAI-1 within its α-
granules  and  is  released  during  platelet  aggregation(168).  PAI-1  indirectly  inhibits  the 
process  of  fibrinolysis  by  binding  and  inactivating  the  3  main  proteases  involved  in 
fibrinolysis (tPA, uPA and plasmin). These complexes are then removed by the liver. PAI-
1 is the primary inhibitor of tPA. Raised PAI-1 levels have been found in obesity, ischemic 
cardiovascular disease(169) and type II diabetes(24). 
 
 
In normal pregnancy, there is an increase in maternal plasma levels of PAI-1(6;170) but 
this has been found to fall quickly after delivery(170-172). Maternal plasma levels of PAI-
1 in pre-eclampsia have been found to be significantly raised when compared to healthy 
pregnant  controls(125;173-175).  Patients  with  pre-eclampsia  with  extensive  placental 
infarction have been found to have increased plasma levels of PAI-1 when compared to 
pre-eclamptics  without  extensive  placental  infarction(172).  However  in  cases  of  pre-
eclampsia complicated with IUGR, lower levels of PAI-1 in maternal serum have been 
found compared to patients with just pre-eclampsia alone(125). Greater levels of PAI-1 
have been found in the syncytiotrophoblasts of pre-eclamptic patients compared to normal 
healthy controls, with greater PAI-1 expression at areas of placental infarction(176).  
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1.4.4  Markers of vascular inflammation and endothelial function 
 
 
1.4.4.1 Intercellular adhesion molecule1 (ICAM-1) 
 
 
Intercellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1) 
belong to the immunoglobulin superfamily of Cell Adhesion Molecules (CAMs). ICAM-1 
and  VCAM-1  are  involved  in  the  leukocyte-endothelial  cell  adhesion  cascade,  where 
circulating leukocytes are attracted to areas of inflammation. In the leukocyte-endothelial 
cell adhesion cascade,  circulating leukocytes are attracted by chemotaxis to the site of 
inflammation and margination towards the vascular endothelium occurs mediated by E- 
and P-selectin. Integrins on the surface of the leukocytes interact with ICAM-1 on the 
surface of the endothelium leading to leukocyte adherence. This then leads to leukocyte 
flattening and eventual transmigration through junctions between endothelial cells into the 
basement membrane. After a brief pause, they migrate into the interstitial tissue [reviewed 
in(177)].  In  inflammation,  pro-inflammatory  cytokines  such  as  interleukin-1,  tumour 
necrosis  factor-α  and  interferon-γ  activate  endothelial  cells  and  leukocytes  leading  to 
shedding  of  CAMs  from  their  surface  into  the  systemic  circulation.  This  leads  to  the 
presence of soluble ICAM-1(sICAM-1) and soluble VCAM-1(sVCAM-1) in plasma. Thus, 
measurement of these soluble forms may serve as markers of endothelial activation and 
vascular  inflammation  [reviewed  in(178)].  ICAM-1  is  produced  by  macrophages  and 
endothelial cells and is present on these cell surfaces. 
 
 
ICAM-1 may have a role in coagulation as a relationship has been discovered between 
ICAM-1  expression  and  acquired  APC  resistance(179).  Monocytes  have  thrombin 
receptors and thrombin has been shown to upregulate monocyte ICAM-1 expression in 
vitro(179). Soluble ICAM-1 levels have been measured in the maternal plasma of healthy 
pregnant women and no significant difference in levels have been found between pregnant 
and non-pregnant women(180;181) although Clark et al noted higher levels of monocyte-
derived ICAM-1 in healthy pregnant compared to non-pregnant women(179). Heimrath et 
al noted higher levels of sICAM-1 in patients with pregnancy-induced hypertension (PIH), 
compared  to  healthy  pregnant  controls(182).  In  patients  with  pregnancy-induced 
hypertension, higher levels of ICAM-1 have been found on the surface of lymphocytes in 
the  peripheral  circulation  as  well  as  decidual  lymphocytes,  with  decidual  lymphocytes   47 
expressing  greater  amounts  of  ICAM-1  than  peripheral  lymphocytes(183).  In  IUGR 
patients without pre-eclampsia, sICAM-1 levels in maternal plasma have been found to be 
higher when compared to healthy pregnant controls(184).  
 
 
In pre-eclampsia, the literature is conflicting with several studies showing maternal plasma 
sICAM-1  levels  significantly  higher  in  pre-eclamptic  patients  compared  to  healthy 
pregnant  controls(181;184;185)  but  in  a  study  of  55  pre-eclamptic  patients, 
Chaiworaposanga et al did not find any significant difference in sICAM-1 levels between 
pre-eclamptic  and  healthy  pregnant  controls(180).  Kim  et  al  also  did  not  find  any 
significant difference in sICAM-1 levels between healthy pregnant and mild pre-eclamptic 
women but sICAM-1 levels were significantly higher in severely pre-eclamptic women 
compared to the healthy pregnant patients(186). Using immunocytochemistry, Lyall et al 
did  not  find  any  difference  in  ICAM-1  expression  on  the  endothelium  between  pre-
eclamptic  and  healthy  controls(187;188).  In  the  placenta,  ICAM-1  was  found  to  be 
expressed by the endothelium of spiral arteries and the trophoblastic cells. There was no 
difference in the amount of ICAM-1 expression between pre-eclamptic pregnancies and 
healthy pregnant controls(189). 
 
 
1.4.4.2 Vascular cell adhesion molecule-1 (VCAM-1) 
 
 
VCAM-1  is  produced  mainly  by  endothelial  cells  but  can  also  be  expressed  by 
macrophages,  myoblasts  and  dendritic  cells(190).  Maternal  serum  soluble  VCAM-1 
(sVCAM-1) levels have been measured in normal healthy pregnancy and no significant 
differences  were  found  between  healthy  pregnant  and  non-pregnant  controls(180;181). 
However  maternal  plasma  sVCAM-1  levels  have  been  found  to  be  higher  in  IUGR 
pregnancies compared to healthy pregnant controls(184). In pre-eclampsia, several studies 
have shown that maternal plasma levels of sVCAM-1 were significantly raised in pre-
eclamptic  pregnancies  compared  to  healthy  pregnant  controls  (180;181;184;186;191). 
sVCAM-1 levels have also been shown to be significantly higher in severe pre-eclampsia 
compared to mild pre-eclampsia(186;191). In pre-eclamptic pregnancies complicated with 
IUGR, greater levels of sVCAM-1 have been found in pre-eclamptic patients with IUGR 
compared  with  patients  who  had  pre-eclampsia  without  IUGR(192).  A  prospective 
longitudinal  study  of  1543  pregnancies  showed  that  taken  together,  raised  levels  of   48 
prenatal  sICAM-1  and  sVCAM-1  had  an  overall  predictive  value  of  64%  towards 
developing pre-eclampsia(193).  
 
 
Lyall  et  al  detected  significantly  higher  levels  of  sVCAM-1  in  pre-eclamptic  patients, 
compared to healthy pregnant controls(187;194). Heyl et al detected increased amounts of 
VCAM-1 and ICAM-1 on the surface of cultured human umbilical vein endothelial cells 
after  stimulation  with  sera  from  pre-eclamptic  pregnancies  suggesting  that  there  was 
endothelial  cell  activation  as  a  result  of  exposure  to  sera(195).  However,  using 
immunocytochemistry, no difference was found in the amount of VCAM-1 expression in 
the endothelium of spiral arteries and the trophoblastic cells of pre-eclamptic pregnancies 
compared to healthy pregnant controls suggesting that the increased levels of sVCAM-1 in 
pre-eclampsia may not be of placental origin(189;196). 
 
 
1.4.4.3 Von Willebrand factor 
 
 
Von Willebrand factor (vWF) is synthesised predominantly  within vascular endothelial 
cells(197).  Von  Willebrand  factor  may  be  released  at  a  constant  rate  into  plasma 
(constitutive pathway) or may be stored within Weibel-Palade bodies in endothelial cells to 
be released when stimulated (regulated pathway). Megakaryocytes also synthesise vWF 
which  are  stored  in  the  α-granules  of  platelets(198).  However,  very  little  platelet-
synthesized vWF is released into plasma. The release of vWF is stimulated by thrombin. 
There are two functions of vWF in haemostasis; it serves as a carrier for factor VIII by 
forming a complex with circulating factor VIII to protect it from degradation and vWF also 
functions  to  mediate  platelet  adhesion  to  the  vascular  subendothelium.  Damage  to  the 
vasculature exposes circulating blood to collagen which is present at the subendothelial 
matrix. Circulating vWF attaches to collagen leading to platelet adhesion, aggregation and 
platelet activation with the release of α-granules at the site of injury. Locally-activated 
endothelial cells can also release stored vWF. Thrombin formation at the site of injury 
further stimulates vWF release. This leads to an increased local concentration of vWF at 
the site of injury encouraging further platelet plugging at the site of endothelial damage. 
The physiological release of vWF by the endothelium allows it to be a useful marker of 
endothelial activation. Increased levels of vWF have been found in various prothrombotic   49 
conditions  such  as  deep  venous  thrombosis(199;200),  active  inflammatory  bowel 
disease(201) and acute stroke(202). 
 
 
Von Willebrand factor levels rise as pregnancy progresses and levels resolve to normal 
after  delivery(203;204).  Von  Willebrand  factor  is  inactivated  by  cleavage  of  a  plasma 
metalloproteinase; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 
member 13 (ADAMTS 13) and ADAMTS 13 activity in healthy pregnant women have 
been found to reduce from around 12 weeks’ gestation until early puerperium, then found 
to increase again(205). In patients with pregnancy-induced hypertension, vWF levels have 
been found to be higher compared to healthy pregnant controls(206) and plasma levels of 
vWF  were  found  to  be  linearly  correlated  to  the  severity  of  pregnancy-induced 
hypertension(207). Higher levels of vWF have been found in women with pre-eclampsia 
compared to healthy pregnant controls(208-210). Elevated levels of vWF were also found 
in patients with HELLP syndrome compared to healthy pregnant controls. However levels 
of  vWF  returned  to  normal  when  measured  6  months  postpartum(211).  Patients  with 
HELLP syndrome also showed reduced levels of ADAMTS 13 when compared to healthy 
pregnant controls. However level of ADAMTS 13 returned to normal when measured 6 
months postpartum(211). 
 
 
1.4.5  Measure of placental function 
 
 
1.4.5.1 Plasminogen activator inhibitor type 2 (PAI-2) 
 
 
PAI-2 is a serpin and is produced by placental villous syncytiotrophoblasts as well as 
monocytes and macrophages. PAI-2 is mainly located intracellularly but has been found to 
be released during cell  activation or  apoptosis [reviewed in (212)]. PAI-2 functions to 
inhibit fibrinolysis by inhibiting uPA and tPA in the plasminogen activation system of 
fibrinolysis by forming stable complexes. Inactivation of uPA and tPA leads to reduced 
conversion of plasminogen to plasmin and consequently reduced degradation of fibrin by 
plasmin.  PAI-2  levels  in  plasma  are  normally  undetectable  but  have  been  found  to  be 
raised in healthy pregnancy(170;172) and there is a progressive increase with increasing 
gestation(172). A positive correlation has been found between maternal serum PAI-2 levels   50 
and birth weight in healthy pregnancy(172). After delivery, maternal PAI-2 levels may 
remain elevated for up to 11 days, suggesting that it may still be secreted from placental 
remnants still present in the uterus(172). 
 
 
In pre-eclampsia, maternal serum PAI-2 levels have been found to be significantly lower 
compared  to  their  healthy  pregnant  controls(125;170;172;213).  Maternal  plasma  PAI-2 
levels have also been found to be low in severe pre-eclampsia, with an associated increase 
in tPA levels (214). PAI-2 levels in pre-eclamptic patients with associated IUGR have been 
found  to  be  lower  compared  to  patients  with  pre-eclampsia  alone(125). 
Immunohistochemical staining of PAI-2 and uPA antigens in pre-eclamptic placental tissue 
was  not  found  to  be  as  intense  compared  to  healthy  pregnant  control  placental  tissue 
suggesting there is less PAI-2 expression in pre-eclampsia(170). The PAI-1/PAI-2 ratio has 
been found to be significantly raised in pre-eclamptic pregnancies compared to healthy 
pregnant controls(213). As plasma levels of PAI-1 have been found to be raised in pre-
eclampsia and the plasma levels of PAI-2 decreased in pre-eclampsia, the PAI-1/PAI-2 
ratio  can  be  a  useful  marker  for  pre-eclampsia.  Indeed,  2  prospective  studies  found 
elevated PAI-1/PAI-2 ratios in pregnant women who subsequently went on to develop pre-
eclampsia (215;216). 
 
 
1.5  Eicosanoids in coagulation 
 
 
1.5.1  Eicosanoids in coagulation and vasoactive properties 
 
 
Platelets are small anucleate cells in the systemic circulation that play a critical role in 
thrombosis. Activated platelets provide a negatively-charged surface for the assembly of 
the prothrombinase complex by externalising phosphatidylserine onto the surface of its cell 
membrane. Activated platelets form a bridge with surrounding polymerised fibrin which is 
generated  in  the  coagulation  cascade.  Activated  platelets  also  provide  additional 
coagulation factors such as factor V, factor VIII and fibrinogen. Platelet activation results 
in the exposure of phosphatidylserine on its plasma membrane surface as well as forms 
membrane blebs with the release of microparticles [reviewed in (217)]. 
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Thromboxane is an eicosanoid and is involved in the process of coagulation, as activated 
platelets release thromboxane at the site of platelet adhesion. Released thromboxane in turn 
activates  other  platelets  via  G-protein  coupled  thromboxane  receptors.  This  leads  to  a 
positive feedback loop of activation and recruitment of more platelets into the growing 
thrombus  [reviewed  in  (217)].  Thromboxane  is  synthesised  by  platelets  as  well  as  by 
placental  trophoblasts(218).  Thromboxanes  are  synthesised  in  vivo  in  platelets  from 
polyunsaturated fatty acids (PUFAs) liberated from cell membrane phospholipids by the 
action of phospholipase A2. 
 
 
Prostacyclin  (PGI2)  is  also  an  eicosanoid.  Prostacyclin  is  synthesised  mainly  by  the 
vascular endothelium and also by the vascular cells of the placenta, the membranes, the 
myometrium  and  the  endothelium  of  umbilical,  placental  and  uterine  vessels(218) 
Prostacyclin is a major endothelium-derived inhibitor of platelet activation, acting through 
a Gs-coupled receptor [reviewed in (217)]. Prostacyclin has been shown to inhibit platelet 
adhesion and thrombus formation on vascular wall subendothelium(219). Prostacyclin, as 
well  as  being  an  inhibitor  of  platelet  aggregation  is  also  a  potent  vasodilator  (220). 
Thromboxane and prostacyclin therefore have antagonistic effects. 
 
 
1.5.2  Thromboxane and prostacyclin in pregnancy and pre-eclampsia 
 
 
In healthy pregnancy, thromboxane and prostacyclin as produced in equal amounts(218). 
In pre-eclampsia, both the trophoblast and the placental villous core secrete higher levels 
of both thromboxane and prostacyclin compared to healthy placentas(221). Pre-eclamptic  
trophoblasts have been found to produce over three times as much thromboxane but less 
than 50% as much prostacyclin compared to healthy placentas(218;222). Greater amounts 
of thromboxane B2 (the metabolite of thromboxane A2) has been found compared to 6-
keto-prostaglandin F1α ( the metabolite of prostacyclin) in the maternal plasma of pre-
eclamptic  pregnancies  compared  to  healthy  pregnant  controls(223).  Higher  levels  of 
thromboxane B2 and lower levels of 6-keto-prostaglandin F1α have also been found in the 
urine of pregnant women who have gone on to develop pre-eclampsia(224). A higher ratio 
of maternal urinary thromboxane A3 to 6-keto-prostaglandin F1α has also been found in 
IUGR pregnancies compared to healthy controls(225). 
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Women with pre-eclampsia have also been found to have higher amounts of thromboxane-
induced  platelet  aggregation  compared  to  healthy  controls  in  both  early  and  late 
pregnancy(226). Plasma levels of prostacyclin are reduced in both mild and severe pre-
eclampsia.  In  contrast,  thromboxane  levels  were  unchanged  in  mild  pre-eclampsia  but 
significantly higher in severe pre-eclampsia, which is consistent with platelet activation in 
pre-eclampsia(218). Cultured pre-eclamptic trophoblasts have been found to produce more 
thromboxane B2 (a metabolite of thromboxane A2) and phospholipase A2 when compared 
to cultured trophoblasts from healthy pregnancies and the production of thromboxane B2 
and phospholipase A2 was further increased when cultured under hypoxic conditions (227). 
 
 
Thromboxane  is  a  vasoactive  substance  and  stimulates  vasoconstriction.  In  contrast, 
prostacyclin is a vasodilator. In pre-eclampsia, there is failure of uterine spiral arteriole 
conversion by extravillous trophoblasts into large capacitance vessels. As a result of failure 
of conversion, these arterioles maintain their muscular coat and they would be influenced 
by the vasoconstrictive properties of thromboxane. Therefore, the increased thromboxane: 
prostacyclin ratio can lead to the features of pre-eclampsia such as vascular hypertension, 
increased platelet aggregation and reduced uteroplacental blood flow (218). 
 
 
1.5.3  Thromboxane and prostacyclin synthesis from fatty acids 
 
 
The  eicosanoids  thromboxane  and  prostacyclin  are  synthesised  from  their  fatty  acids 
precursors arachidonic acid and eicosapentaenoic acid (EPA) [illustrated in figure 1.5.3]. 
Arachidonic acid is the parent compound for the synthesis of the 2-series thromboxane and 
prostacyclin  while  EPA  is  the  parent  compound  for  the  synthesis  of  the  3-series 
thromboxane  and  prostacyclin.  The  2-series  thromboxanes  and  prostacyclines  have  a 
greater potency of action than 3-series thromboxanes and prostacyclines.  As the 2-series 
thromboxanes  and  prostacyclins  are  synthesised  from  n-6  fatty  acids  while  3-series 
thromboxanes and prostacyclins are synthesised from n-3 fatty acids, the balance of n-6 to 
n-3 fatty acids in the body can, by virtue of having greater substrate, determine the quantity 
of which of these types of eicosanoids will be produced. For example, a greater proportion 
of n-6 fatty acids to n-3 fatty acids in membrane phospholipids may shift the balance of   53 
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Figure 1.5.3: Eicosanoid synthesis from the essential fatty acid precursor’s linolenic acid 
(n-6 series) and α-linolenic acid (n-3 series). Adapted from: Dietary long-chain n-3 fatty 
acids for the prevention of cancer: a review of potential mechanisms. Larsson et al. Am J 
Clin  Nutr  2004.  LT,  leucotrienes;  PG,  prostaglandins;  LOX,  lipoxygenase;  COX, 
cyclooxygenase.    54 
eicosanoid synthesis to favour the production of thromboxane A2. As thromboxane A2 has 
a  greater  potency  of  action  compared  to  thromboxane  A3  [reviewed  in  (228)],  greater 
thromboxane A2 synthesis in platelets will lead to greater platelet activity and thus an 
greater procoagulant state. 
 
 
 
1.5.4  Fatty acids 
 
 
Fatty acids are important constituents of the phospholipid layer of cell membranes as well 
as precursors of eicosanoids. In polyunsaturated fatty acid (PUFA) metabolism in humans, 
the precursor of the n-6 series PUFAs is linoleic acid and the precursor of the n-3 series 
PUFAs  is  α-linolenic  acid.  Linoleic  acid  and  α-linolenic  acid  are  essential  fatty  acids. 
These precursors are metabolised into their respective products by the sequential actions of 
desaturases  and  elongases.  These  desaturases  and  elongases  are  shared  between  the 
different  groups  of  fatty  acids  (such  as  the  n-3,  n-6,  n-7  and  n-9  series).  There  is 
competitive inhibition by these fatty acid groups for desaturases and elongases and the 
major determinant of which fatty acid group is preferentially metabolised into its products 
is the amount of substrate present. PUFAs are important precursors of eicosanoids such as 
thromboxanes, prostacyclins and leucotrienes (refer figure 1.5.4). 
 
 
In Western diets, there is a tendency towards greater n-6 fatty acids intake compared to n-3 
fatty  acids  and  this  leads  to  arachidonic  acid  being  the  predominant  substrate  for 
eicosanoid synthesis. This leads to the majority of eicosanoids produced in the body being 
of the 2-series prostaglandins (including thromboxane A2) which have greater potency of 
action compared to the 3-series prostaglandins. Low levels of the n-3 fatty acids EPA and 
DHA have been found to be associated with increased risk of death from cardiovascular 
disease(229) and high intakes of n-3 fatty acids in diet are associated with a significant 
reduction in cardiovascular mortality(230). The balance of n-6 and n-3 fatty acids has been 
shown  to  affect  platelet  function  as  platelet  cultures  with  the  n-3  fatty  acids 
eicosapentaenoic  acid  (EPA),  docosapentaenoic  acid  (DPA)  and  docosahexaenoic  acid 
(DHA) showed a decreased platelet aggregation response to collagen(231) and in culture, 
DPA was found to suppress thromboxane A2 formation by platelets which were exposed to 
collagen(232).    55 
18:3 n-3 
Alpha-linolenic 
acid 
18:4 n-3 
Octadecatetraenoic 
acid 
20:4 n-3 
Eicosatetraenoic 
acid 
 
20:5 n-3 
Eicosapentaenoic 
acid  
(EPA) 
22:5 n-3 
Docosapentaenoic acid 
(DPA) 
22:6 n-3 
Docosahexaenoic acid 
(DHA) 
n-3 series 
22:4 n-6 
Docosatetraenoic acid  
(Adrenic acid) 
20:3 n-6 
Dihomogamma-linolenic 
acid 
20:4 n-6 
Arachidonic acid 
(AA) 
18:3 n-6 
Gamma-linolenic  
acid 
18:2 n-6 
Linoleic acid 
22:5 n-6 
Docosapentaenoic acid 
(DPA) 
n-6 series 
 
6 desaturase 
 
5 desaturase 
 
6 desaturase 
 
6 desaturase 
 
5 desaturase 
 
6 desaturase 
16: 0 
Palmitic acid 
18:0 
Stearic 
18:1 n-9 
Oleic 
18:2 n-9 
n-9 series 
20:2 n-9 
20:3 n-9 
Mead 
 
6 desaturase 
elongase  elongase  elongase 
 
5 desaturase 
elongase  elongase 
Dietary sources  Dietary sources 
elongase 
stearoyl-CoA desaturase / 
 
9 desaturase 
16:1 n-7 
Palmitoleic acid 
stearoyl-CoA 
desaturase / 
  
9 desaturase 
n-7 series 
 Figure 1.5.4: Pathways of the n-3, n-6, n-7 and n-9 groups of fatty acid metabolism. 
Adapted  from:  Unsaturated  fatty  acids-  Nutritional  &  physiological  significance.  The 
report of the British Nutrition Foundation Task Force (1992).   56 
 
1.5.4.1 Fatty acid synthesis 
 
 
Fatty acids may be saturated, mono- or polyunsaturated. Saturated fatty acids do not have a 
double bond in its hydrocarbon chain. Monounsaturated fatty acids have a single double 
bond while polyunsaturated fatty acids have more than one double bond in its hydrocarbon 
chain. A double bond leads to a ‘kink’ in the hydrocarbon chain and a greater number of 
double  bonds  will  lead  to  increased  ‘kinking’.  Cell  membranes  are  composed  of 
phospholipid molecules arranged in a bilayer and phospholipid molecules have two fatty 
acid  tails.  Increased  ‘kinking’  of  fatty  acids  in  adjacent  phospholipids  leads  to  the 
phospholipid  molecules  being  less  densely  packed  together  leading  to  an  increase  in  
membrane  fluidity.  Therefore,  greater  amounts  of  polyunsaturated  fatty  acids  in  cell 
membranes lead to greater membrane fluidity(233). 
 
 
Fatty acids may be obtained from the diet or synthesised by the human body (refer figure 
1.5.4). Fatty acids that can be synthesised by the human body are termed non-essential 
fatty  acids while  fatty acids that cannot be synthesised in the human body  are termed 
essential fatty acids. In mammals, fatty acids consisting of up to 16 carbons in length are 
synthesised by cytoplasmic fatty acid synthase (234). Further lengthening of the carbon 
chain is performed by elongase enzymes which are membrane-bound enzymes located in 
the endoplasmic reticulum. Elongases function to add 2 carbon units to the hydrocarbon 
chain of the fatty acid molecule thereby lengthening the hydrocarbon  chain. There are 
different elongase systems specific for fatty acids of different chain lengths and different 
degrees of unsaturation [reviewed in(235)]. At present, the regulation of elongase enzymes 
are not fully understood [reviewed in(234)]. Desaturase enzymes introduce a double bond 
into the carbon chain of the fatty acid molecule. For example,  
5 desaturase introduces a 
double bond between carbon atoms 5 and 6 in dihomo-γ-linolenic acid to form arachidonic 
acid  (20:4  n-6).  Fatty  acids  of  various  series  utilise  the  same  elongase  and  desaturase 
enzymes and in fatty acid synthesis, there is competition of each of the fatty acid classes 
for the same elongation and desaturation enzymes [reviewed in(236)]. For example, both 
n-6 and n-3 class fatty acids use the same  
6 desaturase enzymes to introduce double bonds 
between carbon atoms 5 and 6 into their respective metabolites.  
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Stearoyl-Co-A desaturase ( 
9 desaturase) is a highly regulated enzyme that catalyses a 
crucial step in the biosynthesis of monounsaturated fatty acids from saturated fatty acids 
leading to the synthesis of membrane phospholipids, triglycerides, cholesterol esters and 
alkyl-1,2-diacylglycerol.  A  deficiency  in   
9  desaturase  can  lead  to  reduced  fatty  acid 
oxidation and thus, reduced lipid synthesis and storage.  
9 desaturase can also lead to 
increased insulin sensitivity and increased metabolic rate(237;238). It is known that there 
is dysfunction of lipid metabolism in pre-eclampsia and pre-eclampsia is associated with 
hypertriglyceridemia(239), raised low density lipoproteins and raised free fatty acids(240).  
 
 
1.5.5  n-6 and n-3 series polyunsaturated fatty acids 
 
 
Polyunsaturated  fatty  acids  (PUFAs)  are  fatty  acids  with  18  carbons  or  more  in  the 
hydrocarbon chain with two or more double bonds. PUFAs are important components of 
cell membranes and they confer fluidity and selective permeability to the cell membrane. 
Two important groups are the n-6 and n-3 PUFAs(235). The pathways of n-6 and n-3 fatty 
acid metabolism are illustrated in figure 1.5.4. The precursors of n-6 and n-3 fatty acid 
metabolism (linoleic acid and α-linolenic acid respectively) are classed as essential fatty 
acids as humans lack the 12-desaturase enzyme that converts oleic acid into linoleic acid. 
The human body also lacks the 15-desaturase enzyme and so cannot convert linoleic acid 
to α-linolenic acid. These desaturase enzymes are found in plants and so linoleic and α-
linolenic acid must be obtained from the diet. Corn, sunflower and soybean oils are high in 
linoleic acid. Linseed oil is high in α-linolenic acid. In a typical diet of the UK population 
the main polyunsaturated fatty acid (PUFA) is linoleic acid (14g/day) with α-linolenic acid 
comprising approximately 2g/day(241). 
 
 
Linoleic acid and α-linolenic acid are metabolised down their respective pathways into 
long-chain polyunsaturated fatty acids (LCPUFAs). The  
6 desaturase enzyme is the rate 
limiting enzyme in n-3 and n-6 metabolism to LCPUFAs and it has the highest affinity first 
for α-linolenic acid (n-3 PUFA), then linoleic acid (n-6 PUFA) and the lowest for oleic 
acid  (n-9  PUFA)(242).  In  the  n-6  series,  linoleic  acid  is  metabolised  into  dihomo-γ-
linolenic acid (20:3 n-6) and arachidonic acid (20:4 n-6). In the n-3 series, α-linolenic acid 
is metabolised into eicosapentaenoic acid (20:5 n-3) (EPA), docosapentaenoic acid (22:5 n-
3) (DPA) and docosahexaenoic acid (22:6 n-3) (DHA).   58 
Arachidonic acid (20:4 n-6) is the most abundant PUFA in cell membranes and the typical 
Western diet contains approximately 20% of total long chain PUFAs as arachidonic acid, 
with the n-6 fatty acid dihomo-γ-linolenic acid making up 2%. In contrast, the n-3 fatty 
acid eicosapentaenoic acid makes up less than 1% of total fatty acids consumed [reviewed 
in(228)]. LCPUFAs may also be obtained directly from fish. Fish is high in n-3 fatty acids. 
In particular, oily fish such as herring, mackerel and sardines contain high amounts of the 
n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty 
acids are also high in the liver of certain fish, for example cod. Both EPA and DHA are 
present in 10 to 100-fold greater amounts in fish compared to land animals (243). Fish oil 
preparations contain approximately 20-30% EPA and DHA. 
 
 
It has been suggested that humans originally evolved on a diet where n-6 to n-3 fatty acid 
intake was in the ratio of 1:1. In contrast, the current western diet n-6: n-3 ratio ranges 
from 10:1 to 25:1(244). As both the n-6 and n-3 fatty acids share desaturase and elongase 
enzymes, an increase in one class of fatty acid results in substrate competition for the 
shared desaturase and elongase enzymes leading to a reduced amount of metabolites of the 
other class. For example, an increase of the n-6 fatty acid linoleic acid in the diet will lead 
to an increased amount of its n-6 metabolites by the  
6 desaturase enzyme but will result in 
a reduced amount of n-3 fatty acid metabolites(242). 
 
 
1.5.6  Fatty acids in healthy pregnancy and pre-eclampsia 
 
 
1.5.6.1 Maternal fatty acid changes in healthy pregnancy 
 
 
Plasma maternal fatty acids have been measured in many studies but were measured from 
plasma lipoproteins and thus affected by maternal fasting status. The results show a general 
trend towards an increase in absolute amounts of total fatty acids, n-6, n-3 fatty acids as 
well as percentages of some fatty acids(245-247) and this is in keeping with the increased 
state of lipolysis in pregnancy. A method of circumventing the problem of maternal fasting 
status  would  be  to  analyse  the  fatty  acid  composition  of  maternal  erythrocyte  cell 
membranes. The half-life of an erythrocyte if 120 days and so a measure of its membrane 
fatty acid composition would be representative of the mother’s fatty acid status over the   59 
preceding 3 months, although, Skeaff et al had noted that dietary-induced changes in the 
fatty acid composition of plasma fatty acids were reflected in erythrocyte cell membrane 
fatty acids after just 2 weeks(248). Nevertheless, a measure of fatty acids from erythrocyte 
membrane would not be confounded by the subject’s immediate fasting status. 
 
 
Stewart et al performed a longitudinal assessment of erythrocyte cell membrane fatty acid 
composition in 47 healthy pregnant women measured in each trimester of pregnancy(249). 
There were significant increases in the percentages and absolute amounts of DPA (22:5 n-
6) α-linolenic acid (18:3 n-3) and DHA (22:6 n-3). There were also significant increases in 
the absolute amounts of palmitoleic acid (16:1 n-7) and nervonic acid (24:1 n-9) but not as 
a percentage of total fatty acids. These changes occurred between the first and second 
trimester(249).  
 
 
Other groups have also measured erythrocyte fatty acid composition in pregnancy(250-
254) and have found that in healthy pregnancy, with regards to n-6 fatty acids, linoleic 
acid, dihomo-γ-linolenic acid, arachidonic acid, and n-6 docosapentaenoic acid (n-6 DPA) 
were found to be higher either as a percentage of total fatty acids or in absolute amounts or 
both. With regards to n-3 fatty acids, α-linolenic acid and DHA were found to be higher 
both as a percentage of total fatty acids and in absolute amounts. With regards to other 
fatty acid classes, nervonic acid (24:1 n-9) and palmitoleic acid (16:1 n-7) were found to be 
higher in healthy pregnancy compared to healthy control. This general increase of fatty 
acids may be due to increased maternal mobilisation of fatty acids in healthy pregnancy. In 
the third trimester, the levels of fatty acids such as arachidonic acid, EPA, n-6 DPA and 
DHA may become reduced compared to the second trimester levels. Therefore, in healthy 
pregnancy, most fatty acids are increased as pregnancy progresses and this is probably as a 
result of increased maternal mobilisation from her stores(247). DHA has been found to be 
higher in women than in men and is further increased in women taking the combined 
contraceptive pill (which contains estrogen)(255). It is possible that estrogen promotes the 
synthesis of DHA which might explain why it can be raised in pregnancy. In the third 
trimester, some fatty acids such as arachidonic acid, EPA, n-6 DPA and DHA may be 
reduced. Arachidonic acid and DHA are important structural components of fetal central 
nervous  system  and  so  a  reduction  may  be  due  to  greater  fetal  accretion  in  the  third 
trimester. In healthy pregnancy, supplementation of fish oil high in n-3 fatty acids was 
shown  to  be  associated  with  a  reduction  of  urinary  excretion  of  thromboxane  A2   60 
metabolites,  suggesting  that  high  dose  n-3  supplementation  in  pregnancy  may  reduce 
maternal thromboxane A2 synthesis(256). 
 
 
1.5.6.2 Maternal fatty acid changes in pre-eclampsia 
 
 
There is some evidence that n-3 fatty acids may be protective against the development of 
pre-eclampsia. A prospective cohort study of 1718 women found that individuals who had 
an increased intake of DHA and EPA (both n-3 PUFAs) were associated with a lower risk 
of developing pre-eclampsia(257). A case-control study of maternal erythrocyte n-3 and n-
6 fatty acids of 99 pre-eclamptic and 100 healthy pregnant women was carried out and it 
was shown that low maternal levels of total n-3 fatty acids as well as low levels of EPA 
and DHA was associated with an increased risk of pre-eclampsia(258). It was also found 
that pregnant women with low levels of total n-3 fatty acids and pregnant women with the 
lowest  ratio  of  n-3  to  n-6  fatty  acids  had  a  higher  risk  of  developing  pre-eclampsia 
(258;259). However there was no reduced risk of developing pre-eclampsia with reduced 
n-6 fatty acid intake(257) and there was no association between arachidonic acid levels 
with risk of developing pre-eclampsia(258). 
 
 
Various changes in fatty acid levels in maternal plasma have been noted in pre-eclampsia 
compared  to  healthy  pregnant  women.  Serum  fatty  acids  have  been  measured  in  the 
maternal plasma of pre-eclamptic pregnancies and there was a trend towards lower levels 
of total PUFAs (260;261) in pre-eclampsia. There were higher absolute levels of palmitic 
(16:0), palmitoleic (16:1 n-7), oleic (18:1 n-9) and dihomogamma-linoleic acid (20:3 n-6) 
in the plasma of pre-eclamptic women in late pregnancy compared to healthy pregnant 
controls(260;262). The relative percentage of 18:1n-9 to total fatty  acids was found to 
increase and the relative percentage of linoleic acid (18:2 n-6) was found to decrease as 
pregnancy progressed in pre-eclamptic patients compared to healthy controls (260). Higher 
levels of arachidonic acid both as absolute levels (262)and as a percentage of total fatty 
acids  have  been  found  in  pre-eclampsia(263).  With  regard  to  n-3  fatty  acids,  lower 
absolute amounts of total n-3 fatty acids, EPA and DHA have been found in pre-eclamptic 
patients compared to healthy pregnant controls(261;264). A greater n-6: n-3 ratio has also 
been found in pre-eclamptic patients compared to healthy controls(264). While these fatty   61 
acid  changes  were  noted  in  maternal  plasma,  there  did  not  appear  to  be  any  studies 
measuring maternal erythrocyte cell membrane fatty acid changes in pre-eclampsia. 
 
 
1.5.6.3 Fatty acid utilisation by the fetus 
 
 
In the third trimester, the fetus begins to deposit fat subcutaneously and a healthy fetus at 
term  would  have  deposited  500g  of  fat  subcutaneously.  Fetal  adipose  tissue  is  rich  in 
saturated fatty acids, especially palmitic acid and oleic acid but is low in linoleic acid(265). 
In normal pregnancy, the developing fetus is dependent on the mother for its supply of 
essential fatty acids. Al et al showed supplementation of linoleic acid (n-6) rich foods from 
20 weeks gestation resulted in a significant increase in the total amount of n-6 PUFAs and 
a significant reduction in n-3 PUFAs(266), while fish oil supplements (rich in n-3 fatty 
acids) given from 30 weeks gestation onwards led to a significant increase in the total 
amount of n-3 PUFAs (including DHA) with a significant reduction in n-6 PUFAs in cord 
blood (267). In the last trimester of pregnancy, the fetal requirements of arachidonic acid 
and DHA as especially high as there is rapid development of fetal retinal as well as brain 
tissue(247;268). DHA is selectively accumulated in the membrane phospholipids of the 
developing fetal retina and the brain grey matter [reviewed in (268)] where it is involved in 
the  structure  and  function  of  the  retina  [reviewed  in  (269;270)].  A  reduction  in  DHA 
supply to the fetus has been found to be associated with visual and learning difficulties 
(268). Placental transfer of arachidonic acid and DHA from the maternal circulation into 
the placenta occurs by active transport by fatty acid binding proteins and arachidonic acid 
and DHA are preferentially taken up by the placenta compared to their parent fatty acids 
linoleic acid and α-linolenic acid(269;271;272). 
 
 
1.6  Aims and objectives 
 
 
Pre-eclampsia is a state of enhanced coagulation as evidenced by an increased amount of 
clotting  factors  in  maternal  circulation  and  increased  fibrin  deposition  in  the  placenta. 
Microparticles are released from apoptotic cells and may have procoagulant properties. 
Microparticle levels have been found to be raised in various prothrombotic diseases. My   62 
primary hypothesis is that there may be a relationship between microparticle procoagulant 
activity and coagulation in the placenta as well as maternal circulation. 
 
 
1.6.1  Coagulation in the placenta 
 
 
There  is  greater  trophoblast  apoptosis  in  pre-eclampsia  and  IUGR  and  microparticles 
(which may be procoagulant in nature) are released from apoptotic cells and this may lead 
to fibrin deposition. Annexin V is located on the maternal surface of syncytiotrophoblasts 
and has anticoagulant properties. Tissue factor is expressed by the placenta and is a potent 
initiator  of  coagulation.  I  hypothesise  that  there  may  be  associations  between  fibrin 
deposition, annexin V and tissue factor expression in pre-eclamptic, healthy and IUGR 
placentas. Immunocytochemistry was chosen as the method to localise fibrin, annexin V 
and tissue factor staining within the placenta. Back-to-back staining was used as a method 
to identify any relationships between these stainings. 
 
 
1.6.2  Coagulation in maternal systemic circulation 
 
 
The levels of circulating microparticles in plasma have been found to be raised in various 
prothrombotic  diseases.  As  pre-eclampsia  is  a  pro-thrombotic  state  with  associated 
endothelial  activation,  platelet  activation  and  trophoblast  apoptosis,  microparticles  may 
play a significant part in this procoagulant state. Microparticle procoagulant activity has 
previously been measured using a plate-based microparticle capture assay(65). I wished to 
develop  and  validate  this  assay  to  measure  microparticle  procoagulant  activity  in  pre-
eclamptic patients and matched healthy pregnant control patients to identify if there is any 
difference in microparticle procoagulant activity between these two groups. With greater 
trophoblast  apoptosis  in  pre-eclampsia,  the  placenta  may  be  a  significant  source  of 
microparticles in maternal circulation. The measure of fetal CRH mRNA in maternal blood 
would  allow  the  identification  and  measure  of  placental  cellular  debris  in  maternal 
circulation.  
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In  pre-eclampsia,  there  is  coagulation  activation,  endothelial  activation  and  reduced 
placental function. I hypothesised that there may be a relationship between microparticle 
procoagulant  activity  as  well  as  placental  cellular  debris  with  coagulation  activation, 
endothelial  activation  and  placental  function  in  pre-eclamptic  and  healthy  pregnant 
patients. 
 
 
1.6.3  Fatty acid changes in pre-eclampsia 
 
 
Fatty acids of the n-6 and n-3 groups are precursors towards the synthesis of thromboxane 
and prostacyclin. The n-6 fatty acids are the precursors of the potent 2-series thromboxanes 
while n-3 fatty acids are precursors of the less potent 3-series thromboxanes. Thromboxane 
is a potent platelet aggregatory factor as well as vasoconstrictor. Pre-eclampsia is a state of 
enhanced  coagulation  along  with  maternal  hypertension,  placental  ischemia  and 
insufficiency.  In  pre-eclampsia,  there  is  greater  thromboxane  and  lesser  prostacyclin 
synthesis by the placenta. There is also greater thromboxane-induced platelet aggregation 
in pre-eclampsia. I hypothesised that maternal fatty acid patterns may be different between 
pre-eclamptic and healthy pregnant women, which may lead to a shift of balance towards 
the  synthesis  of  greater  amounts  of  the  potent  thromboxane  A2.  There  may  also  be  a 
relationship  between  the  maternal  fatty  acid  composition  with  maternal  coagulation 
activation,  endothelial  function  and  placental  function  in  pre-eclamptic  and  healthy 
pregnancies. Fatty acid composition was measured by gas chromatography.   64 
 
Chapter 2  Methodology 
 
2.1  Ethics approval 
 
 
This project was approved by the Ethics Committee of North Glasgow NHS Trust at 
Glasgow Royal Infirmary and all recruits gave written informed consent. 
 
 
2.2  Pre-eclamptic, healthy and type II diabetic subjects 
 
 
2.2.1  Pre-eclamptic cases and healthy pregnant controls 
 
 
Pre-eclamptic and healthy pregnant matched controls were recruited as the primary test 
subjects of this project. Pre-eclamptic patients and matched healthy pregnant controls were 
recruited in their third trimester of pregnancy (28 to 40 weeks’ gestation) from Glasgow 
Royal  Infirmary  Maternity  Unit.  There  were  32  pre-eclamptic  patients  and  32  healthy 
pregnant controls recruited into this study. They were matched by age (+/- 2 years), body 
mass index (BMI +/- 2 kg/m
2) and parity (0, 1, greater than 1). Pre-eclamptic patients were 
defined using the International Society for the Study of Hypertension in Pregnancy criteria 
(diastolic blood pressure greater than 110mmg Hg on one occasion, or greater than 90 
mmHg on repeated readings, with proteinuria of greater than or equal to 0.3g / 24 hours or 
2+ proteinuria on dipstick testing in the absence of renal disease or infection). Patients 
were excluded from this study if they had multiple gestation, any medical conditions which 
led to a procoagulant state or if they were on any anticoagulant medication such as aspirin 
or  heparin.  Patients  with  any  suspected  fetal  anomalies  which  were  likely  to  lead  to 
intrauterine growth restriction were also excluded. 
 
 
All pre-eclamptic and healthy pregnant controls were not in labour at the time of sampling. 
For each patient, blood pressure, smoking status as well as any treatment for hypertension 
was noted. Eleven pre-eclamptic patients were on labetalol at the time of sampling. These   65 
patients  were  on  treatment  for  less  than  3  days  prior  to  blood  sampling.  Pregnancy 
outcome data such as the mode of delivery, fetal weight, and sex of the fetus was obtained 
from the patients’ notes after delivery. Placental weight was not always obtainable as it 
was seldom recorded. The fetal weight values were converted into birth weight centiles 
calculated using the Gestation Network Centile calculator version 5.4 from: 
 
 
http://www.gestation.net/birthweight_centiles/centile_online.htm 
 
 
2.2.2  Healthy volunteers 
 
 
Healthy  subjects  were  recruited  as  a  pilot  study  to  assess  the  range  of  microparticle 
procoagulant activity in healthy population. Healthy lab staff volunteers who did not have 
any medical problems and who were not on any medication were recruited. A total of 13 
volunteers were recruited. 
 
 
2.2.3  Complicated and uncomplicated type II diabetic patients 
 
 
Type II diabetes is a chronic disease marked by high blood glucose levels which occurs as 
a result of insulin resistance. Diabetes may lead to retinopathy, neuropathy, nephropathy 
and  cardiovascular  disease  and  patients  who  develop  these  conditions  are  defined  as 
‘complicated diabetics’. Diabetics without symptoms or signs of these complications are 
defined  as  ‘uncomplicated  diabetics’.  Higher  microparticle  levels  have  been  found  in 
complicated type II diabetic patients compared to uncomplicated type II diabetics (273). 
This may translate to greater microparticle pro-coagulant activity in complicated type II 
diabetics compared to uncomplicated controls. Type II diabetic patients with and without 
complications  were  recruited  as  a  pilot  study  to  assess  if  differences  in  microparticle 
procoagulant  activity  could  be  found  between  complicated  and  uncomplicated  type  II 
diabetic patients. This data would also inform the power calculation for the main study. 
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Type II diabetic patients who attended for their annual review at the diabetic outpatients 
department at Glasgow Royal Infirmary were recruited. Six patients with complications of 
diabetes (3 with ischaemic heart disease, 2 with neuropathy and 1 with retinopathy) and 10 
uncomplicated diabetics were recruited into the study. Patients were excluded from this 
study if they had any other medical conditions which predisposed them to a procoagulant 
state.  Patients  who  were  taking  anticoagulant  medication  such  as  aspirin,  heparin  or 
warfarin were also excluded. 
 
 
2.3  Blood and placental tissue collection and storage 
 
 
2.3.1  Blood collection and storage 
 
 
Approximately  50  mls  blood  was  taken  by  venepuncture  from  pregnant  women  into 
various Vacutainer blood tubes (Becton Dickinson Pty Ltd): 15% EDTA (10mls volume), 
0.105 M citrate (4.5mls volume), 145 i.u lithium heparin (6mls volume), plain silicone 
(6mls  volume)  and  fluoride/oxalate  (2mls  volume).  With  regards  to  complicated  and 
uncomplicated diabetic and healthy volunteer groups, 10mls of blood was collected from 
each individual into 0.105M citrate Vacutainer tubes. All samples were immediately put on 
ice and transferred to the lab. The samples were then spun for 20 minutes at 2000g at a 
temperature of 4ºC to separate plasma from blood cells. The plasma from all samples was 
immediately aliquoted and stored in a -80ºC freezer. Packed cells from EDTA tubes were 
removed  and  stored  in  a  -80°C  freezer.  The  collection  of  platelet-poor  plasma  was 
achieved by spinning the plasma collected in 0.105M citrate tubes at 13000g for 4 minutes 
to pellet the platelets to the bottom of the tube. The supernatant (now platelet-free) was 
removed and stored in a -80ºC freezer for later analysis. 
 
 
2.3.2  Placental tissue collection and storage 
 
 
The  placental  samples  analysed  were  archival  samples  held  at  the  department  of 
reproductive medicine, Glasgow Royal Infirmary. The samples were previously obtained 
by other researchers and collected with informed consent. Samples were analysed from 6   67 
(a) 
(b) 
(c) 
(d) 
IUGR pregnancies, 6 pre-eclamptic pregnancies, 6 healthy first trimester and 6 healthy 
third trimester pregnant controls. The procedure for placental sample collection was thus; 
the placenta was immediately brought to the lab once delivered. Samples of approximately 
2 cubic centimeters in size were taken randomly from 4 quadrants of the placenta, then 
immediately and copiously washed in Phosphate Buffered Saline (PBS). These samples 
were then fixed in 10% buffered formalin (BDH, UK) for 24 hours, followed by 50% 
ethanol for 8 hours and finally 70% ethanol for 24 hours. These placental samples were 
then brought to the Pathology Department of Glasgow Royal Infirmary to be embedded 
into paraffin blocks. 
 
 
2.4  Immunocytochemistry (ICC) 
 
 
Immunocytochemistry  is  the  application  of  immunological  methods  to  cells  or  tissue 
sections to enable protein visualization by the demonstration of a marker conjugated to the 
final  reactant.  The  method  employed  was  the  avidin-biotin  complex  (ABC)  method, 
diagrammatically shown in figure 2.4.1 where (a) is the tissue antigen (b) the primary 
antibody  (c)  the  biotinylated  secondary  antibody  and  (d)  the  avidin-biotin  peroxidase 
complex. 
 
 
 
 
 
 
 
 
 
 
Figure  2.4.1:  The  Avidin-Biotin  Complex  [adapted  from  the  Handbook  of 
Immunochemical Staining Methods, 3
rd Edition, Boenisch et al 2001 (274)]. 
 
 
Annexin V, fibrin, tissue factor and M30 cytodeath immunostaining within the placental 
tissues were studied. Tissue sections were prepared from paraffin embedded tissue using a   68 
microtome (Leica model RM2135), cutting sections of 5µm thickness. In back-to-back 
section preparations, consecutive sections were taken and stained for comparison. Slides 
were  placed  in  plastic  racks,  heated  in  an  oven  at  56°C  for  35  minutes  and  then 
deparafinised using xylene 2 x 10 minutes. They were then rehydrated through graded 
alcohols: 100% ethanol for 2 x 5 minutes, 95% ethanol for 2 x 5 minutes, 70% ethanol for 
1 x 5 minutes and finally Phosphate Buffered Saline (PBS) (1.2g NaH2PO4, 9.0g NaCl, 1L 
distilled  water,  pH  7.6)  for  5  minutes.  Endogenous  tissue  peroxidase  activity  was 
inactivated by immersion in freshly prepared 0.5% hydrogen peroxide (prepared using 5 
ml of 30% hydrogen peroxide in 300 ml methanol) for 30 minutes. Samples were then 
washed twice for 10 minutes in PBS.  
 
 
Antigen retrieval was performed by microwaving for 5 minutes under pressure. One litre of 
0.01M  citrate  buffer  (pH  6.0)  was  prepared  and  poured  into  a  sealed  container.  This 
solution was brought to boil within the microwave oven, the slides added, the container 
covered, locked and then further boiled at full power for 8 minutes (the container was at 
pressure  after  3  minutes,  leaving  the  slides  to  be  microwaved  for  5  minutes  under 
pressure). The slides were then allowed to cool within the sealed container for 20 minutes 
and  then  washed  in  water  for  5  minutes  followed  by  PBS  for  2x5  minutes.  Antigen 
retrieval  was  not  performed  in  the  preparation  of  annexin  V  slides.  Wax  rings  were 
carefully drawn around the sections and the samples were blocked with the appropriate 
serum (see table 2.4.1) in PBS for 30 minutes at room temperature in a humidified box. 
Excess serum was tapped off. The primary antibody was diluted in serum, added to each 
slide and incubated overnight for 16 hours at 4°C in a humidified box (see table 2.4.1 for 
details). The samples were then washed with PBS for 2 x 5 minutes.  
 
 
The secondary antibody was prepared by diluting the appropriate serum with 5% human 
serum added. Details of the secondary antibody and diluting serum are shown in table 
2.4.2.  This  prepared  secondary  antibody  was  added  to  the  slides  and  incubated  for  30 
minutes at room temperature in a humidified box. The samples were then washed in PBS 
for 2 x 5 minutes. Positive controls are listed in table 2.4.3. For negative controls, the 
tissue of interest was incubated with the primary antibody substituted with a monoclonal 
IgG  mouse  antibody  (DAKO  code  no.  X  09312)  directed  towards  Aspergillus  niger 
glucose oxidase which is an enzyme neither present nor inducible in mammalian tissues.   69 
 
 
 
Antigen  Pre-
treatment 
Blocking serum  Primary 
antibody 
Type  Diluting 
serum 
Dilution 
factor 
Source 
Annexin V  none  20% rabbit / 
20% human 
serum 
Goat anti-
human 
annexin V 
 
 
Poly 
IgG 
2% rabbit 
serum 
1:500  Santa Cruz 
(SC-1929) 
Fibrin  microwave 
citrate buffer, 
pH 6.0 
20% horse / 
20% human 
serum 
Mouse 
anti-human 
fibrin 
 
 
Mono 
IgG 
2% horse 
serum 
1:200  Immunotech 
(Cat. No 0541) 
Tissue 
Factor 
microwave  20% horse / 
20% human 
serum 
Mouse 
anti-human 
tissue 
factor 
 
Mono 
IgG 
2% horse 
serum 
1:50  Calbiochem 
(Cat.No 612161) 
M30 
Cytodeath 
microwave  20% horse / 
20% human 
serum 
Mouse 
anti-human 
M30 
cytodeath 
Mono  2% horse 
serum 
1:10  Roche 
Molecular 
Biochemicals  
Cat. No 2 140 
322 
 
Table 2.4.1: Primary antibodies and blocking serum 
 
 
Antigen  Secondary antibody  Diluting serum  Dilution factor 
Annexin V  Biotinylated anti-goat 
IgG 
2% rabbit serum with 5% 
human serum added 
1:200 
 
Fibrin  Biotinylated anti-
mouse IgG 
2% horse serum with 5% 
human serum added 
1:200 
 
Tissue Factor  Biotinylated anti-
mouse IgG 
2% horse serum with 5% 
human serum added 
1:200 
 
M30 Cytodeath  Biotinylated anti-
mouse IgG 
2% horse serum with 5% 
human serum added 
1:200 
 
 
Table 2.4.2: Secondary antibodies and diluting serum 
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Antigen  Positive control tissue 
Annexin V  Placenta 
Fibrin  Placenta and decidua 
Tissue Factor  Breast tissue 
M30 Cytodeath  Tonsil 
 
Table 2.4.3: Positive controls 
 
 
Preparation of the avidin/biotin solution was as described by the manufacturer Vectastain 
ABC (Vector Laboratories) working solutions kit instructions. The avidin/biotin solution 
was added to the slides and incubated for 30 minutes at room temperature in a humidified 
box. The slides were then washed in PBS for 2 x 5 minutes. Diaminobenzidine (DAB) 
solution (1 DAB tablet [DAB/Sigma UK] in 15mls of 50mM Tris with 12µl 30% hydrogen 
peroxide, pH 7.6) was prepared, added to cover each slide and left for 10 minutes at room 
temperature.  DAB  was  oxidised  by  the  peroxidase  attached  to  the  secondary  antibody 
forming an insoluble brown precipitate. The DAB solution was tapped off into sodium 
hypochlorite to be inactivated and the slide was washed in water for 5 minutes. The slides 
were then counterstained with Harris haematoxylin (Sigma) for 15-20 seconds and then 
washed in running tap water. The samples were dehydrated through alcohols (70%, 90%, 
95%, and 100%) to xylene. Finally they were mounted in DPX. 
 
 
An Olympus BX50 microscope equipped with x4, x10, x20 and x40 lenses, connected to a 
3-CCD colour camera (JVC) was used for digital image capture of the slides. Computer 
visualisation of the images was achieved with the image analysis program Image-Pro Plus 
version 4.5.1 (Media Cybernetics Inc). For back-to-back sections, the corresponding photo 
was taken and turned mirror-image by the Image-Pro Plus program to facilitate an easier 
comparison of the staining pattern between the two back-to-back slides. Adobe Photoshop 
Elements version 2.0 was used to correct any background discoloration (as a result of the 
microscope light source) as well as to insert text into the pictures. 
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2.5  Preparation of synthetic phosphatidylcholine: phosphatidylserine vesicles 
 
 
Synthetic phosphatidylcholine (PC): phosphatidylserine (PS) vesicles were prepared as per 
the method of Pigault et al(275) to be used as a standard in the prothrombinase assay to 
measure the procoagulant activity of microparticles in blood samples. 
 
 
2.5.1  Materials and reagents 
 
 
NaCl  and  chloroform  were  purchased  from  BDH  Lab  Supp.  NaN3,  Hepes,  Lα-
phosphatidylcholine  (PC)  and  Lα-phosphatidylserine  (PS)  was  purchased  from  Sigma 
Chemical Co. N-octyl βD-glucopyranoside (β-OG) was purchased from Roche Chemical 
Co. Spectra/Por No.1 dialysis tubing was purchased from Spectrum Laboratories Inc. 
 
 
The following reagents were prepared: 
 
Buffer  A:  This  solution  was  made  with  HEPES  10mM,  NaCl  150mM,  NaN3  0.02%, 
distilled water and made to a pH of 7.4. 
 
40mg/ml Lα-phosphatidylcholine: 10mg Lα-phosphatidylcholine was dissolved in 250 l 
chloroform. 
 
5mg/ml  Lα-phosphatidylserine:  5mg  Lα-phosphatidylserine  was  dissolved  in  1000 l 
chloroform. 
 
20% N-octyl βD-glucopyranoside (β-OG): 0.5g β-OG was dissolved in 2.5mls chloroform. 
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2.5.2  Preparation of synthetic PC:PS vesicles 
 
 
Positive displacement pipettes were used. Lα-phosphatidylcholine (85 l of 40mg/ml) and 
Lα-phosphatidylserine (320 l of 5mg/ml) were added into a glass tube, covered with metal 
foil and shaken gently. To this, 2 mls of 20% N-octyl βD-glucopyranoside solution was 
added, the tubes covered with metal foil and shaken gently again. The tube was put into a 
rotary evaporator (Jouan RC10-22) and dried for 2 hours at 55°C +/- 5° resulting in a 
pearly white residue at the bottom of the tube. The tube was then removed and allowed to 
cool. Two mls of buffer A solution was then added, vortexed gently until the pearly white 
residue at the bottom of the tube had completely dissolved. The solution was then allowed 
to stand for 1 hour. The solution was then poured into a Spectra/Por No.1 Dialysis tube and 
was dialysed against 200mls buffer A with gentle stirring of the buffer. Three bath changes 
of 200mls buffer A were performed with 24 hours between each bath change. The solution 
was then removed and stored in glass screw cap tubes. This solution of PC: PS vesicles had 
a concentration equivalent to 1mM phosphatidylserine.  
 
 
2.6  Preparation of microparticles from BeWo cell culture 
 
 
BeWo cells are a commercially available choriocarcinoma cell line. Induced apoptosis of 
BeWo  cells  in  culture  by  tumour  necrosis  factor  alpha  (TNFα)  and  interferon  gamma 
(IFNγ) would lead to the release of ‘natural’ microparticles into the culture medium. These 
microparticles  could  then  be  isolated  and  utilised  as  a  standard  in  the  prothrombinase 
assay. These ‘natural’  microparticles would have externalised phosphatidylserine on its 
surface as well as contain various cell membrane lipids and proteins that would stabilise 
these microparticles in storage. 
 
 
2.6.1  BeWo cell culture 
 
 
BeWo  cells  were  obtained  from  ATCC  (catalogue  number:  CCL98)  and  grown  as  per 
manufacturers instructions. BeWo cells were cultured in Hams medium (ICN 12-467-S4),   73 
10% Foetal Calf Serum (Sigma F9665), 1% Penicillin/Streptomycin (Gibco BRL 15140-
122), 1% 200mM Glutamine (ICN 1680149) and 1% Fungazone (ICN 16-723-48). BeWo 
cells were cultured in flasks with 15 mls of culture medium in each flask. These flasks 
were stored in the incubator at 37°C (5% CO2), vented and the medium was changed every 
other day. BeWo cells were subcultured once a week and were grown to confluence of 60 
to 70%. 
 
 
2.6.2  Preparation  of  tumour  necrosis  factor  α  (TNFα)  and  interferon  γ 
(IFNγ) solutions 
 
 
Tumour  necrosis  factor  alpha  (TNFα)  [R+D  systems  210-TA]  was  made  up  to  a 
concentration  of  1 g/ml  in  PBS.  Interferon  gamma  (IFNγ)  [R+D  systems  285-IF]  was 
made up to a concentration of 2 g/ml in PBS. These solutions were stored at -20°C until 
use. 
 
 
2.6.3  Stimulation of microparticle release from BeWo cell culture 
 
 
Apoptosis was induced by adding 150 l of 1 g/ml TNFα and 75 l of 2 g/ml IFNγ into 
each flask to give a final concentration of 10ng/ml TNFα and 10ng/ml IFN in each flask. 
The culture was then incubated for another 24 hours at 37°C. The culture medium was then 
removed and centrifuged for 20 minutes at 2000g to remove any non-adherent cells, then 
the  supernatant  further  ultracentrifuged  at  13000g  for  4  minutes.  The  supernatant  was 
removed and 5 mls Biostab biomolecule stabilising storage solution (Fluka 92889, Sigma-
Aldrich)  added.  This  supernatant  was  then  measured  for  microparticle  activity  in  the 
prothrombinase  assay.  In  cases  where  further  concentration  was  required  to  increase 
microparticle  pro-coagulant  activity,  this  was  performed  by  dialysis  through  a  semi-
permeable membrane on sucrose. Storage for analysis was in a 4°C fridge. 
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2.7  Prothrombinase assay 
 
 
The prothrombinase assay was chosen as a method to measure the procoagulant activity of 
microparticles in the blood sample. The method of Aupiex et al (65) was used. This assay 
is  based  on  the  principle  that  phosphatidylserine  is  externalised  on  the  surface  of 
microparticles  and  phosphatidylserine  catalyses  the  conversion  of  prothrombin  to 
thrombin. The prothrombinase assay captures microparticles in the sample and measures 
the coagulation potential of microparticles in the sample by quantifying the amount of 
thrombin generated. 
 
 
2.7.1  Materials 
 
 
NaCl, KCl, CaCl2, EDTA, NaOH pellets and HCl were purchased from BDH Lab Supp. 
Human  Serum  Albumin  (HSA)  and  Tris  were  purchased  from  Sigma  Chemical  Co. 
Annexin-V-Biotin,  Streptavidin  coated  96  well  microtitration  plates,  Factor  Xa  and 
Chromozym  TH  were  purchased  from  Roche  Chemical  Co.  D-Phe-Pro-Arg-
chloromethylketone  HCL  (PPACK)  and  1-5  Dansyl-Glu-Gly-Arg-chloromethylketone 
DiHCL  (DnsGGACK)  were  purchased  from  Calbiochem  Chemicals.  Factor  Va  was 
purchased from American Diagnostica Inc and prothrombin was purchased from Hyphen 
Biomed. 
 
 
2.7.2  Assay reagents 
 
 
TBS-Calcium solution: Tris 50mM, NaCl 120mM, KCl 2.7mM, CaCl2 1mM, pH of 7.5. 
 
TBS-Calcium HSA 0.3% (TBS-Ca-HSA): Human serum albumin (HSA) was added to TBS-
Calcium solution and made up to a concentration of 3g/L. 
 
Annexin-V-Biotin 350ng/ml: Annexin-V-Biotin (0.1  g/ l concentration) was diluted into 
TBS-Ca-HSA (175  l into 49825  l) to make a 50 ml solution. This was stored as 2ml 
aliquots at -20°C.   75 
 
CaCl2 13mM solution: CaCl2 (14.4mg) was dissolved into 10 mls TBS-Ca-HSA. 
 
Factor Va 3.6nM: Factor Va (5 l of 15.5 M) was added to 210  l TBS-Ca-HSA to make a 
final concentration of 360nM. This was stored as 10 L aliquots at -20°C. Prior to use, 
990 l TBS-Ca-HSA was added to make a 3.6nM solution. 
 
Factor Xa 500pM: Factor Xa (10 l of 350 M) was added to 7mls TBS-Ca-HSA to make a 
500nM solution. This was stored at -20°C. Prior to use, 5 l was added to 4995 l TBS-Ca-
HSA to make 500pM solution. 
 
Prothrombin 3.9M: TBS-Ca-HSA (3.6mls) was added to 13.9nmols prothrombin to make a 
3.9 M solution for immediate use. 
 
Chromozym TH 1.52mM: Distilled water (19.87mls) was added to 30.2 mols Chromozym 
to make a final concentration of 1.52mM. This was stored at 4°C. 
 
EDTA  25mM:  This  was  prepared  by  adding  2.326  g  EDTA  to  250mls  distilled  water. 
NaOH pellets were gradually added until EDTA dissolved. The pH was adjusted to 8.0 and 
the solution was then stored at room temperature until ready for use. 
 
PPACK 1mM: PPACK (5mg) was dissolved in 9.54 mls of 10mM HCl solution to make a 
1mM concentration of PPACK. 
 
1-5 Dansyl-GGACK 1mM: 1-5 Dansyl-GGACK (5mg) was dissolved in 7.15mls of 10nM 
HCl solution to make a 1mM concentration of DnsGGACK. 
 
HCl 10mM: This was made by diluting 87 l of 11.5M HCl with 100ml distilled water. 
 
CaCl2 1M: This was made by dissolving 11.099g CaCl2 in 100mls distilled water. 
 
‘Inhibitor mix’: This was prepared by adding 5.5mls of 1mM PPACK, 5.5mls of 1mM 
GGACK  and  14.85  mls  of  1M  CaCl2  to  24.15mls  TBS-Ca  solution  and  the  pH  was 
adjusted to 7.4. This was stored in aliquots of 1ml at -20°C. 
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‘Master mix’: The amounts and reagents required for each well was 15 l of 13mM CaCl2, 
15 l  of  3.6nM  FVa,  15 l  of  500pM  FXa  and  55 l  of  TBS-Ca-HSA.  To  calculate  the 
amount of ‘master mix’ required for the assay, the total number of wells to be used was 
determined.  The  required  amounts  of  each  reagent  were  then  mixed  to  make  a  single 
solution of ‘master mix’ and 100 l of this ‘master mix’ was added into each well. 
 
 
2.7.3  Methodology of prothrombinase assay 
 
 
Into each well of a streptavidin coated 96 well microtitration plate, 100µl of 350ng/ml 
Annexin-V-Biotin (Roche) in TBS-Ca-HSA was added. This was incubated at 37ºC for 30 
minutes with gentle shaking. The plate was washed 3 times with 250µl TBS-Ca-HSA per 
well. ‘Inhibitor mix’ (10 l) was added into each well followed by 100µl of the sample to 
be  measured.  For  negative  control  wells,  100 l  TBS-Ca-HSA  was  used.  This  was 
incubated at 37ºC for 30 minutes with gentle shaking. Each well was then washed out 3 
times with 250µl TBS-Ca-HSA. ‘Master mix’ (100 l) was added into each well followed 
by 50µl of 3.9µM prothrombin solution. The plate was incubated at 37ºC for 30 minutes 
with gentle shaking.  EDTA (50 l of 25nM) was then added into each well. The plate was 
immediately brought to the plate reader. Chromozym TH (50µl of 1.52nM) was added into 
each well, the plate was gently shaken and immediately put into the microtitration plate 
reader  equipped  with  kinetics  software.  Linear  absorbance  changes  were  recorded  at 
405nm wavelength over 20 minutes. 
 
 
2.8  Fetal corticotrophin-releasing hormone (CRH) mRNA measurement 
 
 
While maternal CRH mRNA is undetectable in the maternal systemic circulation, fetal 
CRH mRNA has been detected in maternal plasma in healthy pregnancy and levels have 
found to increase as pregnancy progresses. As CRH has been immuno-localised to the 
placental syncytiotrophoblast layer, the measurement of fetal CRH mRNA can therefore be 
used as a measure of placental-derived cell debris in maternal systemic circulation. The 
method of Ng et al was used(106) 
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Maternal plasma was collected in EDTA and stored in a -80°C freezer as described in 
section  2.3.1.  When  required,  the  plasma  sample  was  thawed;  1.6mls  removed  and 
centrifuged at 16000g for 10 minutes at 4°C.  The supernatant was removed and 2mls of 
Trizol  LS  (Invitrogen)  added  to  the  pellet.  The  RNA  was  then  isolated  as  per  the 
manufacturer’s instructions. The RNA in ethanol was concentrated on an RNeasy mini 
column (Qiagen) and eluted in 30mls RNase-free water according to the manufacturer’s 
instructions. Dithiothreitol (0.3 l, 1nM) and 40 Units RNaseOUT (Invitrogen) were then 
added into each RNA sample before storing at -80°C. This RNA (4 l) was then reverse 
transcribed to cDNA in a final reaction volume of 20 l using a High Capacity cDNA 
Archive kit (from Applied Biosystems, 4322171). The CRH and GAPDH mRNA levels 
were  then  quantified  (in  triplicate)  in  2 l  cDNA  using  commercially  available  primer 
probes sets (Hs00174941_ml and 4310884E respectively from Applied Biosystems) on a 
ABI/7900 sequence detection system (Applied Biosystems) according to the manufactures 
instructions. TaqMan Universal Master Mix, No Amperase UNG was used in a final assay 
volume of 50 l and the number of PCR cycles was increased to 60. Expression of CRH 
was expressed relative to the expression of GAPDH(106) (as an index of total plasma 
RNA). The ratio of CRH to GAPDH was calculated by subtracting the Ct values (threshold 
cycle - logarithmic) values (delta Ct), taking the antilog and multiplying by 100. Ct values 
for  the  control  gene  GAPDH  did  not  differ  between  pre-eclampsia  and  control  groups 
(median Ct 33.0 vs. 33.8, p=0.18). 
 
 
2.9  Markers  of  coagulation  activation,  endothelial  activation  and  placental 
function 
 
 
The blood samples to be analysed were collected and stored as detailed in section 2.3.1. 
Coagulation markers, markers of endothelial activation and markers of placental function 
were analysed using commercially available kits as detailed in table 2.9.1. 
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2.10  Erythrocyte cell membrane fatty acid composition 
 
 
2.10.1  Extraction of fatty acids from erythrocyte cell membranes 
 
 
The method of Stewart et al was used (249). Packed erythrocyte samples were collected 
and stored as detailed in section 2.3.1. Total fatty acid extraction from erythrocyte cell 
membranes was performed by a modified Folch extraction. Packed erythrocytes (400 l) 
were suspended in 10nM Tris buffer at pH 7.0 and incubated at room temperature for 30 
minutes. They were then centrifuged in a Beckman L8-60M Ultracentrifuge Type 50.4 
rotor (Fullerton, CA, USA) at 49000rpm at 4°C for 30 minutes. The erythrocyte membrane 
pellet was then resuspended in 200 l of distilled water and 150 l was transferred to a glass 
screw-top tube. Methanol:toluene at 4:1 ratio (2mls) containing heneicosanoic acid internal 
standard (0.2mg C21H42O2/ml toluene) was then added followed by 200 l of 100% acetyl 
chloride while mixing. The tubes were capped, sealed with teflon tape, and then heated at 
100°C  for  1  hour.  When  cooled,  10%  K2CO3  (3mls)  was  slowly  added  to  each  tube 
followed by 100 l toluene. The tube was then centrifuged for 8 minutes at 3000 rpm, 5°C 
and the upper toluene phase was then transferred to gas chromatography vials and stored at 
-20°C. 
 
 
2.10.2  Identification and quantification of fatty acids 
 
 
Fatty acid analysis was carried out using gas chromatography. Methyl fatty acids were 
separated (1 L injection volume), identified and quantitated on a Shimadzu GC 17A gas 
chromatograph (Kyoto, Japan) using flame ionisation detection and Class VP software. A 
DB-23 fused silica capillary column (J&W Scientific, Folson, CA, USA), 30m x 0.25mm 
internal diameter with a film thickness of 0.25 m was used in conjunction with a Hewlett-
Packard 7673B on-column auto-injector (Palo Alto, CA, USA). Ultra high purity hydrogen 
and  air  was  used  as  carrier  gases  at  a  flow  rate  of  2mL/min.  A  temperature  gradient 
programme was used with an initial temperature of 150°C, increasing at 20°C/min up to 
190°C, then at 5°C/min up to 210°C, then at 2°C/min up to 230°C and then at 4°C/min up 
to 240°C (final time 18.5 minutes), and with an equilibration time of 1 minute. The total 
programme time was 22 minutes. The identification of fatty acid methyl esters was made   79 
by comparison with the retention times of authentic standard mixtures (fatty acid methyl 
ester mixture no. 189-19, product no. L9405, Sigma, Stockholm, Sweden). Absolute values 
of  fatty  acids  were  calculated  by  comparison  against  the  heneicosanoic  acid  internal 
standard. Percentage values of fatty acids were calculated as a percentage of total fatty 
acids in the sample. 
 
 
Measure  Method  Manufacturer of assay kit 
Coagulation markers     
TF  ELISA  Imubind, American Diagnostica, Axis-
Shield 
TFPI  ELISA  Imubind, American Diagnostica, Axis-
Shield 
TAT  ELISA  Enzygnost, Dade Behring 
 
F1+2  ELISA  Enzygnost, Dade Behring 
 
FVIIc  assayed in MDA 180 
coagulometer 
reagents from Biomerieux Ltd, 
Basingstoke, UK 
FXIIa  ELISA  Shield Diagnostics, Axis-Shield 
 
APC  assayed in MDA 180 
coagulometer 
Chromogenix APC resistance kit, 
Quadratech, UK 
PAI-1  ELISA  Tint-Elize, Alpha Laboratories 
 
Markers of endothelial activation 
 
sICAM-1  ELISA  R&D Systems 
 
sVCAM-1  ELISA  R&D Systems 
 
vWF  ELISA  Imubind, American Diagnostica, Axis-
Shield 
Marker of placental function 
 
PAI-2  ELISA  Imubind, American Diagnostica, Axis-
Shield 
 
Table 2.9.1: List of commercially available kits used in the measurement of coagulation 
markers, markers of endothelial activation and marker of placental function. 
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2.11  Statistical analysis 
 
 
An a priori sample size calculation was based on data from a study of acute coronary 
syndrome patients which observed a 2-fold increase in microparticles above control(69). A 
sample size of 8 predicted 95% power at the 5% significance level to detect a difference of 
20%  in  microparticle  levels  measured  with  a  10%  standard  deviation.  All  statistical 
analysis was performed using Minitab version 13.32. 
 
 
2.11.1  Prothrombinase  activity,  measures  of  coagulation  activation, 
endothelial activation, placental function and fetal CRH mRNA measurement 
 
 
The Ryan-Joiner test was used to assess the distribution of values for normality. It was 
found that to achieve a normal distribution, values of F1+2, PAI-1, PAI-1/PAI-2 ratio and 
the microparticle prothrombinase activity required to be transformed to log values. The 
values of sVCAM-1 and TAT required to be transformed to square root values. Analysis 
for  significant  differences  was  carried  out  using  two-sample  T-tests  for  continuous 
variables,  on  transformed  data  where  necessary  and  using  the  chi-square  test  for 
categorical variables. To analyse for correlations, Pearson’s correlation coefficients were 
measured, using transformed data where necessary. As the CRH/GAPDH mRNA ratio of 
some samples included some zero values, the Wilcoxon rank sum test was used to test the 
difference between groups and Spearman rank correlation analysis was used. Multivariate 
analysis was used to assess the independence from smoking by using a General Linear 
Model.  For  the  purposes  of  multivariate  analysis,  the  CRH/GAPDH  mRNA  ratio  was 
divided  into  3  categories:  equal  to  0,  range  from  0  to  1.0  and  range  greater  than  1.0. 
Statistical significance was set at p<0.05. 
 
 
2.11.2  Fatty acids 
 
 
The Ryan-Joiner method was used to assess the distribution of values for normality. It was 
found that to achieve a normal distribution, the percentage values of 24:0, 22:6 n-3 and the 
absolute value of 22:6 n3 required to be transformed to log values.  Analysis for significant   81 
differences  was  carried  out  using  two-sample  T-tests  for  continuous  variables,  on 
transformed  data  where  necessary.  To  analyse  for  correlations,  Pearson’s  correlation 
coefficients  were  measured,  using  transformed  data  where  necessary.  Statistical 
significance was set at p< 0.005 to account for repeated analysis.   82 
 
Chapter 3  Immunocytochemical study of the relationship between 
annexin V, fibrin and tissue factor at the trophoblast 
 
3.1  Introduction 
 
 
3.1.1  Coagulation at the placenta 
 
 
Fibrin is the end product in the process of coagulation. While fibrin has a useful function 
by forming a plug to prevent blood loss from the vascular space, fibrin deposition on the 
surface of the syncytial layer of the placenta can physically obstruct and reduce the surface 
area available for feto-maternal exchange. Large clots may reduce the flow of blood within 
the  intervillous  space,  thus  impeding  fetal  growth  and  development.  Perivillous  fibrin 
deposition  is  a  normal  finding  in  healthy  placentas  but  excessive  perivillous  fibrin 
deposition has been found in conditions of IUGR and pre-eclampsia, both conditions that 
are associated with placental insufficiency(14;17;18). 
 
 
Annexin V is expressed constitutively by syncytiotrophoblast cells and annexin V has been 
localised  to  the  microvillous  surface  of  syncytiotrophoblast  cells.  Several  studies  have 
suggested  that  annexin  V  may  afford  the  syncytial  surface  protection  against  clot 
formation(45-47).  Therefore,  it  is  possible  there  may  be  a  relationship  between  the 
distribution of annexin V and fibrin deposition on the syncytial surface of the placenta. 
Annexin  V  staining  intensity  in  trophoblasts  have  been  found  to  be  reduced  in  pre-
eclamptic patients compared to healthy pregnant controls(39;48). 
 
 
Tissue factor (TF) is a powerful initiator of coagulation. In the coagulation cascade, TF 
combines with activated factor VII forming the activated factor VII-tissue factor (FVIIa-
TF) complex, a key step in coagulation activation. Cultured syncytiotrophoblast cells have 
been found to express TF(27). In healthy pregnancy, TF has been detected in the placenta 
and myometrium(25) and TF expression has also been localised to placental macrophages, 
endothelial  cells  and  fibroblast-like  cells  in  loose  connective  (26).  Estelles  et  al  noted   83 
greater amounts of TF antigen and TF mRNA in the placentas of women suffering severe 
pre-eclampsia with IUGR compared to healthy pregnant controls. 
 
 
3.1.2  Placental development 
 
 
In pregnancy, there is progressive remodelling and development within the placenta with 
constant turnover of the trophoblast layer of placental villi. The trophoblast layer consists 
of cytotrophoblasts and syncytiotrophoblasts. Cytotrophoblasts are the stem cells of and 
are located basal to the syncytiotrophoblasts (which is the trophoblast layer in contact with 
the  intervillous  space).  As  part  of  the  renewal  process  of  syncytiotrophoblasts, 
cytotrophoblast cells proliferate, differentiate and eventually become incorporated into the 
syncytiotrophoblast layer via syncytial fusion. As syncytiotrophoblasts age, their nuclei 
accumulate  and  become  packed  into  membrane-sealed  fragments  within  the  syncytium 
forming syncytial knots. These syncytial knots are eventually extruded into the intervillous 
space where they enter the maternal circulation and are eventually taken up by maternal 
macrophages (which occurs to a large degree in maternal lungs). In the first trimester, there 
is a greater cytotrophoblast volume in relation to syncytiotrophoblast volume. Towards the 
end  of  pregnancy,  the  syncytiotrophoblast  volume  becomes  greater  than  the 
cytotrophoblast  volume  and  there  is  also  a  greater  amount  of  syncytial  knots  and 
bridges(54). Cytotrophoblast cells can be visualised as a distinct layer in the first trimester 
but this layer becomes thinner and less distinct as pregnancy progresses. In comparison to 
placentas in healthy pregnancy, IUGR and pre-eclamptic placentas have a greater number 
of placental knots and bridges along with a greater degree of trophoblast apoptosis(20;56). 
 
 
Apoptosis  is  the  process  of  programmed  and  controlled  cell  death  which  is  initiated 
through the cleavage of native intracellular proteins by caspases (Cysteinyl-aspartic acid 
proteases). Apoptosis can be identified using cellular cytokeratin 18 which is cleaved in 
early  apoptosis.  M30  CytoDEATH  (Roche  Molecular  Biochemicals)  is  a  mouse 
monoclonal antibody that detects a specific caspase cleavage site within cytokeratin 18. 
Thus, M30 is a useful tool for identifying apoptotic cells. A previous study looking at M30 
localisation within the healthy placenta in the third trimester showed that the majority of 
M30  staining  was  localised  to  extravillous  trophoblasts  as  well  as  syncytiotrophoblast 
cells,  with  abundant  M30  staining  of  syncytiotrophoblast  cells  in  areas  of  greater   84 
perivillous fibrinoid deposition(50). As cytokeratin is located within the cell cytoplasm, 
M30 immunoreactivity is confined to the cytoplasm. However non-specific M30 staining 
of the nuclei of highly proliferating cells has also been recorded(51). 
 
 
3.1.3  Histological features of placental villi 
 
 
A  brief  review  of  healthy  placental  villi  would  be  useful  to  interpret  the 
immunocytochemical  findings  in  this  chapter.  In  first  trimester  placentas  both  the 
cytotrophoblast  and  syncytiotrophoblast  layers  are  clearly  seen  to  be  separate.  The 
syncytiotrophoblast layer has flattened nuclei, is the most superficial layer of the placental 
villi  and  is  in  direct  contact  with  the  intervillous  space.  The  cytotrophoblast  layer  is 
directly  under  the  syncytiotrophoblast  layer.  Cytotrophoblast  cells  appear  cuboidal  or 
ovoid in shape and have well demarcated cell borders with lightly staining large nuclei. 
Syncytial  sprouts  are  outgrowths  and  proliferation  of  chorionic  villi.  Syncytial  sprouts 
appear as a prolongation of the villous tip often with multiple syncytial nuclei present at 
the end. The stromal core of each placental villous is comprised of collagen fibres with 
fibroblasts, tissue macrophages (Hofbauer cells), mast cells, plasma cells and capillaries. 
The space between the placental villi is the intervillous space within which flows maternal 
blood. 
 
 
As  the  placenta  develops,  the  cytotrophoblast  layer  becomes  thinned  and  the 
cytotrophoblast cells become incorporated into the syncytial layer by membrane fusion. In 
comparison to first trimester placentas, third trimester placentas have a very much thinner 
cytotrophoblast  layer  as  most  cytotrophoblast  cells  have  differentiated  and  become 
incorporated  into  the  syncytial  layer  at  this  stage.  The  syncytial  layer  is  variable  in 
thickness. It may be thinned to become the vasculosyncytial membrane or the nuclei may 
be piled up in areas forming syncytial knots. Syncytial bridges can also be seen and they 
are  a  result  of  fusion  of  adjacent  villi.  On  the  intervillous  space  side  of  the 
syncytiotrophoblast cell membrane, there are numerous microvilli present and on higher 
magnification, can be identified as a fuzzy appearance on the cell surface. Stem villi are 
present which are large villi involved in the physical support of the villous tree. Larger 
stem villi may have a central artery and vein within the stroma with branching vessels and 
capillaries leading to terminal villi. Villous arteries and veins have an endothelial lining.   85 
Terminal villi appear as bulbous structures and may be single or have side branches. They 
have a thin trophoblastic surface in close contact with the dilated capillaries within. 
 
 
3.1.4  Hypothesis 
 
 
There is greater trophoblast apoptosis in pre-eclampsia and IUGR in comparison to healthy 
pregnancy and this may lead to greater microparticle generation. Microparticles may be 
procoagulant and this may lead to fibrin deposition. Annexin V is located on the maternal 
surface of syncytiotrophoblasts and has anticoagulant properties. Tissue factor is expressed 
by the placenta and is a potent initiator of coagulation. I hypothesise that there may be 
associations between fibrin deposition, annexin V expression and tissue factor expression 
in pre-eclamptic, healthy and IUGR placentas.  
 
 
Objectives: 
 
1)  Identify  areas  of  fibrin  staining  in  healthy  pregnant,  IUGR  and  pre-eclamptic 
placentas. 
 
2)  Identify areas of annexin V staining in healthy pregnant, IUGR and pre-eclamptic 
placentas. 
 
3)  To  investigate  a  possible  relationship  between  annexin  V  expression  and  fibrin 
deposition in healthy pregnant, IUGR and pre-eclamptic placentas using back-to-
back samples. 
 
4)  To  investigate  a  possible  relationship  between  annexin  V  expression  and  TF 
expression in healthy pregnant, IUGR and pre-eclamptic placentas using back-to-
back samples. 
 
5)  Identify areas of apoptosis in healthy pregnant, IUGR and pre-eclamptic placentas 
using the M30 antibody as a marker for apoptotic cells. 
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3.2  Results 
 
 
Six first trimester placentas, six third trimester placentas, six IUGR placentas and six pre-
eclamptic placentas were stained for annexin V, fibrin and tissue factor. For M30 staining, 
placental  samples  from  eight  first  trimester  aborted  pregnancies  and  two  healthy  third 
trimester  pregnancies  that  were  delivered  normally  were  analysed.  All  samples  were 
archival samples. 
 
 
3.2.1  Fibrin localisation in first and third trimester healthy placentas, IUGR 
and pre-eclamptic placentas 
 
 
In  healthy  first  trimester  placentas,  there  were  a  few  sporadic  areas  of  fibrin  (Fib) 
deposition seen (as a brown precipitate) at x 10 magnification. There was perivillous fibrin  
staining seen at lower magnification (figure 3.2.1.1 A). At higher magnification, fibrin was 
identified on the maternal surface of syncytiotrophoblast cells (figure 3.2.1.1 B). The large 
areas of perivillous fibrin deposition appeared to have a foundation on the surfaces of 
syncytiotrophoblasts. Some typical characteristics of first trimester placenta are seen in 
figures 3.2.1.1 A and 3.2.1.1 B: for example the syncytial sprouts (SySp) and the clearly 
defined  and  abundant  cytotrophoblast  (CyT)  layer  (with  large  pale  staining  cuboidal-
shaped nuclei) separate from the syncytiotrophoblast layer (SyT). In healthy third trimester 
placentas,  perivillous  fibrin  (Fib)  deposition  appeared  to  be  more  widespread  in 
comparison to first trimester samples (figure 3.2.1.2 A, B). Once again, the foundation for 
the  deposition  of  fibrin  appeared  to  be  the  syncytiotrophoblast  layer  (SyT)  (figure 
3.2.1.2B). Various characteristics of the third trimester placenta were present, such as the 
thin cytotrophoblast layer, with just the syncytial layer visible in some parts of the villi 
surface.  There  was  also  greater  development  of  the  placental  villi,  with  branching  of 
intermediate  villi  into  terminal  villi  and  syncytial  knots  (SyKn).  There  was  fibrin 
deposition within the villous capillaries (Cap) (figure 3.2.1.2 B). 
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Figure 3.2.1.1:  Fibrin staining in healthy first trimester placenta at x 10 
magnification (A) and x 100 magnification (B).  
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Figure 3.2.1.2: Fibrin staining in healthy third trimester placenta at x 10 
magnification (A) and x 40 magnification (B).   89 
 
In IUGR placentas, perivillous fibrin (Fib) deposition was widespread. There appeared to 
be a greater amount of syncytial knots and bridges (figure 3.2.1.3 A, B) and the terminal 
villi appeared smaller and shorter compared to samples from healthy pregnancies. There 
was also a ‘congested’ appearance to the distribution of villi. In pre-eclamptic placentas, 
large areas of fibrin staining were seen at the perivillous areas (figure 3.2.1.4 A). There 
appeared  to  be  a  greater  amount  of  syncytial  knots  and  bridges  compared  to  healthy 
pregnant samples. On higher magnification (figure 3.2.1.4 B), there appeared to be fibrin 
staining of some syncytial knots. The terminal villi appeared short and branched. 
 
 
3.2.2  Annexin V localisation in third trimester healthy placentas, IUGR and 
pre-eclamptic placentas 
 
 
In healthy third trimester samples, localisation of annexin V (AnnV) was clearly identified. 
The distribution was extensive and was mainly localised to the syncytiotrophoblast layer 
(SyT). Annexin V was seen in the trophoblast layer of all villi types, from stem villi (SV) 
to terminal villi (TV) (figure 3.2.2.1A). However at higher magnification, there were areas 
of absent annexin V staining at the syncytiotrophoblast and in these areas, there appeared 
to be less numbers of syncytial nuclei seen (figure 3.2.2.1 B). 
 
 
In  IUGR  placentas,  there  appeared  to  be  larger  areas  of  absent  annexin  V  staining 
compared to healthy third trimester samples (figure 3.2.2.2 A, B) and in some areas of 
absent  annexin  V  staining,  there  appeared  to  be  an  associated  loss  of  underlying 
trophoblast  and  stromal  architecture  (figure  3.2.2.2  B).  In  these  areas  of  abnormal 
architecture, the trophoblast cell surface and trophoblast nuclei appeared indistinct. The 
underlying  stromal  tissue  appeared  disorganised  and  there  appeared  to  be  less  cellular 
nuclei seen. There were no clear features of fetal capillaries in these disorganised areas. In 
pre-eclamptic samples, there were also large areas of absent annexin V staining and this 
appeared greater in comparison to healthy third trimester samples. In these areas of absent 
annexin  V  staining,  there  were  large  areas  of  villi  with  underlying  loss  of  stromal 
architecture similar to that seen in IUGR samples (figures 3.2.2.3 A, B).   90 
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Figure 3.2.1.3: Fibrin staining in IUGR placenta at x 10 magnification (A) and x 
40 magnification (B). 
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Figure 3.2.1.4: Fibrin staining in pre-eclamptic placenta at x 10 magnification (A) 
and x 40 magnification (B). 
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Figure 3.2.2.1: Annexin V staining in healthy third trimester placenta at x 10 
magnification (A) and x 20 magnification (B)   93 
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Figure 3.2.2.2: Annexin V staining in IUGR placenta x 10 magnification (A) and x 
40 magnification (B).   94 
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Figure 3.2.2.3: Annexin V staining in pre-eclamptic placenta at x 10 magnification 
(A) and x 40 magnification (B). 
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3.2.3  Comparison  of  annexin  V  and  fibrin  localisation  in  back-to-back 
samples in healthy third trimester, IUGR and pre-eclamptic placentas 
 
 
 
In healthy third trimester samples, there appeared to be an inverse relationship between 
annexin V and fibrin staining. Where there was annexin V staining, there was little fibrin 
staining in the same area of the corresponding slide that was cut back-to-back. Conversely, 
in areas of minimal annexin V staining, there was strong fibrin staining in the same place 
on the corresponding slide (figures 3.2.3.1A to F). Essentially there appeared to be an 
inverse localisation between annexin V (AnnV) and fibrin (Fib) between corresponding 
slides that were cut back-to-back.  
 
 
In IUGR samples, there was also inverse localisation between the staining of annexin V 
and fibrin between corresponding back-to-back slides (as shown in figures 3.2.3.2 A to F). 
In figure 3.2.3.2A, numerous syncytial knots were present and these knots were stained 
with annexin V. In the back-to-back slide shown in figure 3.2.3.2B, there was little fibrin 
deposition on these knots. There was prominent fibrin staining in areas of disorganised villi 
architecture (figure 3.2.3.2D and figure 3.2.3.2F) both on the syncytial surface and within 
the underlying area of villous disorganisation. In pre-eclamptic samples, there was also 
inverse localisation between the staining of  annexin V and fibrin in the corresponding 
back-to-back slides (figure 3.2.3.3 A to F). This pattern was consistent for all of the slides 
examined.  Again,  there  was  prominent  fibrin  staining  in  areas  of  disorganised  villi 
architecture (figure 3.2.3.3 D). There was also the impression of more and larger areas of 
fibrin deposition in pre-eclamptic samples compared to samples from healthy pregnancies.   96 
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Figure 3.2.3.1: Inverse localisation between annexin V and fibrin immunocytochemical 
staining in healthy third trimester placentas at x 10 magnification [annexin V (A), fibrin 
(B)], x 20 magnification [annexin V (C), fibrin (D)] and x 40 magnification [annexin V 
(E), fibrin (F)].  
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Figure 3.2.3.2: Inverse localisation between annexin V and fibrin immunocytochemical 
staining in IUGR placentas at x 10 magnification [annexin V (A), fibrin (B)], x 20 
magnification [annexin V (C), fibrin (D)] and x 40 magnification [annexin V (E), fibrin 
(F)].   98 
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Figure 3.2.3.3: Inverse localisation between annexin V and fibrin immunocytochemical 
staining in pre-eclamptic placentas at x 10 magnification [annexin V (A), fibrin (B)], x 20 
magnification [annexin V (C), fibrin (D)] and x 40 magnification [annexin V (E), fibrin 
(F)]. 
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3.2.4  Comparison of annexin V and TF staining in back-to-back samples in 
normal, IUGR and pre-eclamptic placentas 
 
 
In healthy third trimester samples, very little tissue factor (TF) staining was seen with only 
approximately only 4 to 5 small areas of distinct TF seen throughout the whole slide. For 
example, only a single area of TF staining was seen as a brown precipitate in the middle of 
figure 3.2.4.1B at x 10 magnification. TF staining was mainly  at the trophoblast layer 
(figures  3.2.4.1  D  and  3.2.4.12  F).  There  was  very  little  TF  staining  within  the  fetal 
vascular endothelium in these healthy pregnancies. In comparison, there were large areas 
of  annexin  V  (AnnV)  staining  on  the  surface  of  the  syncytiotrophoblasts  with  some 
smaller areas of non-staining (figure 3.2.4.1 A). There was no clear relationship in staining 
pattern between annexin V and TF in these healthy pregnant samples (see figures 3.2.4.1 A 
to F). 
 
 
In IUGR samples, there were very few scattered small areas of TF staining throughout the 
whole slide (figure 3.2.4.2B). In back-to-back slides comparing TF with annexin V, there 
was  no  consistent  relationship  between  the  TF  and  annexin  V  staining.  For  example, 
comparing  between  figures  3.2.4.2C  with  3.2.4.2D  and  between  figures  3.2.4.2E  and 
3.2.4.2 F, there was TF staining in areas of annexin V staining and also TF staining in 
areas with no annexin V staining. In pre-eclamptic samples, there were very few scattered 
small areas of TF staining throughout the whole slide (shown in figure 3.2.4.3 B) but 
staining appeared to be at the trophoblast layer. In back-to-back slides comparing TF with 
annexin  V,  there  was  no  consistent  relationship  between  TF  and  annexin  V  staining 
patterns, (figures 3.2.4.3 C and D and figures 3.2.4.3 E and F). 
 
 
3.2.5  M30 localisation in first and third trimester healthy placentas 
 
 
In first trimester healthy placentas, there was distinct M30 staining at the trophoblast layer 
(figure 3.2.5.1A). There was greater M30 staining at the cytotrophoblast (CyT) compared 
to  the  syncytiotrophoblast  (SyT)  layer  and  this  is  quite  evident  when  seen  at  greater 
magnification at 40 x (figure 3.2.5.1B) and 100 x magnification (figure 3.2.5.1C). This   100 
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Figure 3.2.4.1: Annexin V and TF immunocytochemical staining in healthy third trimester 
placentas at x 10 magnification [annexin V (A), TF (B)], x 20 magnification [annexin V 
(C), TF (D)] and x 40 magnification [annexin V (E), TF (F)].  
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Figure 3.2.4.2: Annexin V and TF immunocytochemical staining in IUGR placentas at x 
10 magnification [annexin V (A), TF (B)], x 20 magnification [annexin V (C), TF (D)] and 
x 40 magnification [annexin V (E), TF (F)].  
   102 
 
A              B 
 
 
 
C              D 
 
 
 
E              F 
 
 
Figure 3.2.4.3: Annexin V and TF immunocytochemical staining in pre-eclamptic 
placentas at x 10 magnification [annexin V (A), TF (B)], x 20 magnification [annexin V 
(C), TF (D)] and x 40 magnification [annexin V (E), TF (F)].  
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Figure 3.2.5.1: M30 staining of first trimester placenta at x  10 magnification (A), 
x 40 magnification (B) and x100 magnification (C).    104 
may represent non-specific staining of the nuclei of the proliferating cytotrophoblast cells. 
There was also some staining of the nucleus of some stromal cells which appear to be 
fibroblasts with their elongated spindle shaped cells.  
 
 
In third trimester healthy  placentas, M30 staining was present at the trophoblast layer. 
However there appeared to be a lesser degree of M30 trophoblast staining in third trimester 
placentas  compared  to  first  trimester  placentas  (figure  3.2.5.2  A,  B).  At  higher 
magnification (figure 3.2.5.2 B), M30 staining was found to be present mainly at the nuclei 
of cytotrophoblast cells with very little M30 staining of the cytoplasm. 
 
 
3.3  Discussion 
 
 
It  is  known  that  initial  deposition  of  fibrin  leads  to  a  cascade  reaction  that  leads  to 
elongation of the fibrin polymer chain leading to the formation of a blood clot. I was 
interested in identifying areas of fibrin deposition in healthy first trimester, healthy third 
trimester, IUGR and pre-eclamptic placentas as perivillous fibrin deposition on the surface 
of  the  trophoblast  can  act  as  a  barrier  between  feto-maternal  exchange,  which  can 
ultimately affect fetal wellbeing. 
 
 
Perivillous fibrin deposition was found to be present in healthy first and third trimester, 
IUGR and pre-eclamptic placentas but there appeared to be a greater amount of fibrin 
deposition  in  pre-eclamptic  and  IUGR  placentas  compared  to  healthy  first  and  third 
trimester placentas. Perivillous fibrin deposition was found to be present on many syncytial 
knots (which are composed of ageing syncytiotrophoblast nuclei prior to extrusion as part 
of the process of villous trophoblast apoptosis  and turnover(52)) and  Nelson et al has 
shown apoptotic changes in the syncytiotrophoblast in areas of fibrinoid deposit(34). It is 
known that apoptotic cells expose phosphatidylserine on the cell surface which is pro-
coagulant and can lead to lead to coagulation and subsequent fibrin deposition. Therefore, 
this deposition of fibrin on syncytial knots may reflect syncytiotrophoblast apoptosis in 
these  knots.  This  impression  of  greater  amount  of  fibrin  deposition  in  IUGR  and  pre-
eclamptic samples was not quantitated however. Quantitation may have been achieved by 
simply directly classifying each fibrin deposit in an area of the slide as small, medium, or   105 
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Figure 3.2.5.2: M30 staining of third trimester healthy placenta at x 10 
magnification (A) and x100 magnification (B).  
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large and the total value added up. This should be done with at least two independent 
observers to reduce operator error. Alternatively stereology could be employed for a more 
quantitative answer. 
 
 
The results from immunocytochemical staining showed that annexin V was present on the 
surface of syncytiotrophoblasts but annexin V staining was found to be discontinuous in 
some  parts.  This  pattern  was  present  in  all  healthy,  IUGR  and  pre-eclamptic  sample 
groups. It was noted that when compared to healthy placentas, IUGR and pre-eclamptic 
placentas appeared to have greater areas of absent annexin V staining (denudation). Some 
areas of annexin V denudation appeared to be located at areas of the placental villi where 
there  was  no  clear  appearance  of  normal  syncytial  cell  morphology  and  where  the 
underlying stromal tissue also appeared disorganised with no clear features of stromal cells 
or blood vessels, thus appearing rather amorphous. It is possible these amorphous areas 
represented areas of villi infarction as infarcted areas of placental villi would not be able to 
sustain  its  trophoblast  layer  thus  leading  to  syncytial  death  with  the  resultant  loss  of 
annexin V expression. However, in some areas of annexin V denudation on the syncytial 
surface, there was normal appearance of underlying villi cellular architecture. Here, the 
lack of annexin V may possibly be due to syncytiotrophoblast damage or apoptosis thus 
leading to reduced annexin V expression. These mechanisms would be in keeping with the 
greater amount of placental infarction and trophoblast damage in the conditions of IUGR 
and pre-eclampsia. 
 
 
As annexin V prevents coagulation, I was interested to discover if there was a correlation 
between the distribution of annexin V expression on the syncytiotrophoblast surface and 
areas of TF expression and areas of fibrin deposition. Back-to-back slides of annexin V 
and fibrin revealed that in areas of annexin V denudation, there was often fibrin deposition 
in the same area in the corresponding slide (inverse localisation). This fibrin deposition 
also often extended into the underlying areas of amorphous-looking stroma in the villi. 
Perivillous fibrin deposition of the intervillous space also occurred in some of these areas. 
This pattern was consistent in all healthy, IUGR and pre-eclamptic samples although it was 
noted that in contrast to healthy pregnant placentas, IUGR and pre-eclamptic placentas 
seemed to have greater areas of annexin V denudation with associated greater areas of 
fibrin staining in the corresponding slides. This would be in keeping with the findings of 
Shu  et  al  who  found  plasma  level  of  the  fibrin  degradation  products  and  thrombin-  107 
antithrombin III complex from pre-eclamptic patients were elevated as the expression of 
annexin V in the placenta was reduced(48). 
 
 
As TF is a potent initiator of coagulation, one might expect that there would be greater 
expression of TF in the areas where there is absent annexin V staining. Certainly, high 
levels  of  TF  as well  as TF mRNA have been  found in the placentas  of pre-eclamptic 
women compared to healthy pregnant controls(29). However there were only very sporadic 
areas of TF staining found (3 to 6 small areas of TF staining per slide) in the placental 
samples of the healthy pregnant, IUGR and pre-eclamptic pregnancies despite the large 
amounts of perivillous fibrin deposition in IUGR and pre-eclamptic placental samples. A 
simple explanation is that there was only very little TF expression in the placenta. Estelles 
et  al  did  not  find  any  appreciable  expression  of  TF  in  either  healthy  or  pre-eclamptic 
placentas although they found a five-fold increase in the amounts of TF mRNA in pre-
eclamptic  compared  to  healthy  placentas(29).  Perhaps  placental  TF  only  becomes 
expressed in more severe pre-eclampsia. It is also possible that as TF is such a potent 
initiator  of  coagulation,  even  slight  expression  of  tissue  factor  in  the  placenta  would 
immediately  lead  to  the  deposition  of  fibrin,  thereby  preventing  the  primary  antibody 
directed towards TF from attaching. As a result of sub-optimal TF staining, a comparison 
of back-to-back staining between TF and fibrin was not possible during this project. It 
would have been interesting to see if there was an increased deposition of fibrin even on 
these very small areas of TF expression in the placenta. 
 
 
It is possible that annexin V prevents coagulation on the trophoblast surface and this may 
be  the  mechanism  by  which  the  placenta  prevents  excessive  fibrin  deposition  on  its 
syncytial  surface  thereby  facilitating  effective  feto-maternal  transfer.  An  absence  of 
annexin V on the surface of the syncytium may lead to fibrin deposition leading to reduced 
feto-maternal  exchange,  subsequent  trophoblast  death  and  followed  by  underlying  villi 
death  and  necrosis.  This  might  explain  the  areas  of  disorganised  villi  architecture 
underlying areas of annexin V denudation. On the other hand, these amorphous areas may 
represent areas of villi infarction as a result of placental vessel thrombosis, villi hypoxia 
and subsequent syncytial death with subsequent loss of annexin V synthesis and expression 
on the syncytiotrophoblast. IUGR and pre-eclamptic placentas had greater areas of annexin 
V denudation with associated greater fibrin deposition in those areas when compared to 
placentas from healthy pregnant individuals. It is likely that the greater syncytial damage in   108 
the conditions of IUGR and pre-eclampsia is reflected in loss of annexin V expression. 
IUGR and pre-eclampsia are also associated with greater placental infarction and this may 
lead  to  villi  ischemia,  loss  of  annexin  V  synthesis  and  subsequent  perivillous  fibrin 
deposition. Another possibility is there may be reduced expression of annexin V in the 
conditions  of  IUGR  and  pre-eclampsia  compared  to  healthy  pregnancy.  A  way  of 
investigating  this  possibility  would  be  by  measuring  and  comparing  total  annexin  V 
mRNA in the placenta of healthy, IUGR and pre-eclamptic pregnancies. 
 
 
M30 was used as a marker to identify cellular apoptosis within the trophoblast layer in first 
and third trimester samples in healthy pregnancies. In first trimester samples, there was 
abundant M30 staining of cytotrophoblast nuclei but little staining of the cytotrophoblast 
cytoplasm. While M30 was utilised as a marker to identify apoptotic cells, it is known that 
M30  can  also  stain  the  nuclei  of  actively  proliferating  cells(51).  The  high  number  of 
cytotrophoblast cell nuclei stained by M30 in the first trimester compared to third trimester 
placenta samples suggests that there was a large degree of cytotrophoblast cell proliferation 
occurring in the first trimester. This is in keeping with the function of cytotrophoblast cells 
being the stem cells of the syncytium, actively proliferating and differentiating into the 
syncytiotrophoblast. Staining of trophoblastic sprouts was also seen, possibly reflecting the 
developing  placenta  where  the  villi  are  actively  growing  and  the  placental  sprouts  are 
remodelling and forming new villi. In the third trimester, there were less cytotrophoblasts 
present and less staining of cytotrophoblast nuclei compared to the first trimester samples. 
This may simply reflect a lower degree of trophoblast proliferation in the third trimester 
compared to the first trimester. The uncertainty over the M30 staining meant that it was not 
possible to investigate any relationship between apoptosis and fibrin deposition or annexin 
V expression in the trophoblast. Perhaps another marker of apoptosis may be employed 
and this may be scope for future work. 
 
 
The main aim of this chapter was to investigate the role of annexin V and apoptosis in 
coagulation  in  pre-eclamptic  placentas.  IUGR  and  pre-eclamptic  placentas  appeared  to 
have greater amounts of fibrin deposition in the perivillous spaces compared to healthy 
pregnancies and this is in keeping with current literature. However, I have discovered that 
there is a relationship of inverse localisation between annexin V and fibrin staining on the 
surface  of  the  syncytiotrophoblasts  in  healthy  pregnant,  IUGR  and  pre-eclamptic 
pregnancies. This suggests that annexin V on the surface of the trophoblast may confer   109 
anticoagulant properties to the placental villi. With regard to TF, there were only a few 
sporadic areas of TF staining in the placentas of healthy pregnant, IUGR and pre-eclamptic 
pregnancies and there was no clear relationship identified between annexin V expression 
and TF expression in these placentas. M30 staining for apoptotic cells was not satisfactory 
and  I  was  therefore  unable  to  identify  if  there  was  any  association  between  cellular 
apoptosis and annexin V, TF expression and fibrin deposition in the placenta.  
 
 
There was the impression of a greater amount of fibrin deposition on the trophoblasts of 
pre-eclamptic  pregnancies  compared  to  healthy  pregnancies.  Microparticles  are 
prothrombotic and the level of microparticles in the systemic circulation has previously 
been  found  to  be  raised  in  various  prothrombotic  conditions  such  as  acute  coronary 
syndrome,  diabetes,  paroxysmal  nocturnal  haemoglobinuria  and  severe  hypertension. 
Microparticle levels have also been found to be raised in late miscarriages(74), suggesting 
they may play a part in placental thrombosis(276). It is possible that there may also be 
greater  levels  or  procoagulant  activity  of  microparticles  in  pre-eclampsia  which  may 
contribute  to  the  procoagulant  state  of  pre-eclampsia.  In  the  next  chapter,  I  set  out  to 
develop an assay to measure the pro-coagulant activity of microparticles in maternal blood 
in pre-eclamptic and healthy pregnant women.   110 
Chapter 4  Microparticle procoagulant activity and placental debris in 
pre-eclampsia 
 
 
4.1  Introduction 
 
 
In mammalian cells, cell membrane phospholipids are asymmetrically distributed with PS 
normally maintained at the inner leaflet of cell membranes by an active process. When the 
cell undergoes activation or apoptosis, PS becomes externalised onto the outer surface of 
the cell membrane by a ‘phospholipid scramblase’ pathway. The cell membrane then forms 
blebs  which  are  released  into  the  blood  circulation  as  microparticles(277). 
Phosphatidylserine is a phospholipid and is known to provide a surface for the conversion 
of prothrombin to thrombin by various clotting factors(278;279). Phosphatidylserine now 
located on the external surface of microparticles, would be in a position to act as a surface 
upon which these clotting factors assemble, forming the prothrombinase complex which 
then catalyses the conversion of circulating prothrombin to thrombin. 
 
 
Microparticles are procoagulant in nature and levels of circulating microparticles in blood 
have  previously  been  quantified  using  flow  cytometry.  Flow  cytometry  has  several 
advantages. It can identify the subpopulation of cells from which the microparticles are 
derived  by  using  an  appropriate  fluorescent  antibody  (for  example  fluorescein 
isothyocyanate [FITC]-conjugated monoclonal antibody) specific to that cell population. 
The  total  amount  of  microparticles  in  the  sample  can  also  be  measured  using  FITC-
conjugated annexin V which binds to all microparticles in the sample. In pre-eclampsia, 
microparticles  from  different  cell  subpopulations  such  as  endothelial,  T-helper,  T-
suppressor, granulocyte and platelets have been measured and all have been found to be 
raised compared to healthy pregnant controls(80;87;89), although one study found lower 
levels of platelet-derived microparticles(86). Despite differences in microparticle levels in 
these cell subpopulations, no difference was found in the total amount of microparticles 
(from all cells of origin) between pre-eclamptic and healthy control groups(86;87). While 
flow cytometry is a useful technique to quantify the amount of microparticles in a sample, 
it  has  a  disadvantage  in  that  it  cannot  measure  the  actual  procoagulant  activity  of 
microparticles in the sample.   111 
One  of  the  primary  aims  of  this  thesis  is  to  measure  the  procoagulant  activity  of 
microparticles in the maternal blood of pre-eclamptic and healthy pregnant controls as well 
as  to  relate  microparticle  pro-coagulant  activity  to  markers  of  coagulation,  endothelial 
function and placental function. While the amounts of microparticles have previously been 
measured by other researchers, I was interested in measuring the procoagulant activity of 
microparticles.  Aupeix  et  al(65)  used  a  plate-based  prothrombinase  assay  to  measure 
procoagulant activity of microparticles in HIV patients. This assay worked by measuring 
the  amount  of  thrombin  generated  from  prothrombin  via  the  phosphatidylserine  (PS) 
component  of  microparticles.  The  amount  of  thrombin  generated  was  then  used  as  a 
surrogate  end-point  to  determine  the  procoagulant  potential  of  microparticles  in  the 
sample. This assay measured the procoagulant activity of all microparticles in the blood 
sample, regardless of its cell of origin and whether they were of placental or maternal 
origin. 
 
 
Aside from the determination of the procoagulant activity of microparticles in maternal 
blood, I was also interested in measuring the amount of placental-derived microparticles in 
maternal  blood.  The  syncytiotrophoblast  layer  of  the  placenta  is  in  direct  contact  with 
maternal blood. In healthy pregnancy, constant placental remodelling and renewing of the 
syncytiotrophoblast layer results in apoptosis of syncytiotrophoblasts (9) and this has been 
proposed to result in the shedding of syncytiotrophoblast membrane fragments(STBMs) 
into the maternal side of placental circulation(76). Microparticles are also released from 
apoptotic  cells  and  therefore,  it  is  possible  that  STBMs  are  placentally-derived 
microparticles.  As  microparticles  are  known  to  be  procoagulant,  so  may  STBMs.  In 
comparison to healthy pregnancy, there is greater placental apoptosis in pre-eclampsia. 
This may lead to greater amounts of microparticles of syncytiotrophoblast origin which 
may contribute to the overall procoagulant state of pre-eclampsia. 
 
 
Fetal  CRH  is  synthesised  by  the  placenta  in  large  amounts  and  its  synthesis  has  been 
localised to the trophoblast(98). When microparticles bleb off from the cell membrane, 
they  are  released  as  little  packets  which  contain  cytoplasm  from  the  cell  of  origin. 
Microparticles  from  the  trophoblast  would  therefore  contain  within  them  fetal  CRH 
mRNA. As maternal CRH mRNA is  undetectable in the maternal systemic circulation(98), 
any measurable CRH mRNA in maternal circulation would originate from the placenta. 
However it is possible that not just microparticles but cellular fragments released from   112 
damaged trophoblasts, for example, may also contain fetal CRH mRNA. Thus any measure 
of fetal CRHmRNA would include a measure of these cell fragments. It would therefore be 
appropriate to collectively term both microparticles and cellular fragments as ‘placental 
cellular debris’. The amount of fetal CRH mRNA was measured as a ratio of CRH to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). At the time of commencement of 
this project, measurement of placental-derived microparticles had not been done although 
subsequently Goswami et al(81) measured syncytiotrophoblast microparticle levels using 
an  anti-trophoblast  antibody  (NDOG2).  This  antibody  was  not  commercially  available 
however.  
 
 
4.2  Principle of the prothrombinase assay 
 
 
The principle of this prothrombinase assay is the capture of PS-expressing microparticles 
using a specific binding protein and quantification of the procoagulant activity of these PS-
expressing microparticles using a chromogenic substrate. The method of Aupeix et al(65) 
was used in the development of this prothrombinase assay. In their assay, results were 
expressed as nanomolar PS equivalents with reference to a standard curve created from 
synthesised  phosphatidylcholine:  phosphatidylserine  (PC:PS)  vesicles  of  known 
composition. I prepared synthetic PC:PS vesicles according to the method of Pigault et 
al(275), as detailed in Chapter 2 of this thesis. This method resulted in the production of 
vesicles  with  a  concentration  of  1mM  phosphatidylserine  in  solution,  i.e:  1mM 
phosphatidylserine equivalents (PS equivalents).  
 
 
4.3  Steps of the prothrombinase assay 
 
 
The different steps of the prothrombinase assay were as follows, with reference to figure 
4.3.1. Biotinylated annexin V was added to the streptavidin-coated wells of a microtiter 
plate and incubated for 30 minutes (Step 1). Biotinylated annexin V became bound to 
streptavidin in the wells with the result that the wells became lined with annexin V (Step 
2). Excess biotinylated annexin V was then washed out and ‘Inhibitor mix’ was then added 
into the well (Step 3). ‘Inhibitor mix’ is a mixture of Phe-Pro-Arg-Chloromethylketone 
[PPACK  (a  rapid  inhibitor  of  thrombin)]  and  1-5  Dansyl-Glu-Gly-Arg-  113 
Chloromethylketone  [DnsGGACK  (an  inhibitor  of  factor  Xa)]  and  ‘inhibitor  mix’ 
functions to inactivate any endogenous thrombin or factor Xa (which converts prothrombin 
to thrombin) that may be present in the sample. 
 
 
The sample to be measured was then added into the well (Step 4) and incubated for 30 
minutes, allowing any PS-containing particles in the sample to be captured by annexin V 
lining the wells (Step 5). The wells were then washed out. ‘Master mix’ (a mix of factor 
Va, factor Xa and calcium chloride in buffer) was then added into the well (Step 6). The 
activated factor V, activated factor X and calcium in the ‘master mix’ assembles on the 
phospholipid surface of the captured microparticle, forming the prothrombinase complex. 
Prothrombin  was  then  added  into  the  wells  (Step  7)  and  was  converted  by  the 
prothrombinase complex assembled on the surface of captured microparticles to thrombin 
during incubation over 30 minutes. The conversion of prothrombin to thrombin was then 
halted by the addition of ethylenediaminetetraacetic acid (EDTA) which chelates calcium, 
which is essential to the functioning of the prothrombinase complex (Step 8). The amount 
of thrombin generated by the prothrombinase complex would be a surrogate measure of the 
procoagulant activity of captured microparticles in the sample. 
 
 
The amount of thrombin generated was quantified by the addition of chromozym TH (a 
chromogen that is converted to a yellow-coloured end product by thrombin) into the well 
(Step 9). The plate was immediately put into a microtitration plate reader to quantify the 
change in optical density of chromozym TH over time (OD/time) at 405nM wavelength 
(Step 10) over the course of 20 minutes. The rate of conversion of chromozym TH to its 
coloured end product is related to the amount of thrombin present, which is in turn related 
to the amount of prothrombinase complex formed by captured microparticles. In this way, 
the procoagulant activity of the microparticles in the sample could be measured. The rate 
of colour change of chromozym TH in an unknown sample is compared to a standard 
curve created by synthetic phosphatidylcholine: phosphatidylserine (PC: PS) vesicles of 
known concentration.   114 
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Step 1: Addition of biotinylated annexin V (Bi-V) into streptavidin coated well. 
 
 
 
 
 
 
 
 
 
Step 2: Annexin V lining the well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3: ‘Inhibitor mix’ added. 
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Step 4: Addition of the sample to be measured (eg. patient’s plasma). 
 
 
 
 
 
 
 
 
 
 
Step 5: Annexin V lining the well captured PS-expressing microparticles from the sample. 
 
 
 
 
 
 
 
 
 
 
Step 6: Addition of ‘master mix’ (a mix of factor Va, factor Xa and calcium chloride in 
buffer) which together with the captured PS formed the prothrombinase complex. 
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Step 7: Prothrombin was converted to thrombin by the prothrombinase complex. 
 
 
 
 
 
 
 
 
 
 
 
Step 8: Addition of EDTA to stop the conversion of prothrombin to thrombin after 30 
minutes. 
 
 
 
 
 
 
 
 
 
Step 9: Chromozym TH is added and was converted to a coloured end-product by the 
generated thrombin. For purposes of clarity, annexin V-Biotin and captured PS particles 
are not shown in the diagram. 
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Step 10: Intensity of the end-product of chromozym TH was quantified in a plate reader 
equipped with kinetics software. Colour change was recorded at set time intervals. 
 
 
Figure 4.3.1: The steps of the prothrombinase assay   118 
 
4.4  Hypotheses and objectives 
 
 
There  is  greater  maternal  endothelial  activation,  platelet  activation  and  trophoblast 
apoptosis in pre-eclampsia and I hypothesise that this may lead to greater microparticle 
generation. This may in turn lead to greater microparticle procoagulant activity in maternal 
blood.  I  also  hypothesised  that  greater  trophoblast  apoptosis  and  possibly  trophoblast 
damage in pre-eclampsia may lead to greater levels of cellular debris of placental origin in 
maternal blood and this debris may contribute to the overall procoagulant activity of total 
microparticles in maternal blood. 
 
Objectives: 
 
1)  To  set  up  and  validate  a  prothrombinase  assay  to  measure  microparticle 
procoagulant activity in blood. 
 
2)  To  recruit  healthy  individuals  and  type  II  diabetics  (with  and  without  diabetic 
complications) in order to pilot the prothrombinase assay. 
 
3)  To recruit pre-eclamptic and healthy pregnant matched controls to measure and 
compare their microparticle procoagulant activity in maternal blood. 
 
4)  To measure the amount of fetal CRH mRNA in maternal blood in pre-eclamptic 
and healthy pregnant matched controls as a measure of placental cell debris. 
 
 
4.5  Development of the prothrombinase assay 
 
 
4.5.1  Concentration: activity relationship 
 
 
The  concentration-activity  relationship  was  first  determined  for  the  standard  vesicles. 
Several dilution series of synthetic PC: PS vesicles were performed to identify a linear 
relationship  between  the  change  in  OD/minute  [measured  as  Absorbance  Units/minute   119 
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(AU/min)] with increasing concentrations of synthetic vesicles. It was found that a linear 
relationship  between  concentration  and  activity  existed  in  the  concentration  range  of 
between 0-50nM PS equivalents (figure 4.5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.1: Concentration: activity relationship of synthetic PS: PC vesicles 
 
 
4.5.2  Assay validation 
 
 
In  order  to  validate  the  assay,  inter-vesicle  preparation,  intra-assay  and  inter-assay 
reproducibilities  were  assessed.  The  inter-vesicle  preparation  variability  was  calculated 
using 3 independently prepared synthetic vesicle preparations (svA, svB and svC) prepared 
and  analysed  on  the  same  day  using  the  same  plate.  The  vesicles  were  analysed  at  a 
concentration range from 0nM to 50nM PS equivalents. All 3 preparations gave a similar 
curve  (figure  4.5.2.1).  Analysis  of  the  slopes  of  the  trendlines  of  all  samples  gave  a 
coefficient of variation of 9.09% (mean 0.0011, SD 0.001 AU/min/nM). 
 
 
The intra-assay variability was analysed by measuring samples of synthetic PC:PS vesicles 
at  20nM  PS  equivalents  in  8  consecutive  wells.  This  was  performed  on  3  different 
preparations (svA, svB and svC) all measured in the same assay. The results are as shown  
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Figure 4.5.2.1: Inter-vesicle preparation variability of 3 separately prepared samples (svA, 
svB and svC). Standard error bars shown. 
 
 
in table 4.5.2.1. The coefficients of variation of the samples were 2.76% (svA), 3.77% 
(svB) and 1.21% (svC) respectively, giving an average coefficient of variation of 2.85% 
between the 3 preparations. 
 
 
In order to obtain the inter-assay variability, three separate prothrombinase assays were 
carried  on  the  same  sample  synthetic  vesicle  preparation  (svB)  on  different  days.  The 
results  are  as  in  figure  4.5.2.2.  It  was  found  that  the  prothrombinase  activity  of  these 
vesicles appeared to decline whilst in storage in a 4°C fridge. These assays were carried 
out 38 days, 43 days and 112 days after the vesicles were synthesized. A comparison of the 
slopes of the trendlines showed that there was a large drop in vesicle activity when stored 
for 112 days when compared to storage at 38 and 43 days [the gradient dropping from 
0.001 AU/min/nM (at 38 and 43 days storage) to 0.0004 AU/min/nM (at 112 days storage); 
a drop of 2.5 fold]. The inter-assay CV was 45.8%. These results suggested that there was 
degeneration of vesicle activity whilst in storage.  
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38 days storage
43 days storage
112 days storage
  Prothrombinase activity (AU/min) 
Well  Preparation svA  Preparation svB  Preparation svC 
1  0.040  0.038  0.038 
2  0.038  0.038  0.038 
3  0.038  0.038  0.038 
4  0.038  0.036  0.038 
5  0.037  0.038  0.039 
6  0.038  0.036  0.039 
7  0.038  0.036  0.038 
8  0.040  0.040  0.038 
Std deviation  0.00106  0.00141  0.00046 
Mean  0.0384  0.0375  0.0383 
Coefficient of 
variation (%) 
2.76  3.77  1.21 
 
Table 4.5.2.1: Measurement of intra-assay variation at 20nM PS equivalents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.2.2: Analysis of inter-assay variability. Note the progressive drop in vesicle 
activity  of  sample  svB  from  38  days  storage  to  112  days  storage.  Standard  error  bars 
shown. 
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4.5.3  Synthetic PC: PC vesicle stability 
 
 
The  results  so  far  suggested  that  these  PC:PS  synthetic  vesicles  could  be  synthesized 
relatively consistently but there appeared to be a decline in vesicle procoagulant activity 
over  time  whilst  in  storage.  A  possible  reason  for  the  reduction  in  activity  could  be 
degradation  of  the  synthetic  PC:PS  vesicles  whilst  in  storage.  In  order  to  test  this 
hypothesis, a new sample of PC:PS vesicles were made (labelled svD). Three different 
methods of storage (fridge, step-freezing and flash-freezing) were carried out using sample 
svD to identify if any one method was superior in maintaining vesicle activity. Fridge 
storage was in a 4°C fridge. In step-freezing, the sample was put in a 4° C fridge for an 
hour, followed by -20°C freezer for an hour and then finally stored in a -80°C freezer. In 
flash-freezing, the freshly made sample was immediately stored in a -80°C freezer. All 3 
samples were analysed on the same day of preparation (day 1), after 2 days, after 10 days, 
after 16 days and after 30 days in storage. The results showed that there was a drop in 
vesicle activity in all 3 methods of storage compared to the fresh sample. The drop was 
greatest within the first 2 days with little further degradation from 2 to 30 days storage. In 
all 3 methods of storage, the slope of the activity vs. concentration curve went from 0.0029 
AU/min/nM for the day 1 sample, dropping to between 0.0012 and 0.0015 AU/min/nM for 
the stored samples (table 4.5.3.1). This showed a drop in activity of between 1.9 to 2.4 
fold. It was evident that none of these 3 methods of storage were able to preserve the 
activity of these vesicles (figures 4.5.3.1 to 4.5.3.3). 
 
Storage 
(days) 
Fridge 
(AU/min/nM) 
Step freezing 
(AU/min/nM) 
Flash freezing 
(AU/min/nM) 
1  0.0029  0.0029  0.0029 
2  0.0015  0.0014  0.0015 
10  0.0014  0.0013  0.0014 
16  0.0013  0.0012  0.0012 
30  0.0014  0.0012  0.0014 
 
Table  4.5.3.1:  Values  of  the  slopes  of  the  concentration-activity  curves  for  synthetic 
PS:PC vesicles by fridge storage, by step-freezing and flash freezing. 
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Figure 4.5.3.1: Synthetic vesicle preparation (svD) analysed on day 1(D1) and after 2(D2), 
10(D10), 16(D16) and 30(D30) days in storage in a 4°C fridge. Standard error bars shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.5.3.2:  Synthetic  vesicle  preparation  (svD)  analysed  on  day  1(D1)  and  after 
2(D2), 10(D10), 16(D16) and 30(D30) days in storage by step freezing. Standard error 
bars shown. 
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Figure 4.5.3.3: Synthetic vesicle preparation (svD) analysed on day 1(D1) and after 2(D2), 
10(D10),  16(D16)  and  30(D30)  days  in  storage  by  flash  freezing.  Standard  error  bars 
shown. 
 
4.5.4  BeWo culture-derived microparticle preparations as a standard 
 
 
Naturally  occurring  microparticles  express  phosphatidylserine  on  their  surface  and 
microparticles are known to be released from cells undergoing apoptosis. There was the 
possibility that ‘natural’ microparticles could be generated from cultured cells in vitro, then 
isolated  and  stored  to  create  a  standard  preparation.  These  ‘naturally-derived’ 
microparticles could potentially be more stable in storage as they would contain various 
proteins and lipids in their cell membrane which may aid surface stability. 
 
 
A BeWo choriocarcinoma cell line was cultured and apoptosis was initiated by addition of 
tumour necrosis factor α (TNF-α) 10ng/ml and interferon γ (IFN-γ) 10ng/ml and incubated 
for 24 hours. The cell culture medium was removed and centrifuged at 3000g to remove 
cellular debris. This solution was then immediately analysed by the prothrombinase assay 
to measure prothrombinase activity. Two cultures were initially prepared: BeA and BeB. 
The change in AU/min of the culture medium was found to be under the required range 
when compared to the values obtained using the synthetic PC: PS vesicles. Clearly, these 
samples were not going to provide the appropriate range of PS equivalents. 
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In order to increase the specific activity of these preparations, it was decided to concentrate 
the  culture  medium.  Two  further  cultures  were  made:  BeC  and  BeD  and  the  culture 
medium was concentrated 10 times by sucrose dialysis. Serial dilutions were performed 
and the OD/min of each dilution was charted. It was found that samples BeC and BeD had 
a higher  activity  compared to non-concentrated samples (BeA and  BeB).  However the 
change in OD/min of BeC and BeD varied greatly. The change in OD/min of sample BeC 
was 0.538 AU/min/µl which was above the range of the standard curve produced from the 
synthetic PC:PS vesicles. In comparison, the change in OD/min of sample BeD was only 
0.127 AU/min/µl. Clearly the microparticles pro-coagulant activities produced by these 2 
separate BeWo cultures were very different. 
 
 
In order to test for stability in storage, the concentrated culture medium of BeC was stored 
at 4°C and measured after 7 days. Sample BeC showed a loss of activity when measured 
after 7 days storage (figure 4.5.4.1) and calculation of the initial slope of the trendline 
showed that there was a 3.1-fold drop in activity (0.0173 AU/min/µl [day 1] to 0.0056 
AU/min/µl [day 7] ). Therefore it appeared that creation of microparticles using a BeWo 
culture was not  a satisfactory way of producing vesicles for the purpose of creating a 
standard as there was high inter-preparation variability as well as degradation in storage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.4.1: Loss of activity of sample BeC when measured after 7 days storage (D7) 
compared to when fresh (D1). Standard error bars shown. 
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4.5.5  Pilot studies of prothrombinase assay 
 
 
The aim of developing the prothrombinase assay was to allow us to measure the degree of 
microparticle pro-coagulant activity in the maternal blood of pre-eclamptic and healthy 
control  patients.  Various  attempts  at  producing  suitable  vesicles  for  the  purposes  of  a 
standard curve showed that the most satisfactory method of producing consistent vesicles 
was by the creation of synthetic PC:PS vesicles but there was the drawback of vesicle 
degradation in a very short time regardless of method of storage. Due to time limitation, 
rather than continue trying to find a solution to the problem of vesicle degradation, it was 
decided to use freshly prepared on-the-day synthetic PC:PS vesicles as a standard when 
analysing blood samples. For purposes of piloting the assay, I recruited healthy volunteers 
from the laboratory to enable me to identify an approximate range of microparticle pro-
coagulant activity in the healthy population. I also recruited groups reported to have had 
higher levels of microparticle procoagulant activity for purposes of informing the power 
calculation of the pre-eclamptic/control analysis. A literature search at the time revealed 
that  plasma  microparticle  levels  had  been  measured  in  uncomplicated  and  complicated 
type  II  diabetics  and  greater  amounts  of  microparticles  were  found  in  type  II  diabetic 
patients with complications. Using flow cytometry, Omoto et al (273) showed that there 
were significantly increased levels of platelet and monocyte-derived microparticles in type 
II diabetics compared to healthy non-diabetic controls.  When microparticle levels were 
compared  between  uncomplicated  diabetics  and  diabetics  with  complications  of  the 
disease, increased levels of microparticles were found in patients with complications such 
as  retinopathy  (approximately  100%  increase)  and  nephropathy  (approximately  160% 
increase)(273). Using flow cytometry, Ogata et al (280;281) also compared the levels of 
platelet-derived microparticles in type II diabetic patients and discovered a 10 % increase 
in microparticle levels in patients who had diabetic complications. The available literature 
therefore indicated that plasma microparticle levels were increased in type II diabetes and 
further increased in diabetic patients with complications. This suggests that microparticle 
procoagulant  activity  may  be  greater  in  complicated  type  II  diabetics  compared  to 
uncomplicated type II diabetics. 
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4.5.5.1 Microparticle pro-coagulant activity in healthy persons 
 
 
Healthy male and female volunteers from the lab were recruited. There were 13 individuals 
recruited, all without any medical illnesses and they were not on any medication. The mean 
was 12.2 (SD 12.2) nM PS equivalents with a 95% confidence interval of 12.2 +/- 6.6. The 
results are as per table 4.5.5.1 and figure 4.5.5.1.  
 
  Mean  SD  95 % confidence interval 
Prothrombinase activity  
(nM PS equivalents) 
12.2  12.2  5.6 to 18.8 
 
Table 4.5.5.1: Prothrombinase activity of healthy individuals in nM PS equivalents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.5.1: Dotplot of prothrombinase activity in normal healthy individuals in nM PS 
equivalents. 
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4.5.5.2 Microparticle pro-coagulant activity in type II diabetic patients 
 
 
Two groups of type II diabetic patients were recruited: well controlled diabetics (n=10) and 
diabetics with microvascular complications (n=6). The results are as per table 4.5.5.2 and 
figure 4.5.5.2. While there was an 80.5% increase in total pro-coagulant activity in the 
group  with  microvascular  complications  compared  to  the  well  controlled  group,  the 
difference was not statistically significant (p value= 0.12). 
 
 
 
 
Table  4.5.5.2:  Comparison  of  prothrombinase  activity  between  diabetics  with 
complications and diabetics without complications measured in nM PS equivalents. The 
results are shown as: mean (SD). *P value was measured by a two sample T-test using log 
transformed values. 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.5.5.2:  Dot  plot  of  prothrombinase  activity  between  complicated  and 
uncomplicated diabetics in nM PS equivalents. 
  Diabetics with 
complications 
(n=6) 
Diabetics without 
complications 
(n=10) 
P value 
Prothrombinase 
activity  
(nM PS equivalents) 
14.8 (8.7)  8.2 (5.3)  0.12* 
5 15 25
Prothrombinase activity (nM PS equivalents)
Uncomplicated
diabetics
Complicated
diabetics  129 
 
Analysis  of  type  II  diabetic  patients  was  used  to  inform the power  calculation for the 
measurement of the pre-eclamptic and control groups and a sample size of 32 cases and 32 
controls predicted 90% power to detect a difference of 53% in procoagulant activity with a 
65% standard deviation. 
 
 
4.6  Results 
 
 
4.6.1  Microparticle  pro-coagulant  activity  in  pre-eclamptic  and  healthy 
pregnant controls 
 
 
Thirty  two  pre-eclamptic  and  32  healthy  control  patients  were  recruited  to  the  study, 
matched  for  age,  body  mass  index  (BMI),  gestation  at  sampling  and  parity.  Their 
characteristics are as per table 4.6.1.1. It can be seen that there was no statistical difference 
between  the  pre-eclamptic  and  control  groups  with  regard  to  age,  BMI,  gestation  at 
sampling and parity, reflecting that they were well-matched. Patients with pre-eclampsia 
delivered earlier and had smaller babies as expected. There were also significantly fewer 
smokers in the pre-eclamptic group. 
 
 
Microparticle pro-coagulant activity was measured in pre-eclamptic and healthy control 
groups. The samples were analysed in a prothrombinase assay along with their matched 
controls on the same plate using freshly made on-the-day synthetic PC: PS vesicles as a 
standard  curve.  The  two-sample  T-test  for  continuous  variables  was  used  to  test  for 
statistical difference between the pre-eclamptic and healthy pregnant control groups. The 
results  showed  that  with  regard  to  microparticle  pro-coagulant  activity,  there  was  no 
significant difference in microparticle prothrombinase activity between the pre-eclamptic 
and  the  healthy  pregnant  control  groups  [pre-eclampsia  mean  107  (SD  137)  nM  PS 
equivalents vs. control mean 108 (SD 85) nm PS equivalents, p=0.36] . When early-onset 
pre-eclamptic (under 34 weeks’  gestation) samples were considered, microparticle pro-
coagulant  activity  was  also  not  significantly  different  between  the  pre-eclamptic  and 
control group [115.3 (59.0) vs. 120.2 (105.0), p=0.87]. These results are as shown in table 
4.6.1.2, figure 4.6.1.1 and figure 4.6.1.2.   130 
Characteristic  Pre-eclamptic 
(n=32) 
Healthy pregnant controls 
(n=32) 
P value 
Age  
(years) 
29.4 (6.3)  29.6 (5.7)  0.88 
BMI 
(kg/m
2) 
26.8 (4.5)  26.5 (4.4)  0.78 
Number of smokers  1 (3)  8 (25)  0.012 
Gestation at sampling (weeks)  35.8 (3.3)  36.0 (4.1)  0.89 
Primiparous  
[number and (% of total)] 
22 (69%)  24 (75%)  0.58 
Gestation at delivery (weeks)  36.3 (3.0)  39.5 (0.9)  <0.001 
Mean birth weight centile  23.2 (27.8)  52.3 (31.2)  <0.001 
Table 4.6.1.1: Patient  characteristics  of  pre-eclamptic  and  healthy  pregnant  controls 
showing mean (standard deviation) and p values. P value was measured by a two sample 
T-test. Statistical significance was set at p<0.05. 
 
Characteristic  Pre-eclamptic 
 
Healthy pregnant 
controls 
P value 
 
All pre-eclamptic samples  n=32  n=32   
Prothrombinase activity *  
(nM PS equivalents) 
107 (137)  108 (85)  0.36 
Early onset pre-eclamptic samples 
(under 34 weeks gestation) 
n=8  n=10   
Prothrombinase activity *  
(nM PS equivalents) 
115.3 (59.0)  120.2 (105.0)  0.87 
Table  4.6.1.2:  Prothrombinase  activity  of  pre-eclamptic  patients  and  healthy  pregnant 
control patients showing mean (standard deviation) and p values. P value was measured by 
a  two  sample  T-test  using  log  transformed  values*.  Statistical  significance  was  set  at 
p<0.05.   131 
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Figure 4.6.1.1: Interquartile range boxplot of prothrombinase activity of all pre-eclamptic 
and matched controls measured in nM PS equivalents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.1.2: Interquartile range boxplot of prothrombinase activity of early-onset pre-
eclamptic and matched controls measured in nM PS equivalents. 
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A post hoc analysis of power for the pre-eclamptic and controls revealed a sample size of 
32  cases  and  32  controls  predicted  90%  power  to  detect  a  difference  of  67%  in 
procoagulant activity with a 81% standard deviation. 
 
 
4.6.2  Measurement of fetal corticotrophin-releasing hormone (CRH) mRNA 
in maternal blood 
 
 
There was significantly greater amounts of fetal CRH mRNA in maternal peripheral blood 
in pre-eclamptic patients compared to healthy pregnant matched controls [pre-eclamptic 
mean 0.75 (SD 2.77) vs. healthy control mean 0.20 (SD 0.74), p=0.014] as shown in table 
4.6.2  and  figure  4.6.2.  This  suggests  that  there  were  significantly  greater  amounts  of 
placental debris in the maternal systemic circulation in pre-eclampsia compared to healthy 
pregnancy. As the CRH/GAPDH mRNA ratio included some zero values, the Wilcoxon 
rank sum test was used to test the differences between groups. Fetal CRH mRNA levels 
were  not  found  to  be  correlated  to  microparticle  prothrombinase  activity  in  either  the 
healthy pregnant or pre-eclamptic groups. When fetal CRH mRNA levels were compared 
between  pre-eclamptic  and  healthy  control  pregnancies  before  and  after  36  weeks 
gestation, a significant increase in fetal CRH mRNA levels were found in pregnancies after 
36 weeks gestation in both pre-eclamptic and healthy pregnant controls. Table 4.6.3 and 
figure 4.6.3. 
 
 
 
Characteristic  Pre-eclamptic 
(n=32) 
Healthy pregnant 
controls (n=32) 
P value 
 
Fetal  CRH  mRNA  relative 
to GAPDH 
0.75 (2.77)  0.20 (0.74)  0.014 
 
 
Table  4.6.2:  Fetal  CRH  mRNA  levels  of  pre-eclamptic  and  healthy  pregnant  controls. 
Mean (standard deviation) and p-values. The difference between control and pre-eclampsia 
groups was tested using a Wilcoxon signed-rank test for CRH/GAPDH mRNA ratio.   133 
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Figure 4.6.2: Fetal CRH mRNA ratio of pre-eclamptic and matched controls measured as 
CRH relative to GAPDH. Means and standard errors are shown. CRH/GAPDH mRNA 
ratio is plotted on a logarithmic scale. 
 
 
 
  Healthy control 
< 36 weeks 
Healthy control 
> 36 weeks 
Pre-eclamptic 
< 36 weeks 
Pre-eclamptic 
> 36 weeks 
Fetal CRH 
mRNA 
relative to 
GAPDH 
0.0 (0.0)  0.30 (0.20)  0.39 (0.23)  1.14 (0.82) 
 
Table 4.6.3: Fetal CRH mRNA levels of pre-eclamptic and healthy pregnant controls 
under and over 36 weeks’ gestation. Mean (standard error). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.3: Fetal CRH mRNA ratio of pre-eclamptic and matched controls under and 
above  36  weeks  gestation  measured  as  CRH  relative  to  GAPDH.  Means  and  standard 
errors are shown. 
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4.7  Discussion 
 
 
One of the main aims of this thesis was to measure microparticle procoagulant activity in 
the  maternal  circulation  in  a  case-control  study  of  pre-eclamptic  patients  and  healthy 
pregnant  matched  controls  to  identify  if  there  was  any  significant  difference  in 
microparticle pro-coagulant activity between the two groups. Phosphatidylserine (PS) is a 
component  of  cell  membranes  and  it  is  normally  located  on  the  inner  leaflet  of  the 
membrane. PS has procoagulant properties in that it provides a surface for the conversion 
of  prothrombin  to  thrombin  by  clotting  factors.  When  a  cell  is  activated  or  undergoes 
apoptosis, PS is externalised to the outer surface of the cell membrane,  the cell membrane 
is blebbed off and released as microparticles into the circulation(282). These circulating 
microparticles in plasma would now potentially be in a position to affect coagulation in 
maternal circulation. 
 
 
The prothrombinase assay was chosen as a method to measure the procoagulant activity of 
microparticles  in  maternal  blood.  The  reason  this  assay  was  chosen  was  that  it  was 
designed  to  physically  capture  microparticles  in  plasma  and  quantify  its  procoagulant 
activity by using its thrombin generating ability as a surrogate measure. This seemed to be 
a most direct assessment of microparticle procoagulant activity. 
 
 
The prothrombinase assay required a standard curve measuring the prothrombinase activity 
in relation to the concentration of PS present. I followed the method of Aupiex et al(65) 
who used synthetic phosphatidylserine : phosphatidylcholine (PC:PS) vesicles to act as a 
standard in their prothrombinase assay. Their method of synthesis of these vesicles was 
based on the method of Pigault et al(275) who created synthetic unilamellar vesicles of 
67%PC:  33%  PS  (mol/mol).  Various  dilutional  series  identified  a  linear  relationship 
between the prothrombinase activity and concentration of PS in these vesicles between the 
range of 0 to 50nM PS equivalents. This activity: concentration relationship now allowed 
me  to  relate  the  prothrombinase  activity  of  the  blood  samples  to  the  standard  curve, 
allowing the measure of the procoagulant activity of PS (and therefore the procoagulant 
activity  of  microparticles)  in  the  blood  sample.  To  validate  the  assay,  inter-vesicle 
preparations  and  intra-assay  coefficients  of  variations  were  measured  and  found  to  be   135 
reasonable,  at  9.09%  (inter-vesicle  preparations)  and  an  average  of  2.6%  (intra-assay 
variability).  However  inter-assay  variability  was  not  satisfactory  with  a  coefficient  of 
variation of 45.8%. 
 
 
It  was  hoped  that  once  the  activity:  concentration  relationship  of  a  batch  of  synthetic 
vesicles was established, this batch could be stored for future use in later experiments i.e. 
used as a quality control. However in the course of our experiments, there appeared to be 
degradation of procoagulant activity of these synthetic vesicles over time with the greatest 
loss of activity occurring within the first day in storage and this accounted for the high 
inter-assay CV. Three different methods of storage were attempted (fridge at 4°C, step 
freezing and flash freezing) to identify if there was a method of storage that maintained 
vesicle  activity.  Unfortunately,  degradation  of  microparticle  pro-coagulant  activity 
occurred with all 3 methods. It was possible the loss of procoagulant activity was the result 
of vesicle instability, as these vesicles were essentially phospholipid complexes in buffer 
solution without any additional stabilising factors such as proteins that are present in cell 
membranes.  The  production  of  ‘natural’  microparticles  from  cultured  BeWo  cells 
undergoing  induced  apoptosis  was  then  attempted  to  see  if  they  maintained  their 
procoagulant  activity  in  storage.  It  was  thought  that  these  naturally-occurring 
microparticles would contain various membrane proteins that would help maintain stability 
in solution. Unfortunately there was no consistency in the procoagulant activity of these 
natural microparticles between batches and these ‘natural’ microparticles also lost their 
procoagulant activity in storage. It was therefore decided to use freshly made on-the-day 
synthetic  PC:PS  vesicles  as  a  standard  when  performing  the  prothrombinase  assay  on 
blood samples. 
 
 
To pilot the prothrombinase assay, 2 types of sample populations were chosen; healthy 
individuals  and  type  II  diabetics  (complicated  and  uncomplicated).  A  literature  search 
revealed  that  microparticle  levels  have  previously  been  measured  in  type  II  diabetic 
populations.  With  regard  to  the  healthy  sample  population,  I  recruited  13  healthy 
individuals and determined microparticle procoagulant activity in the healthy population to 
have a mean of 12.2 (SD 12.2) nM PS equivalents.  
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With  regard  to  the  type  II  diabetic  sample  population,  10  type  II  diabetics  without 
complications and six type II diabetics with complications were recruited from the diabetic 
outpatient clinic. They were not on any anti-thrombotic medication such as aspirin, heparin 
or  warfarin.  Their  microparticle  procoagulant  activity  was  measured  and  the  results 
showed greater procoagulant activity in the blood of type II diabetics with complications 
[mean 14.8 (SD 8.7) nM PS equivalents] compared to uncomplicated diabetics [mean 8.2 
(SD 5.3) nM PS equivalents] but this difference was not statistically significant. However, 
the reason the type II diabetic study was undertaken was to estimate the power calculation 
for the pre-eclamptic and healthy pregnant control study. The type II diabetic study in itself 
was not a primary aim of this project. 
 
 
The measure of microparticle prothrombinase activity in pre-eclamptic patients was one of 
the primary aims of this project. A search of the literature revealed that microparticles had 
been measured in the blood of non-pregnant, healthy pregnant and pre-eclamptic patients 
and quantitated using flow cytometry. However, some results were conflicting. Using flow 
cytometry, Bretelle et al showed that platelet and endothelial-derived microparticles were 
raised  in  healthy  pregnant  women  compared  to  healthy  non-pregnant  women(86).  In 
contrast however, Van Wijk et al did not find any significant difference in endothelial-
derived microparticles between healthy pregnant and healthy non-pregnant women(87). 
When microparticle levels were measured in pre-eclamptic patients, it was found there 
were greater numbers of microparticles derived from endothelial, T-helper, T-suppressor 
and granulocyte cells in the plasma of pre-eclamptic patients compared to healthy pregnant 
controls(80;87;89) and the highest proportions of microparticles in both groups were found 
to be platelet-derived microparticles(87). In contrast, Bretelle et al found a lower amount 
of  platelet-derived  microparticles  in  pre-eclamptic  pregnancies  compared  to  healthy 
pregnant  controls(86).  Despite  differences  in  microparticle  levels  in  these  cell 
subpopulations, no statistically significant difference has been found in the total number of 
microparticles between pre-eclamptic and healthy pregnant control groups(86;87). 
 
 
In  contrast  to  measuring  the  amount  of  microparticles  in  pre-eclamptic  patients,  I  was 
interested in comparing microparticle procoagulant activity in maternal blood between pre-
eclamptic  and  healthy  pregnant  women.  A  prothrombinase  assay  was  selected  for  this 
purpose.  It is important to emphasise here that the prothrombinase assay measures the 
procoagulant activity of microparticles and not the amount of microparticles in the sample.   137 
The prothrombinase assay measures the procoagulant activity of all microparticles in the 
sample regardless of cell of origin or whether they  were of maternal or fetal origin.  I 
recruited 32 pre-eclamptic and 32 healthy pregnant controls. They were matched for age, 
body mass index (BMI), gestation at sampling and parity. The results showed a mean value 
of 107 (SD 137) nM PS equivalents for pre-eclamptic patients and a mean value of 108 
(SD 85) nM PS equivalents for healthy pregnant controls with a p-value of 0.36. This 
indicated that there was no statistically significant difference in microparticle procoagulant 
activity between the pre-eclamptic and matched healthy pregnant control groups. Goswami 
et al measured and found STBM levels to be significantly increased in early onset-pre-
eclamptics (under 34 weeks’ gestation) compared to healthy pregnant controls(81). It was 
possible  that  in  early-onset  pre-eclampsia,  higher  levels  of  syncytiotrophoblast-derived 
microparticles may lead to greater total microparticle procoagulant activity in maternal 
blood. However in my samples, microparticle procoagulant activity was not found to be 
significantly  different  between  early-onset  pre-eclamptics  and  matched  control  groups 
[early onset pre-eclampsia mean 115.3 (SD 59.0) nM PS equivalents vs. control mean 
120.2 (SD105) nM PS equivalents, p value 0.87]. After I had commenced work on this 
project,  Bretelle  et  al(86)  published  a  paper  where  they  measured  microparticle 
procoagulant activity in maternal blood using a prothrombinase assay and found that total 
microparticle procoagulant activity was significantly higher in healthy pregnant women 
compared to non-pregnant controls. However Bretelle et al did not find any significant 
difference in microparticle procoagulant activity either between pre-eclamptic and healthy 
pregnant control groups. My results are thus in keeping with the findings of Bretelle et al. 
 
 
I was interested in comparing the amount of placentally-derived cell debris in the maternal 
blood of pre-eclamptic and healthy control patients. Goswami et al(81) had previously 
measured syncytiotrophoblast-derived microparticle levels in the blood of pre-eclamptic 
patients by means of ELISA using an anti-trophoblast antibody (NDOG2) to capture the 
microparticles. However, the anti-trophoblast antibody (NDOG2) as used by Goswami et 
al(81) was not commercially available. Fetal CRH mRNA in maternal blood can only be 
derived from the fetoplacental unit and measurement of fetal CRH mRNA in maternal 
plasma  would  therefore  act  as  a  direct  measure  of  placental-derived  cell  debris  in  the 
maternal circulation. Several studies have shown that in comparison to healthy pregnancy, 
a 4-10-fold increase in fetal CRH mRNA levels occurs in pre-eclampsia (101;106;107). 
Therefore, a measure of the level of circulating fetal CRH mRNA in maternal plasma was 
proposed. To allow direct comparison with previous reports(106), GAPDH was used as a   138 
control gene and we demonstrated consistent levels of GAPDH mRNA expression in pre-
eclamptic  and  healthy  control  plasma.  The  source  of  fetal  CRH  mRNA  in  maternal 
circulation had previously been proposed to be syncytiotrophoblast microvilli cell debris 
shed from the placenta into the maternal circulation(78) and syncytiotrophoblast microvilli 
cell  debris  has  previously  been  detected  in  maternal  blood  using  trophoblast-specific 
antibodies(80)  as  well  as  male-specific  offspring  DNA(283).  Using  real  time  PCR 
(Taqman), my results showed statistically greater amounts of fetal CRH mRNA in the 
plasma of pre-eclamptic pregnancies compared to the healthy pregnant matched control 
group (Table 4.6.2). 
 
  
With greater placental thrombosis and inflammation in pre-eclampsia, it is possible that the 
placenta may be a significant source of procoagulant microparticles. Fetal mRNA levels 
have  been  found  to  be  raised  in  pre-eclampsia(101;107)  suggesting  that  there  may  be 
greater  trophoblast  shedding  into  the  maternal  systemic  circulation  in  pre-eclampsia.  I 
detected a significant increase in the amount of fetal CRH mRNA in pre-eclamptic samples 
compared to healthy pregnant samples but there was no increase in total microparticle 
procoagulant activity in maternal serum as might be expected if the amount of trophoblast 
shedding was considerable and had contributed significantly to the overall procoagulant 
activity. A possible reason for this is the amount of microparticles of placental origin may 
be  small  in  comparison  to  the  total  amount  of  microparticles  circulating  in  maternal 
plasma, so any increase of placental microparticles (while statistically significant in pre-
eclampsia compared to healthy pregnancy) may not have had much impact on the overall 
procoagulant activity of the total microparticles in maternal plasma. When pre-eclamptic 
and healthy control samples were measured as 2 separate subgroups (patients recruited 
under  36  weeks’  gestation  and  patients  recruited  after  36  weeks’  gestation),  there  was 
higher  mean  fetal  CRH  mRNA  levels  in  the  both  pre-eclamptic  and  healthy  pregnant 
groups over 36 weeks’ gestation. This increase in fetal CRH mRNA levels suggests that as 
pregnancy progresses towards term, there is greater trophoblast apoptosis or release of 
placental cell debris.  
 
 
Microparticles are known to bind to fibrinogen and platelets(284) and in Chapter 3, there 
appeared to be greater fibrin deposition in pre-eclamptic placentas compared to healthy 
pregnant controls. It is possible that the majority of placental-derived microparticles may 
have become bound to perivillous fibrin in the placenta soon after release, thereby reducing   139 
the amount of placental microparticles entering the maternal systemic circulation. These 
placental-derived microparticles may also have become bound to annexin V on the surface 
of the placental syncytiotrophoblast soon after release. Lastly it is possible that placental-
derived microparticles may only exhibit very minimal pro-coagulant properties so while 
there may be greater amounts of placental-derived microparticles in pre-eclampsia, their 
contribution to total microparticle procoagulant activity is minimal. 
 
 
The aims of this chapter were to determine if there was greater microparticle procoagulant 
activity in pre-eclampsia and also to determine if there were greater amounts of placental-
derived microparticles in pre-eclampsia. A prothrombinase assay was set up and validated 
in order to measure the procoagulant activity of microparticles. The results did not show 
any increase in total microparticle pro-coagulant activity in maternal serum between pre-
eclamptic  women  and  healthy  pregnant  controls.  Fetal  CRH  mRNA  was  measured  to 
determine the amount of placental-derived microparticles and was found to be raised in 
pre-eclamptic patients compared to healthy pregnant controls and this is consistent with 
current literature. However I did not find any correlation between fetal CRH mRNA and 
total microparticle pro-coagulant activity suggesting that placental-derived microparticles 
in  maternal  blood  did  not  lead  to  any  significant  contribution  to  total  microparticle 
procoagulant activity. 
 
 
The  condition  of  pre-eclampsia  is  associated  with  changes  in  coagulation,  endothelial 
function  and  placental  function  in  comparison  to  healthy  pregnancy.  As  microparticles 
have procoagulant properties and have been identified to originate from the endothelium 
and  placenta,  I  hypothesise  that  there  may  be  a  relationship  between  microparticle 
procoagulant activity as well as placental cell debris with coagulation, endothelial function 
and placental function in the maternal circulation. I set out to investigate this in the next 
chapter. 
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Chapter 5  Markers of coagulation activation, endothelial activation and 
placental function in relation to microparticle procoagulant activity and 
placental debris in pre-eclampsia 
 
 
5.1  Introduction 
 
 
Healthy pregnancy is a state of coagulation activation in preparation to cope with maternal 
blood  loss  at  delivery(5;285).  This  coagulation  activation  involves  an  increase  in 
procoagulant  factors  and  suppression  of  fibrinolytic  pathways.  High  levels  of  TF  the 
primary  initiator  of  coagulation  have  been  found  in  the  placenta  and  in 
syncytiotrophoblasts(25;27). Procoagulant factors such as FVII, FXIIa and vWF have been 
found to be higher in maternal plasma (5;148;152;157;203;204). There is also an increased 
resistance to endogenous anticoagulant mechanisms such as (APC)(142;159). Thrombin 
generation  is  higher  in  pregnancy  leading  to  increased  fibrin  production(140;142-144). 
There is suppression of fibrinolysis. Activation of plasmin, the key enzyme that degrades 
fibrin is inhibited by raised levels of both PAI-1 and PAI-2, the latter being produced by 
the placenta(172). 
 
 
In pre-eclampsia, there are further changes in the coagulation system when compared to 
healthy pregnancy. There are increases in maternal plasma levels of TF, FVII, FXIIa, vWF, 
thrombin, F1+2 and TFPI. Higher PAI-1 levels have been found and this may suppress 
fibrinolysis.  Markers  of  endothelial  activation;  sICAM-1  and  sICAM-2  have  also  been 
found to be higher in pre-eclampsia. PAI-2, a marker of placental function has been found 
to be lower in pre-eclampsia. These changes are discussed in more detail in chapter 1.4 of 
this thesis. 
 
 
As the only known cure for pre-eclampsia is delivery of the placental unit (regardless of 
gestational  age),  it  is  possible  there  are  factors  released  by  the  placenta  that  provoke 
maternal procoagulant activity and endothelial activation. A number of potential factors 
have been identified, including the release of placental debris into the maternal circulation. 
Cell  membrane  fragments  carrying  specific  placental  trophoblast  markers  and  soluble   141 
mRNA and DNA of placental origin have been found in maternal plasma (91-93;95-97) 
and their amounts are increased in pre-eclampsia(106;107). Microparticles formed as a 
result  of  blebbing  of  cell  membranes  in  apoptosis  have  been  studied  in  pre-eclampsia 
because  of  their  procoagulant  properties(88).  Changes  (both  positive  and  negative)  in 
populations of microparticles derived from different cell types have been observed in pre-
eclampsia(86;87;89).  The  concept  of  trophoblast  membrane  fragments  circulating  in 
maternal  plasma  is  particularly  intriguing  with  regard  to  coagulation  activation  as 
phosphatidylserine(PS) exposed on the surface of apoptotic cell membranes is known to be 
prothrombotic(278;279). 
 
 
5.1.1  Markers of the coagulation cascade 
 
 
With regard to markers of the coagulation cascade, the following factors were measured in 
maternal serum: TF, TFPI, TAT, F1+2, FVIIc, FXIIa and the APC ratio.  
 
 
TF is a potent initiator of coagulation and is expressed on the surface of subendothelial 
cells thus forming a boundary around blood vessels. TF can also be found in soluble form 
in plasma. The coagulant activity of FVIIa  can be measured in a bioassay to give the 
Factor VII coagulant activity (FVIIc). Increased levels of soluble TF and increased FVIIc 
activity in blood reflect an increased potential to initiate the coagulation cascade. TFPI 
antagonises the effects of tissue factor by inactivating the factor VIIa-TF complex and is 
therefore anticoagulant in nature. TFPI has been shown to be positively associated with 
markers of endothelial cell function; t-PA, thrombomodulin and vWF. Therefore increased 
levels of TFPI may also be associated with endothelial cell activation(123). 
 
 
Once thrombin is formed, it circulates bound to endogenous serine protease inhibitors such 
as  anti-thrombin  III  (AT)  resulting  in  an  inactive  complex,  the  thrombin-antithrombin 
complex (TAT). A measurement of TAT levels can therefore be used to reflect the amount 
of thrombin in circulation. During the conversion of prothrombin to thrombin, prothrombin 
fragment 1+2 (F1+2) is released. Therefore, F1+2 can be used as a surrogate marker of the 
amount of thrombin generated. 
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The  precise  role  of  FXIIa  is  not  well  defined  as  FXIIa  may  have  both  pro-  and  anti-
coagulant effects. It has a procoagulant effect in the intrinsic coagulation network and has 
an anticoagulant effect in that it leads to production of plasmin which is involved in blood 
clot dissolution. APC is anticoagulant in nature as it inhibits the activity of activated factor 
V  and  activated  factor  VIII  thereby  inhibiting  the  extrinsic  coagulation  pathway.  The 
activity of protein C can be measured as the APC ratio. A lower ratio corresponds to APC 
resistance and a reduction on the activity of the endogenous anti-coagulant pathway. 
 
 
Plasminogen  activator  inhibitor  type-1  (PAI-1)  inhibits  the  process  of  fibrinolysis  by 
binding and inactivating the 3 main proteases involved in fibrinolysis [tissue plasminogen 
activator  (tPA),  urinary  plasminogen  activator  (uPA)  and  plasmin].  PAI-1  is  therefore 
procoagulant in nature. PAI-1 levels have been found to be significantly raised in pre-
eclampsia compared to healthy pregnant controls. 
 
 
5.1.2  Markers of endothelial function 
 
 
The following markers of endothelial function were measured: sICAM-1, sVCAM-1 and 
vWF. ICAM-1 and VCAM-1 belong to the immunoglobulin super family of Cell Adhesion 
Molecules (CAMs) and are involved in the leukocyte-endothelial cell adhesion cascade 
where circulating leukocytes interact with CAMs on the surface of the endothelium leading 
to  leukocyte  adherence  and  transmigration  into  the  interstitial  tissue.  In  inflammation, 
proinflammatory cytokines activate endothelial cells and leukocytes leading to shedding of 
CAMs from their surface into the systemic circulation resulting in the presence of sICAM-
1 and sVCAM-1 in plasma. sICAM-1 and sVCAM-1 may therefore serve as markers of 
endothelial activation and vascular inflammation. Von Willebrand factor is synthesized 
predominantly within vascular endothelial cells. Von Willebrand factor has two functions 
in haemostasis. It serves as a carrier for factor VIII and also functions to mediate platelet 
adhesion to vascular subendothelium. Thrombin formation at the site of injury stimulates 
further  vWF  release  with  the  net  effect  of  platelet  plugging  of  the  injury  site.  This 
physiological  release  of  vWF  by  endothelial  cells  allows  it  to  be  a  useful  marker  of 
endothelial activation. 
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5.1.3  Marker of placental function 
 
 
PAI-2 is produced by placental villous syncytiotrophoblasts and is released during cellular 
activation or apoptosis. PAI-1 has been found to be raised in pre-eclampsia while PAI-2 
has been found to be reduced in conditions of reduced placental function such as severe 
pre-eclampsia and intrauterine growth restriction. An increased PAI-1/PAI-2 ratio has been 
found in pre-eclampsia and therefore, the PAI-1/PAI-2 ratio can be a useful marker for pre-
eclampsia(216). 
 
 
5.2  Hypothesis 
 
 
In chapter 4, it was shown that microparticle procoagulant activity was not significantly 
different  between  pre-eclamptic  and  healthy  pregnant  controls.  However  there  was 
evidence  that  there  was  a  greater  amount  of  placental  cellular  debris  in  the  maternal 
peripheral circulation in pre-eclampsia. 
 
 
As microparticles have procoagulant properties and have been identified to originate from 
circulating blood cells, the endothelium and placenta, I hypothesise that there may be a 
relationship between microparticle procoagulant activity as well placental cell debris with 
coagulation, endothelial function and placental function in the maternal circulation in pre-
eclamptic and healthy pregnancies. 
 
 
Objectives: 
 
 
1)  To measure levels of coagulation markers (TF, TFPI, TAT, F1+2, FVIIc, FXIIa, 
APC  ratio,  PAI-1),  markers  of  endothelial  function  (sICAM-1,  sVCAM-1  and 
vWF) and placental function (PAI-1/PAI-2 ratio) in the same population of pre-
eclamptic and healthy pregnant control patients as in chapter 4. 
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2)  To correlate microparticle prothrombinase activity as well as fetal CRH mRNA 
levels  in  pre-eclamptic  and  healthy  pregnant  controls  to  these  measures  of 
coagulation activation, endothelial function and placental function. 
 
 
5.3  Results 
 
 
5.3.1  Patient characteristics 
 
 
Both the pre-eclamptic and healthy control samples were from the same population as that 
used  for  the  assessment  of  microparticle  pro-coagulant  activity  in  chapter  4.  The  pre-
eclamptic and healthy pregnant controls groups were matched for age, BMI, parity and 
gestation at sampling (table 4.6.1.1). There were 8 smokers in the healthy control group 
compared to a single smoker in the pre-eclamptic group. This would be consistent with 
previous studies showing an inverse association of  smoking with the incidence of pre-
eclampsia(286).  Pre-eclamptic  patients  delivered  on  average  3.2  weeks  earlier  and  had 
lower birth weight babies compared to their matched healthy controls. 
 
 
5.3.2  Maternal  plasma  markers  of  coagulation  activation,  endothelial 
function and placental function 
 
 
The results are summarised in table 5.3.2. When compared to healthy pregnant controls, 
patients with pre-eclampsia had significantly higher levels of total TFPI [pre-eclampsia 
mean 38.7 (SD 8.2) vs. control mean 33.0 (SD 6.8) ng/ml, p=0.004], F1+2 [3.62 (4.40) vs. 
1.97 (0.60) nmol/l, p=0.008], FXIIa [1.40 (0.43) vs. 1.21 (0.22) ng/ml, p=0.033] and PAI-1 
102.7  (32.6)  vs.  80.0  (27.1)  ng/ml,  p=0.003]  Maternal  plasma  markers  of  endothelial 
function were higher in pre-eclamptic patients compared to controls: sVCAM-1 [732 (136) 
vs. 597.6 (85.5) ng/ml, p<0.001] and vWF [3399 (772) vs. 2579 (1044) mU/ml, p=0.001]. 
The PAI-1/PAI-2 ratio was significantly raised in the pre-eclamptic group compared to the 
healthy pregnant control group [0.29 (0.17) vs. 0.15 (0.13), p=0.001].    145 
 
Parameter  Pre-eclampsia 
(n=32) 
Control 
(n=32) 
P value 
Markers of coagulation activation 
Tissue factor 
(pg/ml) 
166 (27)  161 (19)  0.37 
Tissue factor pathway inhibitor 
(ng/ml) 
38.7 (8.2)  33.0 (6.8)  0.004 
TAT * 
(ug/l) 
20.5 (30.3)  13.0 (5.2)  0.19 
F1 +2 † 
(nmol/l) 
3.62 (4.40)  1.97 (0.60)  0.008 
FVIIc 
(IU/dl) 
240 (44)  247 (44)  0.56 
FXIIa 
(ng/ml) 
1.40 (0.43)  1.21 (0.22)  0.033 
APC 
ratio 
2.74 (0.45)  2.81 (0.43)  0.55 
PAI-1 † 
(ng/ml) 
102.7 (32.6)  80.0 (27.1)  0.003 
Markers of endothelial function 
sICAM-1 
(ng/ml) 
199.7 (41.3)  192.1 (57.5)  0.57 
sVCAM-1 * 
(ng/ml) 
732(136)  597.6 (85.5)  <0.001 
vWF 
(mU/ml) 
3399 (772)  2579 (1044)  0.001 
Markers of placental function 
PAI-1/PAI-2 ratio † 
 
0.29 (0.17)  0.15 (0.13)  0.001 
Microparticle assessment 
Prothrombinase activity † 
(nM PS equivalents) 
107 (137)  108 (85)  0.36 
Fetal mRNA ‡ 
(CRH relative to GAPDH ratio) 
0.75 (2.77)  0.20 (0.74)  0.014 
Table 5.3.2: Maternal third trimester plasma markers of coagulation activation, endothelial 
activation, placental function, microparticle prothrombinase activity and fetal CRH mRNA 
levels.  Mean  (Standard  Deviation)  shown.  †  log  transformed  data,  *square  root 
transformed data, ‡ Wilcoxon rank sum test. Statistical significance set at p<0.05 and are 
highlighted in bold.   146 
5.3.3  Correlation between measures of placental debris and maternal plasma 
markers of coagulation activation, endothelial function and placental function 
 
 
The results are summarised in figures 5.3.3.1 to 5.3.3.3. Fetal CRH mRNA levels were 
found to be correlated with TFPI levels in pre-eclamptic (r=0.38, p=0.031) and healthy 
pregnant control (r=0.37, p=0.039) patients (figure 5.3.3.1). Fetal CRH mRNA levels were 
found to correlate with maternal plasma FVIIc activity in pre-eclamptic (r=0.43, p=0.017) 
but  not  in  healthy  pregnant  patients  (r=0.25,  p=0.18)  (figure  5.3.3.2).  Microparticle 
procoagulant  activity  was  inversely  correlated  with  plasma  F1+2  levels  in  the  pre-
eclamptic group(r= -0.64, p=0.001) (figure 5.3.3.3). There was no significant correlation 
between fetal CRH mRNA levels and microparticle prothrombinase activity in either the 
pre-eclamptic or control groups. 
 
 
 5.4  Discussion 
 
 
I  wished  to  relate  maternal  plasma  levels  of  fetal  CRH  mRNA  and  maternal  plasma 
microparticle  procoagulant  activity  to  markers  of  coagulation  activation,  endothelial 
activation  and  placental  function  in  pre-eclamptic  and  healthy  pregnant  controls.  The 
changes in markers of coagulation activation and endothelial activation in my results were 
consistent with the pattern expected for pre-eclampsia (88;126;158;172;173;181;208). In 
the pre-eclamptic group, there was a higher expression of TFPI (possibly to compensate for 
increased  TF  expression  on  the  maternal  vasculature  or  on  placental  debris),  higher 
prothrombin  fragment  1+2  levels  (increased  conversion  of  prothrombin  to  thrombin), 
higher  PAI-1  (suppressed  fibrinolysis)  and  higher  levels  of  FXIIa  which  has  both 
procoagulant  (activates  FXI)  and  anticoagulant  (leads  to  increased  plasmin  production) 
effects. Higher concentrations of markers of endothelial activation sVCAM-1 and vWF 
were also found.   147 
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Figure 5.3.3.1:  Relationship between TFPI and fetal CRH mRNA in pre-eclamptic and 
healthy control groups. Standard error bars shown. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.3.2:  Relationship between factor VII coagulant activity and fetal CRH mRNA 
in pre-eclamptic and healthy control groups. Standard error bars shown. 
 
 
 
 
 
 
 
 
 
 
Figure  5.3.3.3:    Correlation  between  log  prothrombin  fragment  1+2  and  log 
prothrombinase activity in pre-eclamptic patients (r= -0.64, p=0.001). 
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Fetal CRH mRNA levels in maternal plasma correlated with TFPI levels in both control 
and pre-eclamptic women. The simplest explanation is that placental TFPI is shed along 
with the fetal CRH mRNA and is just another marker of placental debris(27;124). It is also 
possible that the circulating fetal mRNA, or associated material, induces TF expression on 
the maternal endothelial cell surface but without affecting soluble levels of TF in maternal 
plasma, hence inducing an up-regulation of TFPI expression. In the pre-eclampsia group, 
fetal  CRH  mRNA  levels  correlated  with  FVII  coagulant  activity.  It  is  possible  that 
placental debris may carry exposed TF on its surface leading to initiation of coagulation. 
Alternatively, placental cell debris might provide a platform for thrombin generation via 
the  TF/FVII-dependent  coagulation  activation  pathway  as  a  result  of  the  enhanced 
interaction  of  clotting  factors  with  exposed  phosphatidylserine  residues  on  the  debris 
surface. Factor VII coagulant activity was particularly elevated at high levels of fetal CRH 
mRNA. This would suggest that, above a certain circulating level, fetal mRNA initiates 
coagulation  activation  via  the  TF/FVII-dependent  coagulation  activation  pathway.  This 
response may however be limited by the increase in TFPI. 
 
 
In  pre-eclampsia,  the  microparticle  procoagulant  activity  was  inversely  correlated  with 
prothrombin fragment 1 +2. This is a paradox since these particles which are assayed by 
their ability to promote thrombin generation in vitro are found to be negatively associated 
with thrombin generation in vivo. This observation would be consistent with microparticles 
in  the  pre-eclamptic  patient  group  interfering  with  the  coagulation  pathway  in  vivo. 
Berckmans et al(68) who observed a similar inverse relationship between the microparticle 
number and thrombin generating capacity in plasma and TAT levels has suggested that 
microparticles may perform an anti-coagulant function by promoting the generation of low 
amounts of thrombin thus activating protein C. There is evidence that microparticles have 
anticoagulant functions  as platelet-derived microparticles catalysed FVa inactivation by 
APC(75). Van Wijk et al (88) observed that the TF/FVII-dependent coagulation activation 
pathway  induced  by  microparticles  was  active  in  pre-eclampsia  whereas  thrombin 
generation by microparticles was not enhanced. These authors argue that the source of the 
microparticles may affect their pro- or anti-coagulant properties. They concluded that their 
data, which looked at a composite of particles derived from many cell sources (both fetal 
and  maternal),  did  not  support  a  role  for  circulating  microparticles  in  coagulation 
activation. My data on phosphatidylserine-exposing microparticles is in agreement with 
these observations, but the positive correlations between fetal CRH mRNA levels with 
TFPI and FVIIc would suggest that cell debris derived from the placenta might indeed   149 
have  procoagulant  activity.  Further  experimental  evidence  is  required  to  support  this 
concept. 
 
 
It is not yet clear whether elevated circulating levels of fetal mRNA or DNA in maternal 
plasma  are  specific  to  pre-eclampsia  or  intrauterine  growth  restriction(287;288)  but 
increased  levels  of  circulating  fetal  DNA  have  been  observed  in  high  altitude 
pregnancies(289).  Bretelle  et  al  found  no  difference  in  total  annexin  V  positive 
microparticles  or  procoagulant  activity  between  healthy  and  growth  restricted 
pregnancies(86).  Recently  it  has  been  shown  that  mRNA-containing  microparticles, 
derived from endothelial progenitor cells, shuttled a specific subset of cellular mRNA to 
human endothelial cells in vitro thus promoting angiogenic effects(63). Heyl et al detected 
increased amounts of VCAM-1 and ICAM-1 on the surface of cultured human umbilical 
vein  endothelial  cells  after  stimulation  with  sera  from  pre-eclamptic  pregnancies 
suggesting  that  there  was  endothelial  cell  activation  as  a  result  of  exposure  to  pre-
eclamptic sera(195). This raises the possibility that microparticles may have very specific 
cellular effects via targeted delivery of mRNA. 
 
 
In summary, pre-eclamptic patients had higher levels of TFPI, F1+2, FXIIa, sVCAM-I, 
vWF,  PAI-1  and  PAI-1/PAI-2  ratio  compared  to  healthy  controls.  These  changes  in 
markers  of  coagulation  activation,  endothelial  function  and  placental  function  were 
consistent  with  the  pattern  expected  for  pre-eclampsia.  However,  the  main  aim  of  this 
chapter  however  was  to  identify  any  relationships  between  microparticle  procoagulant 
activity and placental cell debris with these markers. I have discovered that placental cell 
debris via the positive correlation with FVIIc may exhibit procoagulant properties in pre-
eclampsia. 
 
 
Pre-eclampsia is a prothrombotic state and platelets play a major role in coagulation. In 
coagulation, activated platelets release thromboxane, a potent platelet aggregator at the site 
of platelet adhesion. Thromboxane (an eicosanoid) is synthesised in vivo by platelets as 
well as by trophoblasts from PUFAs. The levels of thromboxane are significantly raised in 
pre-eclampsia. As thromboxanes are synthesised from PUFAs, it possible that there may be 
changes in the maternal fatty acid profile in pre-eclampsia that may influence the synthesis 
of  thromboxane.  In  the  next  chapter,  I  set  out  to  investigate  this  possibility.  150 
 
Chapter 6  Erythrocyte membrane fatty acid composition in relation to 
coagulation activation, endothelial function and placental function 
 
 
6.1  Introduction 
 
 
6.1.1  Eicosanoids in coagulation and vasoactive properties 
 
 
Platelets are small anucleate cells in the systemic circulation that play a critical role in 
thrombosis. Platelet activation involves the release of thromboxane (an eicosanoid) that 
activates other platelets leading to a positive feedback loop. Thromboxane is synthesised 
by platelets as well as by placental trophoblasts. Thromboxanes are synthesised in vivo in 
from polyunsaturated fatty acids (PUFAs) liberated from cell membrane phospholipids. 
Prostacyclin  (PGI2)  is  also  an  eicosanoid.  Prostacyclin  is  synthesised  mainly  by  the 
vascular endothelium and also the placenta. Prostacyclin is a major endothelium-derived 
inhibitor  of  platelet  activation  and  inhibits  platelet  adhesion  and  thrombus  formation. 
Thromboxane is a vasoconstrictor while prostacyclin is a vasodilator. Thus, thromboxane 
and prostacyclin have antagonistic effects. 
 
 
6.1.2  Thromboxane and prostacyclin in pregnancy and pre-eclampsia 
 
 
In  healthy  pregnancy,  there  is  production  of  equal  amounts  of  thromboxane  and 
prostacyclin(218). However in pre-eclampsia, pre-eclamptic  trophoblasts have been found 
to produce over three times as much thromboxane but less than 50% as much prostacyclin 
compared  to  healthy  placentas  (218;222).  Greater  amounts  of  thromboxane  B2  (the 
metabolite of thromboxane A2) has been found compared to 6-keto-prostaglandin F1α ( the 
metabolite of prostacyclin) in the maternal plasma of pre-eclamptic pregnancies compared 
to healthy pregnant controls and this pattern has also been found in the urine of pregnant 
women who have gone on to develop pre-eclampsia. Plasma levels of prostacyclin are 
reduced  in  both  mild  and  severe  pre-eclampsia.  In  contrast,  thromboxane  levels  were   151 
unchanged in mild pre-eclampsia but significantly higher in severe pre-eclampsia, which is 
consistent with platelet activation in pre-eclampsia. 
 
 
Thromboxane is a vasoactive substance. In pre-eclampsia, as a result of failure of uterine 
spiral arteriole conversion by extravillous trophoblasts into large capacitance vessels, spiral 
arterioles  maintain  their  muscular  coat  which  allows  them  to  be  influenced  by  the 
vasoconstrictive  properties  of  thromboxane.  Therefore,  the  increased  thromboxane: 
prostacyclin  ratio  can  lead  to  the  features  of  pre-eclampsia;  vascular  hypertension, 
increased platelet aggregation and reduced uteroplacental blood flow [reviewed in (218)]. 
 
 
6.1.3  Thromboxane and prostacyclin synthesis from fatty acids 
 
 
The  eicosanoids  thromboxane  and  prostacyclin  are  synthesised  from  their  fatty  acid 
precursors [illustrated in figure 1.5.3]. The 2-series eicosanoids have a greater potency of 
action than 3-series eicosanoids. The 2-series eicosanoids are synthesised from n-6 fatty 
acids  while  3-series  eicosanoids  are  synthesised  from  n-3  fatty  acids.  Therefore,  the 
balance of n-6 to n-3 fatty acids in the body can determine the balance of which of these 
types of eicosanoids will be synthesised. As thromboxane A2 has a greater potency of 
action compared to thromboxane A3, greater thromboxane A2 synthesis in platelets will 
lead to greater platelet activity leading to a procoagulant state. 
 
 
6.1.4  Fatty acids 
 
 
Fatty acids are precursors of eicosanoids. In PUFA metabolism in humans, the precursor of 
the n-6 series PUFAs is linoleic acid and the precursor of the n-3 series PUFAs is α-
linolenic  acid.  These  precursors  are  metabolised  into  their  respective  products  by  the 
sequential  actions  of  desaturase  and  elongase  enzymes.  Desaturases  and  elongases  are 
shared between the different groups of fatty acids which lead to competitive inhibition and 
the major determinant of which fatty acid group is preferentially synthesised is the amount 
of substrate present (see figure 1.5.4). It has been suggested that humans originally evolved 
on a diet where n-6 to n-3 fatty acid intake was in the ratio of 1:1. In the current western   152 
diet,  the  n-6:  n-3  ratio  ranges  from  10:1  to  25:1(244),  leading  to  the  majority  of 
eicosanoids produced being of the potent 2-series prostaglandins (including thromboxane 
A2). The can lead to a state which favours thrombosis and vasoconstriction.  
 
 
6.1.4.1 Maternal fatty acid status in healthy pregnancy 
 
 
Various changes in maternal plasma levels of fatty acids have been identified in healthy 
pregnant women versus non-pregnant women. Most studies measured fatty acid levels in 
plasma but this measure can be confounded by the subjects’ fasting status. A more accurate 
measure  of  fatty  acids  may  be  obtained  by  analysing  the  fatty  acid  composition  of 
erythrocyte cell membranes. The half-life of an erythrocyte if 120 days and so a measure of 
erythrocyte membrane fatty acid composition would be representative of the mother’s fatty 
acid status over the preceding 3 months. 
 
 
Various  groups  have  measured  erythrocyte  fatty  acid  composition  in  healthy 
pregnancy(249-254). With regards to n-6 fatty acids, linoleic acid, dihomo-γ-linolenic acid 
(DHLA), arachidonic acid, and n-6 docosapentaenoic acid (n-6 DPA) were found to be 
higher in pregnancy compared to healthy non-pregnant controls. With regards to n-3 fatty 
acids,  α-linolenic  acid  and  DHA  were  found  to  be  higher  compared  to  healthy  non-
pregnant  controls.  Nervonic  acid  (24:1  n-9)  and  palmitoleic  acid  (16:1  n-7)  were  also 
found to be higher in healthy pregnancy compared to healthy non-pregnant controls. This 
general increase of fatty acids may be due to greater maternal mobilisation of fatty acids in 
healthy pregnancy. In the third trimester, some fatty acids such as arachidonic acid, EPA, 
n-6 DPA and DHA become reduced compared to the second trimester levels. 
 
 
6.1.4.2 Maternal fatty acid status in pre-eclampsia 
 
 
There is some evidence that n-3 fatty acids may be protective towards the development of 
pre-eclampsia.  Individuals  who  had  an  increased  intake  of  some  n-3  PUFAs  were 
associated with a lower risk of developing pre-eclampsia. Conversely, low levels of total n-
3 fatty acids as well as low levels of EPA and DHA were associated with an increased risk   153 
of pre-eclampsia. It was also found that pregnant women with the lowest ratio of n-3 to n-6 
fatty acids in maternal erythrocytes had a higher risk of developing pre-eclampsia (259). 
 
 
Fatty acids have been measured in the maternal plasma of pre-eclamptic pregnancies and 
there was a trend towards lower levels of total PUFAs, EPA and DHA in pre-eclampsia 
compared to healthy pregnant controls. Higher levels of arachidonic acid as a percentage of 
total fatty acids have been found in pre-eclampsia. While these studies measured fatty acid 
changes  in  maternal  plasma  in  pre-eclampsia,  there  did  not  appear  to  be  any  studies 
looking at fatty acid changes in maternal erythrocyte cell membranes in pre-eclampsia.  
 
 
6.2  Hypothesis 
 
 
I hypothesised that there may be an imbalance of maternal levels of n6 and n3 fatty acids 
in pre-eclampsia. As fatty acids are the precursors in the synthesis of various eicosanoids, 
an imbalance in n6 and n3 fatty acids may lead to greater synthesis of potent thromboxanes 
and this may influence coagulation activation, endothelial activation, placental function 
and microparticle procoagulant activity in the maternal circulation. 
 
 
Objectives: 
 
 
1)  To measure the fatty acid profile of pre-eclamptic and healthy pregnant control 
populations from chapter 5 of this thesis. To avoid the subjects fasting status as a 
confounder,  erythrocyte  cell  membranes  fatty  acids  were  measured.  Statistical 
significance was set at p=0.005 to account for multiple analyses. 
 
 
2)  To  correlate  these  fatty  acids  to  markers  of  coagulation,  endothelial  function, 
placental function as well as microparticle procoagulant activity (as per chapter 5) 
in both pre-eclamptic and healthy control samples. 
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6.3  Results 
 
 
6.3.1  Patient groups 
 
 
The patient groups are a subset from the sample population in chapter 5 of this thesis. Pre-
eclamptic  patients  (n=26)  and  healthy  pregnant  control  patients  (n=25)  were  analysed. 
They were matched for age, body mass index (BMI), gestation at sampling and parity (0 or 
≥1).  The  patient  characteristics  are  shown  in  table  6.3.1.  There  were  significantly  less 
smokers in the pre-eclamptic group in keeping with the known inverse association between 
smoking  and  risk  of  pre-eclampsia(286).  The  pre-eclamptic  patients  also  delivered 
significantly earlier and their babies had significantly lower mean birth weight centiles in 
keeping with the known characteristics of pre-eclamptic pregnancies. 
 
 
6.3.2  Erythrocyte fatty acid composition 
 
 
The  following  fatty  acid  groups  were  analysed:  saturated  fatty  acids  (SaFA), 
monounsaturated fatty acids (MUFA) and the n-3 and n-6 groups of polyunsaturated fatty 
acids  (PUFA).  These  fatty  acids  were  measured  both  as  a  percentage  (%)  of  the  total 
amount of fatty acids in the sample and also in absolute quantities (nmol/ml). The results 
are shown in tables 6.3.2.1 (percentage) and 6.3.2.2 (absolute quantity). 
 
 
6.3.2.1 Measurement as a percentage of total fatty acids 
 
 
In the saturated fatty acid group, there was a higher percentage of palmitic acid (16:0) in 
pre-eclamptic samples compared to healthy pregnant controls [pre-eclampsia mean 28.61 
(SD 4.08) % vs. controls mean 24.26 (SD 3.96) %, p<0.001]. In the monounsaturated fatty 
acid (MUFA) group, there was a higher percentage of palmitoleic acid (16:1 n-7) in pre-
eclamptic samples compared to healthy pregnant controls [0.90 (0.44) vs. 0.55 (0.36) %, 
p=0.004]. There was a higher percentage of oleic acid (18:1 n-9) in pre-eclamptic samples 
compared to healthy pregnant control samples [16.15 (1.62) vs. 14.70 (1.68) %, p=0.003].    155 
 
 
 
Characteristic  Pre-eclamptic 
(n=26) 
Healthy pregnant controls 
(n=25) 
p-value 
 
Age 
(years) 
28.0 (6.3)  28.7 (6.0)  0.70 
BMI 
(kg/m
2) 
26.4 (5.0)  26.0 (4.5)  0.76 
Number of Smokers 
n (%) 
0  5  0.02 
Gestation at sampling 
(weeks) 
35.9 (3.4)  36.2 (4.1)  0.80 
Primiparous 
(number of) 
20  21  0.53 
Gestation at delivery 
(weeks) 
36.3 (3.2)  39.5 (1.0)  <0.001 
Mean birth weight 
centile 
20.5 (25.5)  46.6 (28.3)  0.001 
 
Table  6.3.1:  Patient  characteristics  of  pre-eclamptic  and  healthy  control  groups  in 
erythrocyte  cell  membrane  fatty  acid  analysis.  Mean  (standard  deviation).  Statistical 
significance set at P < 0.05. 
 
 
 
In the n-6 polyunsaturated fatty acid (PUFA) group, dihomogamma-linolenic acid (20:3 n-
6)  was  found  to  be  significantly  lower  in  pre-eclamptic  samples  compared  to  healthy 
pregnant control samples [1.05 (0.64) vs. 1.70 (0.71) %, p=0.001]. Arachidonic acid (20:4 
n-6) was found to be significantly lower in pre-eclamptic samples compared to healthy 
pregnant controls [7.19 (4.17) vs. 11.14 (3.88) %, p=0.001]. In the n-3 group of PUFAs, 
docosahexaenoic  acid  (22:6  n-3)  was  found  to  be  significantly  lower  in  pre-eclamptic 
samples compared to healthy pregnant controls [1.84 (1.73) vs. 2.89 (1.66) %, p=0.002]. 
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 Fatty acid  
 
Pre-eclamptic  
(n=26) 
Control 
(n=25) 
Two-sample T test 
p value 
SaFA       
12:0  0.15 (0.31)  0.02 (0.11)  0.05 
14:0  0.65 (0.34)  0.55 (0.39)  0.33 
16:0  28.61 (4.08)  24.26 (3.96)  <0.001 
17:0  0.19 (0.28)  0.22 (0.25)  0.69 
18:0  16.61 (2.37)  16.92 (3.16)  0.70 
20:0  0.62 (0.23)  0.59 (0.210)  0.60 
22:0  2.27 (0.64)  1.76 (0.88)  0.02 
24:0*  5.34 (1.49)  4.53 (1.66)  0.04 
MUFA       
16:1 n7  0.90 (0.44)  0.55 (0.36)  0.004 
17:1 n7  0.05 (0.19)  0.004 (0.02)  0.20 
18:1 n9  16.15 (1.62)  14.70 (1.68)  0.003 
20:1 n9  0.26 (0.32)  0.37 (0.21)  0.14 
22:1 n9  0.21 (0.41)  0.09 (0.30)  0.27 
24:1 n9  6.58 (0.90)  6.03 (1.13)  0.06 
PUFA n6         
18:2 n6  6.41 (1.72)  7.59 (1.55)  0.01 
18:3 n6  0.01 (0.07)  0.08 (0.16)  0.07 
20:2 n6  0.11 (0.21)  0.15 (0.20)  0.46 
20:3 n6  1.05 ( 0.64)  1.70 (0.71)  0.001 
20:4 n6  7.19 (4.17)  11.14 (3.88)  0.001 
22:4 n6  1.71 (1.41)  2.05 (0.85)  0.30 
22:5 n6  0.24 (0.36)  0.56 (0.35)  0.008 
PUFA n3       
18:3 n3  0.06 (0.14)  0.17 (0.31)  0.11 
20:5 n3  1.06 (0.77)  1.11 (0.64)  0.80 
22:3 n3  0.31 (0.31)  0.31 (0.26)  1.00 
22:5 n3  1.35 (1.02)  1.61 (0.68)  0.30 
22:6 n3*  1.84 (1.73)  2.89 (1.66)  0.002 
 
Table 6.3.2.1: Comparison of erythrocyte fatty acid composition (as a % of total fatty 
acids) in maternal blood between pre-eclamptic patients and healthy pregnant controls. * 
using log transformed values. SaFA (saturated fatty acids), MUFA (monounsaturated fatty 
acids) and PUFA (polyunsaturated fatty acids). Statistical significance is set at a p-value of 
0.005 and highlighted in bold.  
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6.3.2.2 Measurement as absolute amounts of fatty acids 
 
 
In the n-6 polyunsaturated fatty acid (PUFA) group, dihomogamma-linolenic acid (20:3 n-
6)  was  found  to  be  significantly  lower  in  pre-eclamptic  samples  compared  to  healthy 
pregnant  control  samples  [pre-eclampsia  mean  19.89  (SD  15.06)  nmol/ml  vs.  controls 
33.52  (15.99)  nmol/ml,  p=0.003].  Arachidonic  acid  (20:4  n-6)  was  found  to  be 
significantly lower in pre-eclamptic samples compared to healthy pregnant controls [136.0 
(108.8) vs. 224.9 (96.0) nmol/ml, p=0.003]. In the n-3 group of PUFAs, docosahexaenoic 
acid (22:6 n-3) was found to be significantly lower in pre-eclampsia compared to healthy 
pregnant controls in absolute amounts [34.50 (37.87) vs. 53.98 (31.74) nmol/ml, p=0.002]. 
 
 
6.3.3  Summary measures of erythrocyte fatty acid composition 
 
 
The results of summary measures for fatty acids are shown in table 6.3.3. Total MUFA was 
significantly higher in pre-eclamptic patients compared to healthy pregnant controls (pre-
eclamptic mean 23.09 (SD 2.20) % vs. controls mean 20.88 (SD 1.63) %, p<0.001]. There 
was significantly lower total PUFAs as a percentage of total fatty acids in pre-eclamptic 
compared to healthy controls [20.39 (8.78) vs. 28.06 (8.06) %, p=0.002]. 
 
 
The different fatty acid classes (n-9, n-7, n-6 and n-3) were measured as a percentage of 
total fatty acids in the pre-eclamptic and healthy pregnant control groups. There was a 
higher percentage of total n-9 fatty acids in pre-eclamptic vs. healthy pregnant control 
samples [pre-eclamptic mean 22.02 (SD 2.04) % vs. control mean 20.24 (SD 1.75) %, 
p=0.002]. There was also a higher percentage of total n-7 fatty acids in pre-eclamptic vs. 
healthy pregnant control samples [1.06 (0.60) vs. 0.63 (0.41) %, p=0.004]. In contrast, 
there was a lower percentage of total n-6 fatty acids in pre-eclamptic vs. healthy pregnant 
control  samples  [16.26  (7.10)  vs.  22.61  (6.62)  %,  p=0.002].  There  was  no  statistical 
difference in total n-3 PUFAs in the pre-eclamptic group compared to healthy pregnant 
controls [4.14 (2.02) vs. 5.48 (1.85) %, p=0.02]. The ratio of total n-6 to n-3 fatty acids (n-
6/n-3) was compared and it was found that there was no significant difference between the 
pre-eclamptic and healthy pregnant control groups [4.41 (2.25) vs. 4.30 (1.31) %, p=0.83].    158 
 
 
Fatty acid   Pre- eclamptic 
(n=26) 
Control 
(n=25) 
Two-sample T test 
p value 
SaFA       
12:0  4.57 (9.18)  0.59 (2.94)  0.04 
14:0  14.73 (6.78)  13.77 (8.80)  0.67 
16:0  564.4 (108.7)  539.7 (104.1)  0.41 
17:0  3.51 (5.08)  4.88 (5.67)  0.37 
18:0  299.6 (68.8)  336.5 (60.3)  0.05 
20:0  10.55 (3.86)  11.12 (4.41)  0.63 
22:0  33.60 (10.16)  31.18 (15.11)  0.51 
24:0  72.65 (19.34)  67.62 (12.78)  0.28 
MUFA       
16:1 n7  18.19 (8.48)  12.20 (7.22)  0.01 
17:1 n7  0.46 (1.99)  0.08 (0.38)  0.34 
18:1 n9  294.2 (69.8)  305.3 (83.8)  0.61 
20:1 n9  4.41 (5.72)  7.27 (4.65)  0.06 
22:1 n9  2.93 (6.03)  1.26 (3.58)  0.23 
24:1 n9  91.45 (20.02)  95.42 (26.32)  0.55 
PUFA n6         
18:2 n6  122.1 (55.7)  162.70 (54.0)  0.01 
18:3 n6  0.38 (1.92)  1.81 (3.73)  0.10 
20:2 n6  2.16 (4.10)  3.25 (4.43)  0.37 
20:3 n6  19.89 (15.06)  33.52 (15.99)  0.003 
20:4 n6  136.0 (108.8)  224.9 (96.0)  0.003 
22:4 n6  25.85 (22.01)  37.70 (17.86)  0.04 
22:5 n6  5.38 (7.24)  10.44 (6.74)  0.01 
PUFA n3       
18:3 n3  1.34 (3.29)  3.15 (5.02)  0.14 
20:5 n3  15.92 (8.20)  20.07 (9.51)  0.10 
22:3 n3  5.00 (4.92)  5.78 (4.90)  0.57 
22:5 n3  18.90 (13.93)  29.42 (13.79)  0.01 
22:6 n3*  34.50 (37.87)  53.98 (31.74)  0.002 
 
 
Table  6.3.2.2:  Comparison  of  erythrocyte  fatty  acid  composition  in  absolute  amounts 
(nmol/ml) in maternal blood between pre-eclamptic patients and healthy pregnant controls. 
* using log transformed values. SaFA (saturated fatty acids), MUFA (monounsaturated 
fatty acids), PUFA (polyunsaturated fatty acids). Statistical significance is set at a p-value 
of 0.005 and highlighted in bold. 
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Fatty acid  
 
Pre-eclamptic 
(n=26) 
Control 
(n=25) 
Two-sample T test 
p value 
% saturated  56.52 (7.41)  51.07 (7.49)  0.01 
% unsaturated  43.48 (7.41)  48.93 (7.49)  0.01 
% MUFA  23.09 (2.20)  20.88 (1.63)  <0.001 
% PUFA  20.39 (8.78)  28.06 (8.06)  0.002 
Total n-9   22.02 (2.04)  20.24 (1.75)  0.002 
Total n-7   1.06 (0.60)  0.63 (0.41)  0.004 
Total n-6   16.26 (7.10)  22.61 (6.62)  0.002 
Total n-3   4.14 (2.02)  5.48 (1.85)  0.02 
n-6/n-3 ratio  4.41 (2.25)  4.30 (1.31)  0.83 
Unsaturated index  105.23 (32.45)  130.65 (32.46)  0.01 
Average chain length   18.33 (0.23)  18.51 (0.28)  0.02 
C20-22   20.81 (6.22)  26.01 (6.44)  0.005 
20:4n6/20:3n6 ratio  6.11 (1.47)  6.91 (2.22)  0.15 
22:6n3/22:5n3 ratio  1.40 (0.89)  1.89 (0.75)  0.047 
18:1n9/18:0     ratio  0.99 (0.12)  0.89 (0.13)  0.01 
18:0/16:0         ratio  0.53 (0.06)  0.63 (0.07)  <0.001 
 
Table 6.3.3: Comparison of erythrocyte fatty acid composition (as a % of total fatty acids) 
between pre-eclamptic patients and healthy pregnant controls. Statistical significance is set 
at a p-value of 0.005 and are highlighted in bold. The 20:4n6/20:3n6 ratio is an index of  
5 
desaturase  activity,  the  22:6n3/22:5n3  ratio  is  an  index  of   
6  desaturase  activity,  the 
18:1n9/18:0 ratio is an index of stearoyl-CoA desaturase activity and the 18:0/16:0 ratio is 
an index of elongase activity. 
 
 
 
Long chain fatty acids [chain length of 20 to 22 carbon atoms (C20-22)] were measured as 
a percentage of the total amount of fatty acids. It was found that there was a significantly 
lower percentage of long chain fatty acids in the pre-eclamptic group compared to the 
healthy pregnant control group [20.81 (6.22) vs. 26.01 (6.44) %, p=0.005]. 
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In order to assess the activity of the various desaturase enzymes, the product: precursor 
ratios  were  calculated.  There  was  no  significant  difference  in   
5  desaturase  activity 
between pre-eclamptic and healthy pregnant control patients as measured by the 20:4 n-
6/20:3 n-6 ratio [pre-eclamptic mean 6.11 (SD 1.47) % vs. control mean 6.91 (SD 2.22) %, 
p=0.15]. There was no significant difference in  
6 desaturase activity in the pre-eclamptic 
group compared to the healthy pregnant control group as measured by the 22:6n3/22:5n3 
ratio  [1.40  (0.89)  vs.  1.89  (0.75)  %,  p=0.047].  There  was  no  significant  difference  in 
stearoyl-CoA  desaturase  activity  in  the  pre-eclamptic  group  compared  to  the  healthy 
pregnant group as measured by the 18:1 n-9/18:0 ratio [0.99 (0.12) vs. 0.89 (0.13) %, 
p=0.01]. The ratio of total 18:0 to 16:0 fatty acids was compared as an estimate of elongase 
activity and it was found that this ratio was significantly  reduced in the pre-eclamptic 
group  compared  to  the  healthy  pregnant  control  group  [0.53  (0.06)  vs.  0.63  (0.07)  %, 
p<0.001]. 
 
 
6.3.4  Correlation of fatty acids to coagulation factors, markers of endothelial 
function, placental function and microparticle procoagulant activity 
 
 
In healthy pregnant control patients, tissue factor pathway inhibitor (TFPI) was found to be 
positively  correlated  with  the  absolute  amounts  of  24:1  n-9  (nervonic  acid)  [r=0.40, 
p=0.05]. TFPI was also found to be positively correlated with the absolute amounts of 18:2 
n6  (linoleic  acid)  [r=0.54,  p<0.01]  as  well  as  its  metabolites  20:3  n6  (dihomogamma-
linolenic acid) [r=0.48, p=0.02] and 20:4 n6 (arachidonic acid) [r=0.52, p= 0.01]. These 
correlations are illustrated in figure 6.3.4.1 (A to D). Plasminogen activator inhibitor-1 
(PAI-1),  was  found  to  be  positively  correlated  with  the  absolute  amounts  of  18:2  n6 
[r=0.44, p=0.03] and 20: 3 n6 [r=0.41, p= 0.04]. These correlations are illustrated in figure 
6.3.4.2 (A and B). Plasminogen activator inhibitor-2 (PAI-2) was found to be positively 
correlated  with  the  absolute  amounts  of  18:2  n6  [r=0.49,  p=0.02].  This  correlation  is 
illustrated in figure 6.3.4.3.  
 
 
In pre-eclamptic patients, activated factor XII (FXIIa) levels were found to be positively 
correlated with the absolute amounts of the monounsaturated fatty acid 24:1 n9 (nervonic 
acid) [r=0.418, p=0.03)]. FXIIa levels were also found to be positively correlated with the   161 
absolute amounts of polyunsaturated the fatty acids 18:2 n6 (linoleic acid) [r=0.41, p=0.04] 
and its metabolites 20:3 n6 (dihomogamma-linolenic acid) [r=0.44, p= 0.03], and 20:4 n6 
(arachidonic acid) [r=0.44, p=0.03]. These correlations are illustrated in figure 6.3.4.4 (A 
to D).  
 
 
There was no correlation with the results of other markers of coagulation activation (tissue 
factor, thrombin-antithrombin, factor 1+2, factor VII or APC ratio) endothelial function 
(soluble ICAM, soluble VCAM, vonWillebrands factor), placental function (PAI-1/PAI-2 
ratio) or plasma microparticle pro-coagulant activity as measured in Chapter 5. 
 
 
6.4  Discussion 
 
 
This study of fatty acids was a cross-sectional case-control study examining the differences 
in  fatty  acid  levels  between  pre-eclamptic  and  healthy  pregnant  controls.  It  must  be 
remembered however, that the balance of fatty acids in body may be described as a flux, as 
the amount of fatty acids in the body is continually affected by dietary intake, synthesis 
from fatty acid precursors and utilisation of fatty acids to create various substances such as 
eicosanoids,  phospholipids  and  triglycerides.  Additionally,  in  pregnancy,  the  placenta 
removes fatty acids from maternal stores to supply the growing fetus. This cross-sectional 
study would only examine the amount of fatty acids in the mother at steady-state levels and 
cannot identify if the change in level of a particular fatty acid was due to increased or 
decreased synthesis or  utilisation. More sophisticated labelling of fatty acids would be 
required to identify the fatty acids along its metabolic pathways. 
 
 
The  measurement  of  a  fatty  acid  as  a  concentration  defines  the  actual  amount  of  that 
particular  fatty  acid  in  the  sample.  The  measurement  of  a  fatty  acid  expressed  as  a 
percentage defines the proportion of that fatty acid out of the total amount of fatty acids in 
the sample. Therefore, the value of a fatty acid expressed as a percentage can be affected 
by changes in the amounts of other fatty acids present in that sample. 
   162 
45 35 25
150
100
 50
TFPI (ng/ml)
2
4
:
1
 
n
9
 
(
n
m
o
l
/
m
l
)
 
45 35 25
60
50
40
30
20
10
 0
TFPI (ng/ml)
2
0
:
3
 
n
6
 
(
n
m
o
l
/
m
l
)
45 35 25
250
150
 50
TFPI (ng/ml)
1
8
:
2
 
n
6
 
(
n
m
o
l
/
m
l
)
 
A  r=0.397          B  r=0.54 
    p=0.05             p <0.01 
 
C  r=0.48           D  r=0.52 
    p=0.02             p=0.01 
     
 
 
Figure 6.3.4.1: Correlation between fatty acids 24:1 n9 (A), 18:2 n6 (B), 20:3 n6 (C) and 
20:4 n6 (D) with TFPI in healthy pregnant control patients. 
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Figure 6.3.4.2: Correlation between fatty acids 18:2 n6 (A) and 20:3n6 (B) with PAI-1 in 
healthy pregnant control patients 
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Figure 6.3.4.3: Correlation between fatty acid 18:2 n6 (A) with PAI-2 in healthy pregnant 
control patients 
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Figure 6.3.4.4: Correlation between fatty acids 24:1 n9 (A), 18:2 n6 (B), 20:3 n6 (C) and 
20:4 n6 (D) with factor XIIa in pre-eclamptic patients 
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The  percentage  of  palmitic  acid  (16:0)  was  significantly  higher  (by  18%)  in  the  pre-
eclamptic  group  compared  to  the  healthy  pregnant  control  group  but  there  was  no 
significant difference in the absolute amounts of palmitic acid between the pre-eclamptic 
and healthy pregnant groups (p=0.41). There was also a significantly higher percentage of 
16:1 n-7 (by 64%) and 18:1 n-9 (by 9.9%) in the pre-eclamptic group compared to the 
healthy pregnant group. When measured in absolute amounts, there was a substantially 
higher amount of 16:1 n-7 in the pre-eclamptic group compared to the control group (by 
49%). In the n-6 series of fatty acids, there were significantly lower percentages of 20:3 n-
6 (by 38%) and 20:4 n-6 (by 35.5%) in the pre-eclamptic group compared to the healthy 
pregnant group and when measured in absolute amounts, both 20:3 n-6 and 20:4 n-6 were 
also significantly reduced (by 40.7% and by 39.5% respectively). In the n-3 fatty acid 
series, DHA (22:6 n-3) was lower both as a percentage of total fatty acids (by 36.3%) and 
in absolute amounts (by 36%) in pre-eclamptic samples. The pattern of fatty acids changes 
in  pre-eclampsia  are  similar  to  the  literature  in  some  respects.  Absolute  amounts  of 
palmitoleic acid were higher in pre-eclampsia in keeping with the findings of Lorentzen et 
al(260). There were lower absolute values of the long chain n-3 PUFAs 22:5 n-3 and 22:6 
n-3 in pre-eclampsia in keeping with the findings of Wang et al(261). However in contrast 
to the findings of Ogburn et al(263), there was a lower percentage of arachidonic acid in 
pre-eclampsia.  Although  there  are  differences  between  my  findings  and  that  of  other 
studies, it must be noted that the fatty acids in this study was measured from erythrocyte 
cell membranes while other studies looked at fatty acids in maternal serum, which is open 
to confounders such as maternal fasting status. The measure of fatty acids in erythrocyte 
cell membranes are a more accurate reflection of maternal fatty acid status. 
 
 
These fatty acid changes are reflected in the summary indices. In pre-eclamptic samples, 
there were significantly higher percentages of total MUFAs (by 10.6%), total n-9 fatty 
acids  (by  8.8%)  and  total  n-7  fatty  acids  (by  68.3%)  and  this  corresponds  with  the 
significantly  higher  percentages  of  16:0,  18:1  n-9  and  16:1  n-7  in  pre-eclampsia.  In 
contrast, there were significantly lower percentages of total PUFAs (by 27.3%) total n-6 
fatty  acids  (by  28.1%)  and  total  long  chain  fatty  acids  (C20-22)  (by  20%)  which 
corresponds with the significantly lower percentages of 20:3 n-6, 20:4 n-6 as well as 22:6 
n-3 in pre-eclampsia. When measured in absolute values, it was found that these same fatty 
acids 20:3 n-6, 20:4 n-6 and 22:6 n-3 were also significantly lower in pre-eclampsia. This 
suggests that the reduction in percentage of these three long chain PUFAs are due to a   166 
reduction in absolute amounts of these fatty acids in pre-eclampsia and not necessarily as a 
result of higher amounts of other fatty acids. 
 
 
One explanation for the higher percentages of palmitic acid, palmitoleic acid and oleic acid 
in pre-eclampsia may be greater mobilisation of these fatty acids from maternal stores. The 
predominant fatty acid in storage in adipocytes is palmitic acid and if there is increased 
maternal mobilisation of palmitic acid in pre-eclampsia, there will be a greater amount of 
substrate available for the synthesis of palmitoleic acid and oleic acid. Indeed, in the pre-
eclampsia group, there was a 49% greater absolute amount of 16:1 n-7 along with a trend 
towards greater steroyl Co-A desaturase activity (by 11%) compared to healthy controls, 
suggesting  that  there  may  have  been  a  higher  amount  of  its  substrate  palmitic  acid 
available. 
 
 
There were significantly lower absolute amounts as well as percentages of dihomogamma-
linolenic acid (20:3 n-6) and arachidonic acid (20:4 n-6) in pre-eclampsia. It is possible 
that this may be due to a dietary deficiency of 20:3 n-6 and 20:4 n-6 prior to and during 
pregnancy. Another reason why there may be lower absolute amounts of 20:3n-6 and 20:4 
n-6 in pre-eclamptic patients may be due to a dietary deficiency of the essential fatty acid 
precursor linoleic acid. Pre-eclamptic women may have had a lower intake of linoleic acid 
prior to and during pregnancy compared to healthy controls and certainly, the absolute 
amounts of linoleic acid (18:2 n-6) was found to be lower in pre-eclamptic samples by 
25%, but this difference was not statistically significant (p=0.01). However, there was no 
dietary  data  obtained  from  the  pre-eclamptic  and  healthy  control  patients  and  so  I  am 
unable to address this hypothesis. 
 
 
Pre-eclampsia is a procoagulant state and it is possible that the fatty acids 20:3 n-6 and 
20:4 n-6 may have been utilised into the synthetic pathway of the potent procoagulant 
eicosanoid  thromboxane  A2  (refer  to  figure  1.5.3  for  the  eicosanoid  synthesis  pathway 
from n-6 and n-3 fatty acids). Greater utilisation of these n-6 fatty acids into the synthesis 
may thus lead to a reduced maternal level of these fatty acids storage in erythrocytes. 
Certainly, this shift of balance towards the synthesis of more potent eicosanoids would be 
in keeping with the procoagulant state of pre-eclampsia and pre-eclamptic placentas have 
been found to produce up to three times as much thromboxane A2 as healthy placentas   167 
(221;222). It would be desirable to measure the amount of thromboxane produced by these 
pre-eclamptic patients, perhaps by measuring the plasma level of thromboxane metabolites 
(eg.  thromboxane  B2)  and  correlate  the  concentrations  of  20:3  n-6  and  20:4  n-6  with 
thromboxane B2. 
 
 
The n-3 fatty acid DHA (22:6n-3) has been found to be lower both as a percentage and in 
absolute amounts in pre-eclampsia. However, there was no significant difference in the 
other n-3 fatty acids either as a percentage or in absolute values between the pre-eclamptic 
and  healthy  controls  nor  was  there  any  significant  difference  in   
6  desaturase  or   
5 
desaturase activity. DHA is abundant in neural and retinal tissues. It is possible that in 
comparison to healthy pregnancy, pre-eclamptic women had lower amounts of dietary 22:6 
n-3 and as 22:6 n-3 is involved in the synthesis of the less potent thromboxane A3 (refer to 
figure 1.5.4), a reduced dietary intake of 22:6 n-3 would lead to lower maternal stores 
which would lead to a lower amount of less potent thromboxane A3 synthesis. Certainly, 
low levels of 22:6 n-3  as well as  a low n-3:n-6 fatty  acid  ratio has been found to be 
associated with an increased risk of developing pre-eclampsia(258;259) and supplementary 
studies of fish oil (high in n-3 fatty acids) in pregnant women led to higher levels of the 
less potent thromboxane A3 and lower levels of the more potent thromboxane A2 (290). In 
the last trimester of pregnancy, the fetal requirements of 20:4 n-6 and 22:6 n-3 (DHA) are 
especially  high  as  there  is  rapid  development  of  fetal  retinal  as  well  as  brain 
tissue(247;268)  and  this  reduced  amount  of  maternal  22:6  n-3  may  be  due  to  fetal 
accretion. 
 
 
Fatty acids measured in the pre-eclamptic and healthy control group were correlated to 
markers  of  endothelial  activation,  placental  function  and  microparticle  pro-coagulant 
activity as measured in chapter 5. Total TFPI was found to be positively correlated with the 
absolute  amounts  of  nervonic  acid  (24:1  n-9)  in  healthy  pregnant  controls.  TFPI  is 
expressed by cytotrophoblasts, syncytiotrophoblasts and the vascular endothelium(124). In 
chapter 5 of this thesis, TFPI was shown to be positively correlated with fetal CRH mRNA 
levels (a measure of placental debris) in maternal plasma suggesting that TFPI may simply 
be shed along with the placental debris. As healthy pregnancy progresses, Stewart et al 
(249) had shown an increase in absolute amounts of 24:1 n-9 (p=0.0032) as well as a 
positive correlation of 24:1 n-9 with placental weight. Therefore, this finding of a positive 
correlation of total TFPI with 24:1 n-9 may simply reflect greater TFPI shed along with   168 
placental  debris  with  the  growing  placenta  as  pregnancy  progresses.  Certainly  in  my 
samples, there was an increase in fetal CRH mRNA levels in healthy pregnancies above 36 
weeks’ gestation. TFPI was also positively correlated with the n-6 fatty acids 18:2 n-6, 
20:3 n-6 and 20:4 n-6 in healthy pregnancy. As healthy pregnancy progresses, Stewart et al 
(249) has shown a trend towards an increase in amounts of 18:2 n-6 (p=0.041) and 20:3 n-
6  (p=0.02).  In  vitro  studies  have  shown  that  TFPI  enhances  lipoprotein  lipase  activity 
which increases triglyceride hydrolysis (291). This may explain the correlation of TFPI 
with 18:2 n-6, 20:3 n-6 and 20:4 n-6 as increased triglyceride hydrolysis may result in the 
release of 18:2 n-6 and the subsequent conversion of 18:2 n-6 to longer chain PUFAs.  
 
 
PAI-1 is synthesised by various cell types including the placenta and adipose tissue and its 
levels have been found to be increased in obesity(292). In our healthy pregnant control 
group, PAI-1 was found to be positively correlated with absolute amounts of linoleic acid 
(18:2 n-6) and dihomogamma-linolenic acid (20:3 n-6). PUFAs have been found to be able 
to regulate the expression of genes by binding to nuclear receptor proteins and alter the 
transcription of target  genes(293;294).  Human  umbilical vein endothelial cells cultured 
with DHA (22:6 n-3) and dihomo-γ-linolenic acid (20:3 n-6) have been shown to result in 
an increase in the amount of PAI-1 mRNA suggesting that 22:6 n-3 and 20:3 n-6 may 
directly induce PAI-1 transcription (295). In vitro experiments have also shown PAI-1 
production from HepG2 cells when cultured with linoleic acid(296). It is possible that both 
linoleic acid and dihomo-γ-linolenic acid may both induce PAI-1 mRNA transcription thus 
leading to greater PAI-1 synthesis.  
 
 
PAI-2 is produced by the placenta and is correlated with infant birth weight(172). In our 
healthy pregnant control group, PAI-2 was found to be positively correlated with absolute 
amounts of linoleic acid (18:2 n-6). Stewart et al (249)showed a trend towards an increase 
in maternal levels of linoleic acid as healthy pregnancy progressed (p=0.041). It is possible 
this correlation of linoleic acid with PAI-2 may simply be a reflection of placental growth. 
 
 
In pre-eclamptic patients, activated factor XII (FXIIa) levels were found to be positively 
correlated with the monounsaturated fatty acid  nervonic acid (24:1 n-9) as well as the 
polyunsaturated  n-6  fatty  acid  18:2  n-6  and  its  metabolites  20:3  n-6  and  20:4  n-6.  In 
chapter 5,  FXIIa levels  were found to be significantly higher in pre-eclamptic patients   169 
compared to healthy pregnant controls. Factor XIIa can be both pro- and anticoagulant in 
nature and there is little in the literature regarding FXIIa in relation to thromboxane and 
prostacyclines or the fatty acids 24:1 n-9, 18:2 n-6, 20:3 n-6 and 20:4 n-6. However it has 
been  noted  in  vitro  that  FXIIa  binding  to  the  platelet  glycoprotein  Ib-IX-V  complex 
inhibits thrombin-induced platelet aggregation(297). It is possible that FXIIa levels may be 
raised in pre-eclampsia to counteract increased platelet activation and thus adhesion. 
 
 
In summary, my findings of fatty acid patterns in pre-eclampsia are similar to what is in 
current literature but the measure of maternal fatty acids using erythrocyte cell membranes 
as opposed to plasma measures would mean that my results are not open to the influence of 
maternal  fasting  status.  With  regard  to  coagulation,  the  most  relevant  finding  was  the 
reduced amounts of total n-6, 20:3 n6 and 20:4 n-6 fatty acids which may be a reflection of 
greater utilisation of n-6 fatty acids into the synthesis of the potent thromboxane A2 which 
may contribute to the procoagulant state of pre-eclampsia. 
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Chapter 7  Discussion 
 
 
Pre-eclampsia affects approximately 2-7 % of all pregnancies in the United Kingdom and 
is a significant cause of maternal and fetal morbidity and mortality. The development of 
the syndrome of pre-eclampsia is multifactorial and may include a disorder in coagulation, 
endothelial  function  and  placental  function.  The  aetiology  of  pre-eclampsia  is  still 
unknown. However it is clear that there are both fetal and maternal factors involved. A 
two-stage model of pre-eclampsia has been proposed(298). The first stage of pre-eclampsia 
involves  abnormal  placentation  and  is  considered  the  ‘root  cause’.  Reduced  placental 
perfusion  is  a  feature  in  pre-eclampsia.  In  healthy  pregnancy,  extravillous  trophoblasts 
invade  into  the  myometrium  converting  uterine  spiral  arteries  into  large  capacitance 
vessels  which  provide  low  resistance  blood  flow  into  the  intervillous  spaces  of  the 
placenta.  These  large  capacitance  vessels  lose  their  elastic  lamina  and  become 
unresponsive  to  vasoactive  stimuli,  allowing  greater  blood  flow  into  the  intervillous 
spaces. This remodelling of spiral arteries does not occur to any appreciable degree in pre-
eclampsia; the spiral arteries maintain their muscular coat and continue to be responsive to 
vasoactive stimuli. This has the net effect of reduced placental perfusion. The second stage 
of  pre-eclampsia  involves  the  maternal  syndrome  which  may  result  from  abnormal 
placentation.  There  is  activation  of  the  coagulation  cascade,  leading  to  a  procoagulant 
state.  There  is  greater  platelet  activation,  platelet  consumption  and  widespread  fibrin 
deposition  with  acute  atherosis.  In  severe  pre-eclampsia,  disseminated  intravascular 
coagulation  may  occur.  Increased  endothelial  dysfunction,  systemic  inflammation  and 
insulin  resistance  are  also  features  of  pre-eclampsia.  There  is  also  dyslipidemia  with 
elevated triglycerides and free fatty acids. Certainly, obesity and diabetes are risk factors 
towards  the  development  of  pre-eclampsia,  suggesting  a  metabolic  component  to  the 
disease. 
 
 
The fetus is wholly dependent on the mother for nutrition and to this end the placenta is 
responsible  for  effective  feto-maternal  transfer.  The  placental  villi  are  constantly 
enveloped in maternal blood and mechanisms exist to prevent coagulation on the surface of 
syncytiotrophoblast cells to allow effective feto-maternal transfer. Annexin V is expressed 
on the surface of syncytiotrophoblasts. Annexin V has an affinity to phospholipids and 
trimerises  on  the  syncytiotrophoblast  cell  membrane  forming  a  lattice  and  effectively   171 
shields  the  phospholipids  exposed  on  cell  membranes  from  contact  by  circulating 
coagulation  factors.  This  prevents  the  formation  of  the  prothrombinase  complex  and 
subsequent  clot  formation  on  the  cell  membrane.  Annexin  V  therefore  confers 
anticoagulant properties to the surface of syncytiotrophoblasts, in effect forming a ‘non-
stick’ coating at the feto-maternal interface. Annexin V expression has been found to be 
decreased on trophoblasts of pre-eclamptic placentas(39;48) and certainly my results have 
suggested larger areas of discontinuity of annexin V staining in pre-eclamptic placentas 
compared to healthy control placentas. 
 
 
In pre-eclampsia, there is increased perivillous fibrin deposition and certainly in chapter 3, 
there was the impression of greater perivillous fibrin deposition in pre-eclamptic samples 
compared to healthy pregnant samples although this was not quantitated. I hypothesised 
that there may be an association between annexin V expression and fibrin deposition on the 
trophoblast in pre-eclampsia as annexin V is anticoagulant in nature and may have a role in 
preventing  fibrin  deposition  on  the  surface  of  the  syncytiotrophoblast.  Using 
immunocytochemistry, I noted that there was inverse localisation between annexin V and 
fibrin staining on the syncytiotrophoblast surface in healthy third trimester placentas. In 
pre-eclamptic and IUGR samples, there appeared to be larger areas of fibrin staining as 
would be expected but there still remained inverse localisation between annexin V and 
fibrin staining. This would be in keeping with the findings of Shu et al who found elevated 
plasma levels of fibrin degradation products and thrombin-antithrombin III complex from 
pre-eclamptic patients as the expression of annexin V in the placenta was reduced(48). 
There are several possibilities to explain this inverse localisation. It would be reasonable to 
presume that areas of healthy syncytiotrophoblast would express annexin V on its surface 
thus  conferring  anticoagulant  properties  to  the  surface  of  the  syncytiotrophoblast.  In 
contrast, areas of apoptotic or necrotic trophoblast may have reduced annexin V expression 
on  the  cell  membrane  along  with  externalisation  of  PS  on  to  the  surface  of  the  cell 
membrane,  leading  to  the  assembly  of  procoagulant  factors  and  subsequent  fibrin 
deposition. Therefore, there would be greater annexin V staining on the surface of healthy 
syncytiotrophoblasts but little fibrin deposition. However, on the surface of apoptotic or 
necrotic syncytiotrophoblasts, there would be less annexin V staining and greater fibrin 
deposition. Another explanation for the appearance of this inverse localisation between 
annexin  V  and  fibrin  may  be  that  fibrin  has  deposited  on  the  surface  of  the 
syncytiotrophoblast regardless of the presence of annexin V expression and the deposition 
of fibrin on the trophoblast surface had physically prevented the primary antibody from   172 
binding to annexin V. A possible method of resolving these two possibilities may be by 
using a substance that is able to dissolve fibrin in vitro. Ammodytase is a metalloprotease 
from viper venom and is able to dissolve fibrin clots by direct hydrolysis of the α and β-
chains of fibrin(299). It may be possible to use ammodytase to dissolve the fibrin clots on 
the surface of the trophoblast which may then uncover any underlying annexin V. This 
slide may then be stained for annexin V. A counterpart back-to-back slide may then be 
prepared and stained for fibrin. If annexin V staining was found in the same location as 
fibrin staining in these back-to-back slides, this would suggest that fibrin had physically 
obstructed the primary antibody from attaching to annexin V. 
 
 
Tissue  factor  is  a  potent  initiator  of  coagulation  and  is  expressed  by  placental 
syncytiotrophoblasts. I was interested in identifying if there was any relationship between 
annexin V which has anticoagulant properties and tissue factor which is the potent initiator 
of coagulation. Tissue factor mRNA levels have previously been found to be high in pre-
eclamptic placentas. Back-to-back slides of the placentas of healthy third trimester, IUGR 
and  pre-eclamptic  pregnancies  were  prepared.  Despite  the  positive  control  staining 
strongly for tissue factor, there were only very few small scattered areas of tissue factor 
staining  in  all  the  placentas.    This  made  any  attempt  of  identifying  any  relationship 
between annexin V and tissue factor difficult. The most likely reason for my results is that 
there were only very small amounts of tissue  factor protein expressed in the placenta. 
However, Estelles et al found a five-fold increase in TF mRNA levels in pre-eclamptic 
compared to healthy placentas(29). It is possible that in pre-eclampsia, there is priming of 
coagulation in the placenta resulting in higher levels of TF mRNA synthesis and placental 
TF protein only becomes expressed in severe pre-eclampsia. Another possibility for this 
very slight staining of tissue factor is that as tissue factor is such a potent initiator of 
coagulation, any slight expression of tissue factor in the placenta immediately led to the 
deposition  of  fibrin  on  these  areas,  thereby  preventing  the  primary  antibody  directed 
towards tissue factor from attaching. It is also possible that while the antibody worked on 
the positive controls, the primary antibody had not worked so well on the trophoblasts. 
Perhaps an alternative primary antibody may be tried out.  
 
 
The placental syncytiotrophoblast layer envelops the placental villi and is in contact with 
maternal blood. Placental cytotrophoblast cells are the stem cells of syncytiotrophoblasts 
that  proliferate  and  eventually  fuse  into  the  syncytiotrophoblast  layer.  As  the  placenta   173 
develops,  ageing  syncytiotrophoblasts  undergo  apoptosis.  As  there  is  greater  placental 
apoptosis in pre-eclampsia, I wished to identify areas of the placenta undergoing apoptosis 
in pre-eclamptic, IUGR, healthy third trimester and healthy first trimester placentas with 
the  aim  of  relating  these  areas  to  fibrin  deposition.  It  is  possible  areas  of  trophoblast 
apoptosis may have lower annexin V expression, which can then lead to deposition of 
fibrin. Austgulen et al (50) used M30 to detect apoptotic placental cells in healthy third 
trimester placentas and noted abundant staining at the syncytiotrophoblast layer, more so in 
areas  where  there  was  greater  perivillous  fibrinoid  deposition.  M30  CytoDEATH 
antibodies detect a caspase cleavage site within cytokeratin 18 in the cell cytoplasm and 
Austgulen et al noted that M30 was more sensitive and had less non-specific staining 
compared  to  terminal  deoxynucleotidyl  transferase-mediated  deoxyuridine  triphosphate 
nick end labelling (TUNEL) staining. I initiated preliminary investigations by attempting 
to immunolocalise apoptotic cells in healthy first trimester and third trimester placentas 
using M30 CytoDEATH antibodies. Unfortunately, in all my samples, it was the majority 
of cytotrophoblast nuclei and most of the syncytiotrophoblast nuclei that was found to be 
heavily stained with M30, with very little staining of cell cytoplasm. It is known that M30 
can non-specifically stain the nuclei of highly proliferating cells and both cytotrophoblasts 
and syncytiotrophoblasts actively proliferate. It was unfortunate that M30 did not perform 
as anticipated. Perhaps for future experiments, alternative markers for cellular apoptosis 
such as bcl-2 and caspase-3 may be tried as had been done by Aban et al(21).  
 
 
During the process of cellular apoptosis, phosphatidylserine (which is normally located on 
the inner leaflet of cell plasma membranes by an active process) becomes externalised to 
the outer surface of the cell plasma membrane. Small blebs form on the surface of the cell 
membrane  and  are  released  into  the  circulation  as  microparticles.  In  the  extrinsic 
coagulation pathway, prothrombin, activated factor X, activated factor V and calcium ions 
assemble  on  a  phospholipid  surface  forming  the  prothrombinase  complex. 
Phosphatidylserine  (a  phospholipid)  exposed  on  the  surface  of  apoptotic  cells  and 
microparticles  may  also  allow  for  the  assembly  of  the  prothrombinase  complex  by 
providing a procoagulant surface. The amount of microparticles in the systemic circulation 
has been found to be raised in various prothrombotic conditions such as acute coronary 
syndrome,  diabetes,  heparin  induced  thrombocytopenia,  paroxysmal  nocturnal 
haemoglobinuria  and  severe  hypertension,  suggesting  that  microparticles  may  be 
procoagulant  in  nature.  Using  flow  cytometry,  microparticles  have  previously  been 
identified from various cell sources, such as platelets, endothelium and leukocytes.   174 
 
 
Earlier, it was proposed that there was a 2-stage model towards the development of the 
maternal syndrome of pre-eclampsia. It is tempting to speculate that the placenta releases a 
factor that directly leads to the maternal manifestation of pre-eclampsia. However as yet, 
this proposed ‘Factor X’ has yet to be identified. There is a high turnover of trophoblast in 
pregnancy as the placenta constantly remodels itself. Cytotrophoblast cells fuse to form 
syncytiotrophoblast cells which when they age, accumulate to form syncytial knots which 
then undergo apoptosis. In the placenta, the syncytiotrophoblast layer envelops the villous 
portion of the placenta  which is the side of the placenta that is in direct contact with 
maternal blood. Syncytiotrophoblast membrane particles (STBMs) have been identified in 
the maternal circulation and are proposed to originate from apoptotic syncytial cells. In that 
regard, they may be considered as placental-derived microparticles. However, as there is 
the  possibility  that  circulating  placental  cell  membrane  particles  may  also  originate  by 
cellular damage, it may be more accurate to describe circulating placental cell membrane 
particles  collectively,  as  placental  cellular  debris.  In  pre-eclampsia,  there  is  greater 
placental apoptosis compared to healthy pregnancy and it was an intriguing possibility that 
greater  placental  apoptosis  may  lead  to  the  release  of  greater  amounts  of  placentally-
derived  microparticles.  Greater  amounts  of  placentally-derived  microparticles  may 
contribute to an increase in total microparticle (derived from all cell types) levels in the 
maternal  circulation  which  may  in  turn  contribute  to  the  procoagulant  state  of  pre-
eclampsia. 
 
 
It is possible that in the maternal systemic circulation, circulating cell membrane particles 
(regardless  of  cell  of  origin)  may  expose  phosphatidylserine  on  its  surface  and  may 
therefore be procoagulant. I hypothesised that circulating microparticles in the maternal 
systemic  circulation  makes  a  significant  contribution  to  the  procoagulant  state  of  pre-
eclampsia. However, a simple measure of the amount of microparticles (which could be 
achieved  by  flow  cytometry)  in  blood  would  not  necessarily  reflect  the  procoagulant 
activity  of  microparticles.  To  measure  the  procoagulant  activity  of  microparticles,  a 
prothrombinase  assay  was  validated  and  utilised.  In  this  assay,  captured  microparticles 
from the blood sample were incubated with clotting factors and the measure of thrombin 
generated  was  utilised  as  a  measure  of  the  procoagulant  activity  of  the  captured 
microparticles.  This  assay  in  fact  replicates  the  events  of  coagulation  in  the  body  as 
coagulation in vivo also involves the assembly of various clotting factors on a phospholipid   175 
surface. In the process of developing this assay for our use we encountered difficulties in 
the storage of the standard vesicles. Limitations of time precluded further attempts towards 
finding  a  suitable  method  to  avoid  degradation  of  these  standard  vesicles  in  storage. 
Therefore, all measures of microparticle prothrombinase activity in the blood samples were 
done using freshly prepared standard vesicles, directly comparing pre-eclamptic samples 
and  controls  in  the  same  assay.  The  microparticle  prothrombinase  activity  of  maternal 
systemic  blood  was  measured  and  there  was  no  significant  difference  found  in  total 
microparticle prothrombinase activity between pre-eclamptic patients and healthy pregnant 
controls. 
 
 
It must be remembered that the prothrombinase activity of total microparticles in maternal 
systemic blood would be a measure of the procoagulant activity of microparticles derived 
from  both  maternal  and  placental  cells.  As  there  is  greater  placental  apoptosis  in  pre-
eclampsia it would have been interesting to measure the procoagulant activity of placental-
derived microparticles. However that would require an anti-trophoblast antibody to capture 
the placental-derived microparticles and such an antibody was not commercially available. 
Therefore  a measure of fetal corticotrophin-releasing hormone (CRH)  mRNA levels in 
maternal  blood  was  undertaken  as  a  method  of  simply  quantifying  the  amount  of 
placentally-derived  cell  debris  in  maternal  blood.  Fetal  CRH  is  synthesised  by  the 
trophoblast and it is presumed that when trophoblast microparticles bleb off, they would 
contain within them mRNA representative of the genes expressed in those cells, including 
CRH mRNA. Maternal CRH mRNA is not present in the systemic circulation and so any 
measure of CRH mRNA in maternal blood would be of placental origin. When fetal CRH 
mRNA levels were measured, the levels were four-fold higher in pre-eclamptic samples 
compared to healthy pregnant controls. This suggests that there were greater amounts of 
placental-derived cell debris in maternal circulation in pre-eclampsia. However it must be 
remembered that we cannot presume that all fetal CRH mRNA in maternal blood comes 
from  placentally-derived  microparticles,  as  placental  cell  debris  derived  from  damaged 
trophoblast, for example, may also contain fetal CRH mRNA. Thus, a measure of fetal 
CRH  mRNA  would  encompass  both  placentally-derived  microparticles  and  trophoblast 
cell debris, collectively termed ‘placental cell debris’. 
 
 
It is interesting that the greater amounts of placentally-derived cell debris by a factor of 
four in pre-eclamptic patients did not contribute significantly to their total microparticle   176 
procoagulant  activity.  It  is  possible  that  the  higher  amount  of  placentally-derived  cell 
debris was too small a fraction of the total microparticles in maternal blood to make any 
significant  difference.  It  is  also  possible  that  placentally-derived  cell  debris  may  not 
express  much  phosphatidylserine  on  its  surface.  Another  possibility  is  that  while  the 
amounts of placentally-derived cell debris were low at the time of collection, perhaps over 
time, the levels may gradually increase as a consequence of gradually worsening placental 
dysfunction and increasing trophoblast apoptosis. Certainly, when we looked at our pre-
eclamptic samples as 2 separate subgroups (patients recruited under 36 weeks’ gestation 
and  patients  recruited  after  36  weeks’  gestation),  there  was  a  higher  mean  fetal  CRH 
mRNA level in the group over 36 weeks’ gestation, suggesting there may an increase in 
fetal CRH mRNA levels as pre-eclampsia progresses. As the condition of pre-eclampsia is 
known  to  worsen  suddenly,  it  is  tempting  to  hypothesise  that  a  sudden  increase  in 
placentally-derived cell debris that may be the precipitant for a worsening of the condition. 
It  would  be  desirable  in  future  experiments  to  measure  fetal  CRH  mRNA  levels  as 
pregnancy  progresses  and  to  correlate  duration  of  pre-eclampsia  to  fetal  CRH  mRNA 
levels to get a more accurate representation of this relationship. 
 
 
The measure of fetal CRH mRNA measures the amount of placental cell debris but does 
not  measure  the  procoagulant  activity  of  placental-derived  cell  debris.  At  the  time  of 
commencement of this project, there were no reports in the literature of isolating placental 
cell  debris  in  maternal  circulation  although  subsequently,  Goswami  et  al(81)  used  an 
antitrophoblast  antibody  to  measure  STBM  levels  in  pre-eclampsia.  With  some 
adjustments,  it  may  be  possible  to  modify  our  prothrombinase  assay  to  use  such  an 
antibody to capture placentally-derived microparticles onto a plate in order to measure 
their procoagulant activity. 
 
 
As  microparticles  are  known  to  exhibit  procoagulant  properties,  I  wished  to  correlate 
microparticle  procoagulant  activity  and  placentally-derived  cell  debris  to  markers  of 
coagulation activation, endothelial function and placental function in pre-eclamptic and 
healthy controls. The pattern of changes in markers of coagulation activation, endothelial 
activation and placental function I observed were in keeping with that expected for pre-
eclampsia. Tissue factor pathway inhibitor (TFPI) was higher in pre-eclampsia possibly as 
a  reflection  of  endothelial  activation  in  pre-eclampsia  or  possibly  in  response  to  cell-
surface  tissue  factor  expression.  There  were  higher  prothrombin  fragment  1+2  (F1+2)   177 
[increased  conversion  of  prothrombin  to  thrombin]  levels  in  pre-eclampsia,  reflecting 
greater  conversion  of  prothrombin  to  thrombin.  Higher  levels  of  activated  factor  XII 
(FXIIa)  which  has  both  procoagulant  activity  (activated  factor  XI)  and  anticoagulant 
activity (increases plasmin) effects were found as well as higher PAI-1 levels (suppressed 
fibrinolysis) were found in pre-eclampsia. With regard to markers of endothelial activation, 
there were higher levels of soluble VCAM-1 and vonWillebrand factor in pre-eclamptic 
samples. The PAI-1/PAI-2 ratio was also raised in pre-eclampsia in keeping with current 
literature.  Interestingly,  the  levels  of  soluble  tissue  factor  (the  potent  initiator  of 
coagulation), thrombin-antithrombin (a measure of the amount of thrombin) and the APC 
ratio (APC inactivates activated factor V and activated factor VIII) were not significantly 
different between pre-eclamptic and healthy controls. These results suggest that although 
there were higher levels of priming factors towards coagulation, there did not appear to be 
much evidence of greater amounts of clot formation between pre-eclamptic and healthy 
control groups. 
 
 
TFPI  was  correlated  with  fetal  CRH  mRNA  levels  in  both  pre-eclamptic  and  healthy 
controls, possibly reflecting shedding of placental TFPI along with fetal CRH mRNA as 
part of placental debris. It is also possible that placental-derived cell debris may induce 
maternal  endothelial  cell-surface  tissue  factor  expression  thus  inducing  upregulation  of 
TFPI synthesis. It is also possible that placental-derived cell debris may carry exposed 
tissue  factor  on  its  surface  thus  upregulating  TFPI.  Alternatively,  as  a  result  of 
phosphatidylserine exposed on the surface, placentally-derived cell debris may present a 
platform  for  thrombin  generation  via  the  tissue  factor/activated  factor  VII-dependent 
coagulation activation pathway. In the pre-eclamptic group, factor VII coagulant activity 
correlated  with  fetal  CRH  mRNA  levels  and  FVII  coagulant  activity  was  particularly 
elevated at high levels of fetal CRH mRNA, suggesting an association between factor VII 
coagulant  activity  and  circulating  placentally-derived  cell  debris.  This  is  interesting 
because the measure of factor VII coagulant activity is not a measure of factor VII levels 
but a measure of the procoagulant ability of factor VII.  
 
 
The pattern of changes in the measured coagulation factors in the pre-eclamptic samples 
seemed to show a state of priming towards the generation of clots. Factor VII coagulant 
activity  was  higher  in  pre-eclampsia  and  this  positively  correlated  with  the  amount  of 
placentally-derived cell debris in maternal circulation. There was also the suggestion that   178 
levels of placentally-derived cell debris may increase as pre-eclampsia progresses. It is 
possible that all these factors in combination may lead to a state of coagulation priming in 
pre-eclampsia  and  all  that  is  required  is  a  trigger  to  set  off  a  chain  of  coagulation 
dysfunction  that  may  precipitate  a  worsening  of  pre-eclampsia.  Placental-derived  cell 
debris is associated with factor VII coagulant activity, and the surface of the cell debris 
may expose phosphatidylserine which would present a surface for the assembly of the 
prothrombinase complex. There is the possibility that levels of placental-derived cell debris 
may increase as pre-eclampsia progresses. It is tempting to speculate that placental-derived 
cell debris may be a candidate for ‘Factor X’ in the development of pre-eclampsia. More 
work is required to explore this intriguing possibility. 
 
 
I hypothesised that there may be a relationship between maternal fatty acid status and 
coagulation  in  pre-eclampsia  and  healthy  pregnancy  as  fatty  acids  are  precursors  of 
eicosanoid synthesis. The balance of n-6 to n-3 fatty acids is long known to affect the 
balance of eicosanoid synthesis, with n-6 fatty acids leading to the synthesis of more potent 
thromboxanes and prostacyclines such as thromboxane A2 while n-3 fatty acids lead to the 
synthesis of less potent eicosanoids such as thromboxane A3. Thromboxanes are involved 
in platelet activation and aggregation and greater amounts of thromboxane A2 (being more 
potent)  leads  to  greater  degrees  of  platelet  activation  and  aggregation  and  therefore 
enhanced procoagulant status. Prostacyclin is another eicosanoid that is synthesised by n-6 
and n-3 fatty acids. Prostacyclin is mainly synthesised by the vascular endothelium and 
functions as a vasodilatory agent as well as a platelet inhibitor. 
 
 
I correlated maternal fatty acids to markers of coagulation activation, endothelial function 
and  placental  function.  Measurements  of  fatty  acids  in  plasma  can  be  subject  to  the 
subjects fasting status and therefore, to obtain an accurate representation of maternal fatty 
acid status in pre-eclamptic patients and healthy pregnant controls, erythrocyte fatty acid 
levels were measured. Pre-eclamptic and healthy control groups were matched for body 
mass index (BMI), an index of body fat. This matching was important to rule out any 
differences in fatty acid levels that are simply as a result of different BMI as fatty acids are 
stored in adipose tissue and so increased amounts of adipose tissue may provide higher 
amounts of fatty acid precursors. I was interested in identifying any differences in fatty 
acid levels between pre-eclamptic and healthy pregnant conditions and to relate the fatty 
acids to markers of coagulation activation, endothelial function and placental function as   179 
fatty  acids  are  associated  with  eicosanoid  synthesis  and  so  may  affect  the  maternal 
coagulation status. 
 
 
Fatty acids were measured in absolute values and also as a percentage of total fatty acids. 
The results of the measurements in pre-eclampsia showed a shift of the fatty acid pattern 
towards  a  lower  percentage  of  total  PUFAs  and  a  higher  percentage  of  total 
monounsaturated fatty  acids (MUFAs), in keeping with previously identified fatty acid 
patterns measured in the maternal serum of pre-eclamptic patients. Pre-eclamptic patients 
had a lower percentage of total long-chain fatty acids. Pre-eclamptic patients also had a 
lower percentage of total n-6 fatty acids and a trend towards lower total n-3 fatty acids 
compared  to  the  control  group.    Dihomo-γ-linolenic  acid  and  arachidonic  acid,  both 
precursors to the potent thromboxane A2 were lower in pre-eclampsia. It is possible that 
this  may  represent  greater  utilisation  of  these  n-6  fatty  acids  in  order  to  synthesise 
thromboxane A2 and this would be in keeping with the procoagulant state of pre-eclampsia. 
Pre-eclampsia is associated with a procoagulant state as well as maternal hypertension and 
placental ischemia. Thromboxane A2 is associated with increased platelet activation which 
may  contribute  to  the  prothrombotic  state  of  pre-eclampsia.  Thromboxane  is  also  a 
vasoactive substance which stimulates vasoconstriction and this may have a role in the 
development  of  maternal  hypertension  in  pre-eclampsia.  In  the  pre-eclamptic  placenta, 
there is failure of extravillous trophoblast invasion into the muscular coat of the spiral 
arterioles resulting in reduced conversion of uterine spiral arteries into large capacitance 
vessels.  The  muscular  coat  of  unconverted  spiral  arterioles  would  remain  under  the 
influence  of  vasoactive  agents  and  high  levels  of  thromboxane  A2  can  promote 
vasoconstriction thus leading to placental ischemia. Indeed, the ratio of thromboxane A2 to 
prostacyclin (a vasodilator) has been found to higher in pre-eclamptic placentas compared 
to healthy placentas. 
 
 
There  was  a  lower  absolute  amount  as  well  as  percentage  of  the  n-3  fatty  acid 
docosahexaenoic  acid  (DHA)  in  pre-eclampsia  compared  to  healthy  controls.  DHA  is 
important  for  neural  and  retinal  development.  It  is  difficult  to  determine  if  the  pre-
eclamptic women had a lower intake of DHA or if the fetus has accreted greater amounts 
of DHA as a survival mechanism in pre-eclampsia. One method of assessing this would be 
by measuring the DHA ratio between maternal blood and umbilical cord blood to identify 
any  differences between pre-eclamptic  and healthy pregnant  controls. Another possible   180 
reason  for  the  lower  amounts  of  DHA  in  pre-eclampsia  was  a  reduced  conversion  of 
docosapentaenoic  acid  to  DHA  by   
6  desaturase.  Certainly,  long-chain  PUFAs  in 
erythrocyte phospholipids have been found to be are associated with insulin resistance in 
type II diabetics, which may be as a result of reduced insulin-mediated activation of  
6 
desaturases(300) and indeed, pre-eclampsia is also a state of insulin resistance (187;301). 
 
 
In  pre-eclampsia,  there  were  also  higher  levels  of  palmitic  acid  and  its  precursor 
palmitoleic acid. Palmitic acid is the main fatty acid stored in adipose tissue and a high 
maternal BMI is a risk factor towards developing pre-eclampsia. However, as our pre-
eclamptic and healthy control samples were well-matched, both cases and controls should 
have relatively similar amounts of body  fat. This higher level of palmitic acid in pre-
eclamptic patients may reflect greater mobilisation of fatty acids from maternal stores in 
pre-eclampsia and this may be contributory to the dyslipidemia in pre-eclampsia. Obesity 
is  associated  with  insulin  resistance  and  so  is  pre-eclampsia,  suggesting  a  metabolic 
component in the maternal manifestation of pre-eclampsia. 
 
 
PAI-1 is synthesised by the placenta as well as by adipose tissue and PAI-1 levels are 
increased in obesity. PAI-1 was positively correlated with the n-6 fatty acids linoleic acid 
and dihomo-γ-linolenic acid in healthy pregnancy. Human umbilical vein endothelial cells 
cultured with DHA and dihomo-γ-linolenic acid (20:3 n-6) have been shown to result in an 
increase in the amount of PAI-1 mRNA suggesting that some fatty acids may directly 
induce PAI-1 transcription (295).  This suggests that fatty acids may be able to alter the 
haemostatic balance by increasing PAI-1 levels. An in vitro culture of placental cells with 
linoleic  acid  and  dihomo-γ-linolenic  acid  measuring  PAI-1  mRNA  levels  would  be  a 
method to investigate this possibility. 
 
 
Clinically, as the balance of n-6 to n-3 fatty acids in the mother may affect the synthesis of 
either more potent eicosanoids or less potent eicosanoids and possibly other coagulation 
factors, perhaps supplementation to restore the balance of n-6 to n-3 fatty acids may be a 
potential therapeutic option in pregnancies at risk of excessive thrombosis. For example, 
perhaps a method of reducing the synthesis of the potent eicosanoid thromboxane A2 is by 
n-3 fatty acid supplementation into the diet. This may lead to competition for desaturases   181 
and elongases in fatty acid metabolism which may lead to a reduction in the synthesis of 
the potent thromboxane A2. Further studies are warranted.  
 
 
My  thesis  provides  evidence  of  an  increased  coagulation  potential  in  pre-eclampsia  as 
reflected  by  the  raised  levels  of  markers  of  coagulation  activation.  Total  microparticle 
procoagulant activity in maternal blood has not been shown to be raised in pre-eclampsia 
but the four-fold rise in placental-derived cell debris levels in maternal plasma in pre-
eclampsia may be significant. The coagulation potential of placental-derived cell debris 
should  be  further  elucidated.  It  is  possible  that  pre-eclampsia  is  a  state  of  enhanced 
coagulation potential awaiting a precipitous event and certainly, the change of maternal 
state from pre-eclampsia to eclampsia can be very sudden indeed. The balance of maternal 
fatty acids is disrupted in pre-eclampsia and there is a shift of fatty acid balance towards 
one which may contribute to greater platelet activity and coagulation potential. My results 
present a case that pre-eclampsia is a state of increased coagulation potential resulting from 
multiple pathways. 
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